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In	the	Saltpêtrière	asylum	in	France,	physician	Augustin	Jacob	Landré-Beauvais	first	noticed	and	
described	the	symptoms	and	signs	of	patients	with	severe	joint	pain	that	could	not	be	explained	
by	other	conditions	of	the	joints	known	at	that	time	(1820s).	This	condition	affected	mainly	the	
poor,	women	more	often	 than	men	and	 it	was	 first	described	as	 rheumatoid	arthritis	 (RA)	by	
Archibald	Garrod	 in	1890.[1]	 Its	etiology	was	unclear,	and	many	theories	have	been	proposed	
since	 then.	 Today,	 the	exact	 cause	of	RA	 remains	unknown.	However,	 extensive	 research	has	
generated	much	knowledge	about	its	presentation	and	diagnosis,	the	pathophysiology,	disease	
course,	 prognosis	 and	 treatment.[2-6]	 RA	 is	 an	 auto-immune	 disease	 that	 is	 characterized	 by	
chronic	systemic	inflammation	that	mainly	affects	the	small	joints	of	the	hands	and	feet,	leading	
to	pain	and	stiffness,	fatigue	and	disability,	and	largely	irreversible	joint	damage	if	left	untreated.	
The	prognosis	for	patients	with	RA	has	improved	significantly	during	the	last	two	decades.	This	
achievement	 can	 be	 primarily	 attributed	 to	 earlier	 diagnosis,	 and	 treatment	 targeted	 to	 low	
disease	activity	or	remission	by	using	(combinations	of)	disease-modifying	anti-rheumatic	drugs	
(DMARDs)	including	biological	DMARDs.[7,	8]	
Cardiovascular	disease	in	RA	
Despite	 these	 advances,	 cardiovascular	morbidity	 and	mortality	 rates	 in	 patients	with	 RA	 are	
increased	 compared	 to	 the	 general	 population.[7,	 9-11]	 Extensive	 research	 has	 shown	 that	
cardiovascular	 disease	 (CVD)	 accounts	 for	 a	 substantial	 part	 of	 the	 excess	mortality	 found	 in	
RA.[12-16]	Reported	age	and	gender	adjusted	 standardized	mortality	 ratios	 for	 cardiovascular	
death	are	approximately	1.3-1.6	times	higher	than	in	the	general	population.[13,	17-19]	A	study	
by	Peters	et	al.	found	the	risk	to	be	comparable	to	the	risk	of	CVD	reported	in	patients	with	type	
2	diabetes	mellitus.[20]	Illustratively,	the	incidence	of	myocardial	infarction	(MI)	in	RA	patients	
was	found	to	be	significantly	higher	compared	to	age	and	gender	matched	controls.[15,	21]	In	a	
prospective	cohort	study	that	included	114342	women,	with	2.4	million	years	of	follow-up,	the	
risk	of	an	acute	MI	was	found	to	be	two	times	higher	 in	women	with	RA	compared	to	women	
without	RA.[22]	It	has	also	been	shown	that	an	increased	risk	of	CVD	is	present	even	in	preclinical	
stages	and	in	very	early	RA.[23-25]	RA	patients	are	more	likely	to	develop	atherosclerotic	plaques,	
silent	ischemic	disease	and	they	have	an	increased	risk	of	sudden	cardiac	death,	compared	to	the	
general	population.[13,	25]	In	order	to	decrease	CVD	morbidity	and	mortality	in	RA,	tangible	risk	
factors	that	can	be	targeted	for	the	prevention	of	CVD	need	to	be	identified.	Consequently,	it	is	
necessary	 to	gain	detailed	knowledge	on	mechanisms	 that	 cause	 the	excess	CVD	 risk	and	 the	
predictive	power	of	appointed	risk	factors	in	this	population.		
Risk	factors	for	cardiovascular	disease	in	RA	
In	the	general	population,	CVD	risk	management	is	focused	on	identifying	and	treating	risk	factors	
included	 in	 the	 CVD	 risk	 profile	 such	 as	 smoking,	 hypertension,	 diabetes	 mellitus,	 high	 total	
cholesterol	(TC)	levels,	high	levels	of	low-density	lipoprotein	cholesterol	(LDL-c),	or	low	levels	of	
the	 protective	 high-density	 lipoprotein	 cholesterol	 (HDL-c).[26,	 27]	 It	 has	 been	 reported	 that	
these	“traditional”	risk	factors	may	have	a	different	effect	on	CVD	risk	in	RA	patients	compared	
to	 the	general	population.[28-30]	Also,	 the	prevalence	of	certain	risk	 factors	such	as	smoking,	
insulin	resistance,	sedentary	lifestyle	and	hypertension	was	shown	to	be	increased	in	RA.[31-35]	
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At	 the	 same	 time,	 there	 is	 evidence	 that	 suggests	 that	 RA	patients	 are	undertreated	 for	 CVD	
risk.[36,	37].	Interestingly,	it	has	become	evident	that	traditional	risk	factors	do	not	fully	account	
for	the	excess	risk	of	CVD	in	RA.[13,	22,	28,	38]	Therefore,	there	may	be	other	useful	targets	that	
contribute	 to	 the	 development	 of	 CVD	 in	 RA.	 It	 being	 an	 auto-immune	 disease,	 systemic	
inflammation	and	immune	mechanisms	have	been	suggested	as	important	disease-related	CVD	
risk	factors	in	RA.[39,	40]	This	is	particularly	supported	by	the	fact	that	atherosclerosis,	which	has	
been	described	as	an	inflammatory	disease,	appears	to	be	accelerated	in	RA.[40-43]	In	addition,	
C-reactive	protein	 (CRP),	 an	 inflammatory	marker	used	 to	determine	disease	 activity	 in	RA,	 is	
predictive	for	atherosclerosis.[44,	45]	Indeed,	both	acute	phase	reactants	CRP	and	erythrocyte	
sedimentation	 rate	 (ESR),	 have	 been	 associated	 with	 CVD	 in	 RA	 and	 polyarthritis.[9,	 46-49]	
Moreover,	 atherosclerotic	 plaques	 appear	 to	 be	more	 severe	 and	 prevalent	 in	 RA	 patients	 in	
comparison	to	the	general	population.[42,	50-53]	These	findings	have	been	reported	in	both	early	
and	established	RA.[42]	Also,	in	comparison	to	healthy	controls	and	RA	patients	in	remission,	RA	
patients	with	active	disease	have	an	increased	risk	of	unstable	plaques	that	are	more	prone	to	
rupture	and	cause	CVD.[54]	 Inflammation	also	appears	 to	modify	 the	effect	of	 traditional	 risk	
factors,	particularly	lipoproteins.[55-61]	Notably,	the	anti-atherogenic	properties	of	HDL-c	appear	
to	 be	 diminished	 as	 a	 consequence	 of	 chronic	 inflammation,	 even	 becoming	 pro-
inflammatory.[58-61]	This	may	in	part	be	due	to	altered	composition	of	HDL-c	particles,	however	
this	has	not	been	investigated	in	RA	patients.	In	addition	to	determinants	of	inflammatory	activity,	
other	‘disease-related’	markers	have	been	identified	as	potential	novel	risk	factors	for	CVD	in	RA,	
notably	 rheumatoid	 factor	 (RF)	 positivity	 and	 anti-citrullinated	 protein	 antibody	 (ACPA)	
positivity.[19,	47,	62]	
Disease	activity	as	risk	factor	for	CVD	in	RA	
In	RA	patients,	inflammatory	activity	can	be	quantified	by	disease	activity	measures	such	as	the	
28-joint	 disease	 activity	 score	 (DAS28).	 The	 DAS28	 is	 a	 combined	 index	 that	 consists	 of	 four	
components;	 number	 of	 swollen	 joints,	 number	 of	 tender	 joints,	 an	 inflammatory	 biomarker	
(either	CRP	or	ESR)	and	the	general	health	score	(Visual	Analogue	scale	[VAS]).	Twenty-eight	joints	
are	 scored	 and	 disease	 activity	 is	 estimated	 by	 entering	 the	 found	 results	 into	 the	 DAS28-
formula.[63]	There	is	conflicting	evidence	about	the	association	between	disease	activity	and	CVD	
events.	Using	the	DAS28,	Radovits	et	al.	reported	that	disease	activity	overall	was	not	significantly	
associated	with	the	occurrence	of	MI	in	a	case-control	study.[64]	On	the	other	hand	it	was	shown	
that	exposure	to	frequent	flare	ups	of	disease	activity	and	increased	burden	of	RA	disease	activity	
over	 time	 increases	 the	 risk	 of	 CVD.[65,	 66]	 Solomon	et	 al.	 demonstrated	 that	 reduced	 time-	
averaged	disease	activity	was	associated	with	fewer	CV	events	in	a	cohort	of	RA	patients	with	a	
median	 follow-up	of	 2.7	 years.[65]	 Furthermore,	 a	meta-analysis	 investigating	 the	 association	
between	anti-rheumatic	drugs	and	CVD	in	RA	and	psoriatic	arthritis	reported	a	reduced	risk	of	
CVD	in	patients	treated	with	methotrexate	or	TNF-alpha	blocking	agents.	Whether	this	reduction	
is	(partially)	achieved	through	a	reduction	in	disease	activity	has	not	been	fully	elucidated.[67]	
Conversely,	the	absence	of	clinical	disease	activity	(i.e.	remission)	may	protect	against	excess	CVD	
risk.	However,	this	hypothesized	association	also	requires	further	investigation	as	it	is	unclear	if	
low	disease	activity	would	be	sufficient,	or	if	absolute	remission	is	required.	In	addition	to	disease	
1		
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activity,	 disease	 duration	 could	 be	 a	 factor	 that	 contributes	 to	 the	 risk	 of	 CVD.	 Studies	
investigating	the	effect	of	disease	activity	on	CVD	risk	in	RA	are	likely	to	be	limited	by	small	patient	
samples,	a	relatively	short	follow-	up,	lack	of	data	on	traditional	CVD	risk	factors	in	RA	cohorts	or	
cross-sectional	designs	not	quite	suited	to	investigate	such	relationships	or	long-term	outcomes	
such	 as	CVD.	 Furthermore,	 heterogeneity	of	 patient	 samples,	 fluctuating	disease	 activity	 over	
time	and	 the	 large	variety	of	applied	 treatment	strategies	between	 individual	patients	 further	
complicates	most	studies.	Overall	the	relationship	between	clinically	measured	disease	activity	
and	CVD	has	not	been	sufficiently	clarified.	Additional	research	is	necessary	to	determine	whether	
suppression	of	the	inflammatory	process	with	effective	treatments	would	have	a	lasting	beneficial	
effect	on	the	risk	of	CVD.	
The	interplay	between	traditional	and	disease	related	CVD	risk	factors	
The	discovery	of	disease-related	CVD	risk	factors	eventually	led	to	the	‘smaller	slice	of	a	larger	
pie’	hypothesis	(Fig.1.1).[68]	RA	patients	have	an	increased	risk	of	developing	CVD	and	traditional	
risk	factors	are	certainly	of	importance	in	that	respect.	However,	it	is	likely	that	they	account	for	
a	smaller	proportion	of	total	risk	of	CVD	in	RA	compared	to	the	general	population.	The	CVD	risk	
profile	 in	RA	appears	 to	consist	of	a	complex	 interplay	of	pathophysiological	mechanisms	that	
influence	 each	 other	 and	 contribute	 to	 the	 risk	 of	 CVD	 in	 RA.	 As	 discussed	 in	 the	 previous	
paragraphs,	inflammation	may	modify	the	effect	of	traditional	CVD	risk	factors,	as	well	as	act	as	a	
CVD	risk	factor	in	its	own	right.	Consequently,	risk	prediction	in	individual	RA	patients	using	only	
the	traditional	risk	factors	as	they	are	defined	in	the	general	population	would	probably	lead	to	
suboptimal	results.	
	
Figure	 1.1.	 Hypothetical	 distribution	 of	 cardiovascular	 risk	 factors	 in	 patients	 with	 systemic	 lupus	
erythematosus	 or	 rheumatoid	 arthritis	 in	 comparison	 with	 the	 general	 population.	 Risk	 of	
cardiovascular	disease	is	increased	in	these	two	patient	populations,	however	compared	to	the	general	
population	 the	 relative	 contribution	 of	 traditional	 cardiovascular	 risk	 factors	 is	 smaller	 due	 to	
competing	 risks	 caused	 by	 the	 presence	 of	 inflammatory	 rheumatic	 disease.	 Reprinted	 from	
Epidemiology	of	CVD	in	rheumatic	disease,	with	a	focus	on	RA	and	SLE,	by	DP.	Symmons	and	Gabriel	
SE,	2011,	Nat	Rev	Rheumatol,7,	p387.	Copyright	2016	Macmillan	Publishers	Limited,	part	of	Springer	
Nature.	Reprinted	with	permission.	
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Risk	prediction	in	Rheumatoid	Arthritis	
Risk	prediction	is	widely	applied	in	the	field	of	CVD.	It	is	the	process	in	which	information	that	is	
available	now	is	transformed	into	a	probability	that	estimates	the	actual	state	of	the	subject	at	
some	point	in	the	future.	When	risk	prediction	research	is	performed	properly	it	can	contribute	
to	 the	 identification	 of	 suitable	 (new)	 risk	 factors	 and	 potential	 therapeutic	 targets.[69]	 Risk	
prediction	in	individuals	can	be	used	for	primary	or	secondary	prevention	and	risk	estimates	can	
also	be	used	to	raise	awareness	of	CVD	within	a	target	population.[69]	Furthermore,	in	clinical	
practice	 it	 can	be	 a	 useful	 tool	 to	 communicate	 the	message	of	 an	 increased	 risk	 of	 a	 future	
outcome,	motivating	patients	to	adhere	to	lifestyle	adjustments	and/or	drug	therapy.	In	the	field	
of	CVD,	decades	of	research	have	produced	a	certain	set	of	predictors	that	have	proven	to	be	
strongly	associated	with	the	risk	of	future	CVD	and	are	therefore	included	in	most	current	risk	
CVD	risk	algorithms.[70-72]	Many	of	these	traditional	risk	factors	for	CVD	were	identified	in	the	
Framingham	Heart	Study	that	was	initiated	in	1948.	This	US	research	group	also	developed	one	
of	 the	 first	 CVD	 risk	 algorithms	 that	 could	 be	 used	 in	 clinical	 practice;	 the	 Framingham	 risk	
score.[73]	A	European	counterpart	was	developed;	the	Systematic	Coronary	Risk	evaluation	score	
(SCORE).[70]	The	FRS	and	SCORE	algorithms	were	adapted	to	predict	CVD	morbidity	as	well	as	
CVD	mortality.[71,	74]	However,	the	FRS,	SCORE	and	other	CVD	risk	models	were	not	validated	
for	use	in	the	RA	population.	This	may	be	of	importance	as	these	risk	algorithms	mainly	include	
traditional	risk	factors	and	do	not	account	for	the	effect	of	 inflammation	on	these	risk	factors.	
More	recently	developed	risk	models	that	include	rather	crude	measures	of	inflammatory	activity	
such	as	the	Reynolds	Risk	Score	that	includes	CRP	[72,	75]	or	the	QRISK	II	score	[76]	that	includes	
diagnosis	of	RA	as	a	risk	factor	have	not	been	validated	in	RA	patients	either.		
	
In	conclusion,	there	 is	a	growing	body	of	evidence	that	not	only	supports	the	notion	that	CVD	
substantially	contributes	to	premature	mortality	in	RA	patients,	but	also	leads	to	the	hypothesis	
that	 the	 CVD	 risk	 profile	 of	 RA	 patients	 significantly	 differs	 from	 the	 general	 population,	
questioning	the	validity	of	existing	risk	management	strategies	for	the	prevention	of	CVD.	There	
is	a	need	for	evidence	based	guidelines	for	the	management	of	CVD	risk	in	RA	patients	that	specify	
targets	for	CVD	prevention	and	risk	estimation	in	this	population.	
Outline	thesis	
Overall	 the	 purpose	 of	 this	 thesis	 is	 to	 further	 support	 the	 formation	 of	 evidence	 based	
recommendations	for	CVD	risk	management	strategies	in	the	RA	population.	The	main	focus	of	
this	thesis	will	be	on	the	analysis	of	CVD	risk	prediction	in	RA	and	on	contributing	to	the	definition	
of	the	CVD	risk	profile	in	RA	patients.	More	specifically,	in	this	thesis,	the	performance	of	CVD	risk	
prediction	models	is	evaluated	in	RA	patients	and	the	added	value	of	RA-related	risk	factors	as	
predictors	of	CVD	risk	are	 investigated.	This	thesis	aims	to	shed	more	light	on	the	relationship	
between	disease	activity	and	CVD.	To	investigate	CVD	in	RA,	long-term	follow-up	is	often	required	
as	it	generally	takes	years	to	develop	CVD.	Also,	data	on	CVD	risk	factors,	comorbidity	and	detailed	
follow-up	 data	 that	 includes	 disease	 activity	 is	 needed.	 In	most	 existing	 RA	 cohorts,	 data	 on	
traditional	CVD	risk	factors	are	not	routinely	acquired.	For	this	thesis,	almost	all	of	the	necessary	
data	could	be	extracted	from	the	Nijmegen	inception	cohort	database,[77]	with	the	exception	of	
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lipid	levels	that	were	not	determined	at	baseline.	Instead,	stored	serum	samples	were	available	
for	the	determination	of	cholesterol	 levels,	but	the	integrity	of	these	samples	may	be	affected	
after	frozen	storage.	Literature	regarding	this	issue	is	limited,	particularly	when	it	involves	long-
term	 storage.	 Therefore,	 in	 Chapter	 2,	 the	 effect	 of	 long-term	 storage	 on	 the	 validity	 of	
cholesterol	 measurements	 using	 stored	 serum	 samples	 is	 investigated.	 In	 Chapter	 3,	 the	
predictive	performance	of	four	current	risk	algorithms	(FRS,	SCORE,	Reynolds	risk	score,	Q-Risk	II)	
used	for	the	estimation	of	the	10-year	risk	of	CVD	in	the	general	population	is	evaluated.	These	
risk	models	form	the	basis	of	widely	propagated	CVD	risk	management	guidelines	used	in	both	
the	US	and	Europe.	However,	they	have	not	yet	been	validated	in	an	RA	population.	Next,	disease	
specific	risk	factors	are	investigated	in	order	to	further	define	the	CVD	risk	profile	of	RA	patients,	
focusing	particularly	on	the	effects	of	inflammation	on	the	risk	of	CVD.	Inflammation	appears	to	
affect	lipoprotein	patterns	found	in	RA	patients.	Both	the	concentration	and	function	of	certain	
lipoproteins	 appear	 to	 be	 modulated	 under	 the	 influence	 of	 inflammation.[57,	 60,	 78-80]	 In	
Chapter	4,	the	effect	of	inflammation	on	the	composition	of	HDL-c	is	determined	in	patients	with	
RA.	 Evidence	 suggests	 that	 chronic	 inflammation	 may	 lower	 HDL-c	 levels.[57,	 79]	 Also,	
inflammation	may	alter	or	even	diminish	the	beneficial,	anti-atherogenic	properties	of	HDL-c,[58-
60]	possibly	by	affecting	HDL	composition.	Furthermore,	TC	and	HDL-c	are	of	particular	interest	
as	the	TC:HDL-c	ratio	or	atherogenic	index	(AI)	is	used	in	most	CVD	risk	algorithms.	The	AI	is	the	
ratio	of	the	“bad”	cholesterol	(TC)	versus	the	“good”	cholesterol	(HDL-c).	The	concentrations	of	
these	 two	 types	 of	 cholesterol	 seem	 to	 rise	 and	 fall	 in	 the	 same	 direction,	 subsequent	 to	
fluctuations	in	disease	activity	during	the	course	of	RA.[81,	82]	This	phenomenon	has	led	to	the	
hypothesis	 that	 the	AI	 is	 less	 susceptible	 to	 changes	 in	disease	activity.	 To	 clarify	 this	 issue,	 a	
systemic	review	of	the	available	literature	was	performed,	focusing	on	the	relationship	between	
therapy	with	biological	disease	modifying	anti-rheumatic	drugs	(DMARDs)	and	its	effect	on	the	
AI.	This	review	is	presented	in	Chapter	5.	Disease	activity	has	been	suggested	as	an	important	
disease	specific	risk	factor	for	CVD	in	RA.	Particularly	patients	with	poorly	controlled	disease	over	
time	are	exposed	to	long-term	systemic	inflammatory	activity	which	could	increase	CVD	risk	in	
these	patients.	However,	this	hypothesis	is	primarily	based	on	research	focusing	on	the	effect	of	
inflammation	on	atherosclerosis.	Also,	the	effect	of	disease	duration	on	the	risk	of	CVD	during	
long-term	 follow-up	 requires	 further	 clarification.	Therefore,	 the	effect	of	disease	activity	and	
disease	duration	on	the	risk	of	“hard”	CVD	outcomes	was	investigated	in	Chapter	6.	Effective	anti-
rheumatic	 treatment	 seems	 to	 reduce	 CVD	 morbidity	 and	 mortality.[67,	 83-85]	 Treatment	
strategies	 aimed	 at	 significant	 reduction	 or	 even	 complete	 (clinical)	 eradication	 of	 the	
inflammatory	auto-immune	response	(i.e.	remission)	in	RA	may	reduce	CVD	risk	even	further.	In	
Chapter	 7,	 the	 effect	 of	 low	disease	 activity	 and	 remission	 over	 time	on	 the	 risk	 of	 CVD	was	
investigated.	Finally,	this	thesis	focuses	on	the	development	of	a	CVD	risk	model	specifically	suited	
for	use	in	RA	patients.	In	Chapter	8,	the	SCORE	risk	model	was	recalibrated	and	adapted	for	use	
in	 the	 RA	 population,	 integrating	 disease	 specific	 risk	 factors	 into	 the	 model.	 The	 predictive	
performance	of	this	adaptation	was	evaluated	and	compared	to	the	original	SCORE	algorithm.	A	
comprehensive	discussion	of	our	findings	and	recommendations	for	future	research	are	provided	
in	the	general	discussion	in	Chapter	9.	A	summary	of	all	results	and	the	conclusions	of	this	thesis	
are	presented	in	Chapter	10	&	11.		
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CHAPTER	2	
Serum	samples	that	have	been	stored	long-term	(>10	years)	are	
a	suitable	data	source	for	developing	cardiovascular	risk	
prediction	models	in	large	observational	rheumatoid	arthritis	
cohorts	
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ABSTRACT	
Objective		
There	is	an	unmet	need	for	a	specific	cardiovascular	risk	(CV)	algorithm	for	rheumatoid	arthritis	
(RA)	patients.	Often,	data	on	lipoproteins	are	not	available	in	RA	cohorts	but	could	be	obtained	
from	frozen	blood	samples.	The	objective	of	this	study	was	to	estimate	the	storage	effect	on	
lipoproteins	in	long-term	(>10	years)	frozen	serum	samples.		
Methods	
Data	were	used	from	an	inception	RA	cohort.	Multiple	serum	samples	from	152	patients	were	
analyzed	for	lipoproteins,	being	frozen	for	1–26	years	at	−20	C.	Storage	effect	on	lipoproteins	
was	estimated	using	longitudinal	regression	analyses	and	a	lipid	decay	correction	factor	was	
developed.	Clinical	impact	of	the	storage	effect	on	lipoproteins	was	assessed	by	calculating	the	
number	of	patients	reclassified	to	another	CV	risk	group	according	to	the	SCORE	risk	calculator	
after	applying	the	decay	correction	factor.		
Results	
There	was	a	significant	effect	of	storage	time	on	total	cholesterol	(TC)	(p<0.001)	and	high	
density	lipoprotein	cholesterol	(HDL-c)	levels	(p<0.001),	not	LDL-c	(p=0.83).	The	lipid	decay	
correction	factor	was	0.03	mmol/L	and	0.02	mmol/L	per	additional	year	of	storage	for	TC	and	
HDL-c,	respectively.	The	TC:HDL	ratio	decreased	after	correction	for	storage	effect.	After	
correction,	5%	of	patients	were	reclassified	to	another	CV	risk	group.		
Conclusion	
A	modest	storage	decay	effect	on	lipoproteins	was	found	that	is	unlikely	to	significantly	affect	
CV	risk	stratification.	Serum	samples	that	have	been	stored	long-term	(>10	years)	can	be	used	
to	obtain	valid	lipid	levels	for	developing	CV	risk	prediction	models	in	RA	cohorts,	even	without	
applying	a	decay	correction	factor.	
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INTRODUCTION	
Cardiovascular	 risk	 is	 increased	 in	 patients	 with	 rheumatoid	 arthritis	 (RA).[1]	 Cardiovascular	
disease	 (CVD)	accounts	 for	50%	of	all	excess	mortality	 in	RA	patients.[1]	RA	 itself	as	a	chronic	
inflammatory	condition	may	increase	CVD	risk.	Also,	studies	have	shown	that	inflammation	may	
modulate	traditional	CVD	risk	factors.[2,	3]	Atherosclerotic	plaques	in	the	carotid	artery	appear	
more	 severe	 and	 prevalent	 in	 RA	 patients	 compared	 to	 the	 general	 population.[4–7]	 In	
comparison	to	healthy	controls	and	RA	patients	in	remission,	RA	patients	with	active	disease	seem	
to	have	less	stable	plaques	that	are	more	vulnerable	to	rupture,	which	increases	the	probability	
of	 a	 cardiovascular	 event.	 Considering	 the	 increased	 risk,	 prevention	 of	 CVD	 is	 important.	
According	 to	 international	 guidelines	 this	 includes	 adequate	 risk	 assessment	 using	 a	 CVD	 risk	
algorithm.	Several	risk	algorithms	are	available	in	the	general	population,	such	as	the	systematic	
coronary	risk	evaluation	(SCORE)	and	the	Framingham	risk	score	[9,	10]	which	were	not	validated	
in	RA	patients.	As	traditional	risk	factors,	upon	which	these	models	are	based,	do	not	fully	account	
for	the	excess	CVD	risk,	 their	predictive	performance	may	be	suboptimal.	 It	has	recently	been	
reported	that	both	the	SCORE	and	Framingham	risk	score	algorithm	provide	suboptimal	CVD	risk	
estimates	 in	patients	with	RA.[11,	12]	To	 improve	CVD	risk	assessment	 in	RA	patients,	disease	
specific	risk	factors	may	be	required	such	as	RA	disease	activity.	Also,	other	cardiovascular-related	
parameters	not	incorporated	in	the	present	algorithms,	such	as	carotid	artery	intima-media	index	
(cIMT),	the	presence	of	plaques	in	these	patients,	or	certain	genetic	markers	associated	with	CVD	
risk	 factors,	might	 also	 be	 taken	 into	 consideration.[13–17]	 There	 is	 an	 unmet	 need	 for	 a	 RA	
specific	CVD	risk	calculator.	In	order	to	evaluate	current	risk	models	and	develop	and	validate	an	
RA	specific	CVD	risk	model,	it	would	be	advantageous	to	use	data	from	existing	cohorts	with	long	
follow-up.	 In	existing	cohorts	of	RA	patients,	 lipid	 levels	are	often	not	determined	at	baseline.	
Long-term	 storage	 may	 lead	 to	 degradation	 of	 cholesterol,	 that	 is,	 a	 lipid	 decay	 effect.	
Consequently,	if	lipids	were	to	be	measured	in	samples	that	have	been	stored	for	longer	periods	
of	time,	cholesterol	levels	could	be	underestimated.	Furthermore,	if	these	measurements	were	
used	in	CVD	risk	algorithms,	the	result	may	be	an	underestimation	of	CVD	risk.	Within	a	timeframe	
of	1-2	years	of	storage,	no	change	to	moderate	decreases	in	lipid	levels	have	been	reported,[18–
20]	as	well	an	increase	of	high	density	lipoprotein	cholesterol	(HDL-c)	levels.[21,	22]	Lipid	decay	
seems	to	be	smaller	at	lower	temperatures.[18–20]	This	has	led	to	the	hypothesis	that	the	HDL-c	
concentration	 influences	 the	 effect	 of	 storage	 on	 lipoproteins.[23]	Overall,	 the	 storage	 decay	
effect	in	total	cholesterol	(TC)	and	triglyceride	(TG)	levels	seems	smaller	when	stored	than	in	HDL-
c	levels.[24,	25]	One	study	has	investigated	the	effect	of	long-term	storage	on	cholesterol	levels	
for	up	to	seven	years	of	storage.	A	significant	mean	decrease	of	2.0%	per	year	storage	in	TC	levels	
and	a	nonsignificant	average	1.3%	decrease	per	year	storage	in	HDL-c	levels	were	reported.[26]	
To	our	knowledge,	the	effect	of	longer	storage	(>10	years)	on	serum	cholesterol	levels	has	not	
been	investigated.	Although	deterioration	of	cholesterol	content	in	stored	serum	samples	can	be	
expected,	the	magnitude	of	this	effect	after	long	periods	of	time	is	unknown.	The	objective	of	this	
study	is	to	estimate	the	long-term	storage	decay	effect	on	TC	and	HDL-c	levels	in	frozen	serum	
samples	of	RA	patients	and	to	evaluate	the	clinical	effect	of	the	decay	in	a	CVD	risk	model.	
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METHODS	
Study	Design	
Serum	samples	 taken	at	baseline	and	at	1,	2,	3,	5,	7,	and	10	years	of	 follow-up	 from	patients	
included	in	the	RA	inception	cohort	of	the	Radboud	University	Nijmegen	Medical	Centre,	from	
1985	up	 to	2009	 (!	=	640),	were	used	 for	measurements	of	 lipoproteins.	To	 test	 for	a	period	
effect,	 patients	were	 stratified	 in	 five	 subcohorts	 according	 to	 year	 of	 inclusion	 in	 the	 cohort	
during	1985–1989,	1990–1994,	1995–1999,	2000–2004,	and	2005–2009	 (Figure	1).	The	 study	
was	 approved	 by	 the	 Medical	 Ethical	 Committee	 and	 CMO	 Arnhem	 Nijmegen	 and	 informed	
consent	was	acquired	from	all	participants.	
	
	
	
	
	
	
	
	
Figure	1.	Storage	and	blood	sampling	times	for	the	5	subcohorts.	Symbols	represent	the	time	points	of	
the	included	selection	of	stored	serum,	during	follow-up	(baseline	and	year	1,	2,	3,	5,	7	and	10).	
	
Patients	
Inclusion	criteria	for	the	early	RA	cohort	were;	fulfillment	of	the	1987	ACR	classification	criteria	
for	RA,	disease	duration	<1	year,	and	being	DMARD	(disease-modifying	antirheumatic	drug)	naive.	
From	 this	 cohort,	 we	 selected	 at	 random	 150	 RA	 patients	 from	 the	 inception	 cohort	 using	
computer	generated	random	numbers,	to	obtain	30	samples	per	subcohort.	
Serum	Samples	
During	 follow-up,	 nonfasting	 blood	 samples	 were	 drawn	 annually	 by	 a	 trained	 nurse.	
Approximately	400	mL	of	serum	was	stored	from	each	sample	and	divided	into	four	separate	vials.	
The	 samples	were	 initially	 stored	 at	 −20	 C.	 In	 2008,	 all	 samples	were	 transferred	 to	 storage	
facilities	at	−80	C.	Blood	samples	collected	 from	2008	and	 thereafter	were	stored	directly	at	
−80	C.	Blood	samples	obtained	before	2007	were	stored	in	1.5	mL	Eppendorf	vials	and	samples	
obtained	after	2007	were	stored	using	Greiner	“pp	Cryovials.”	Serum	samples	that	were	taken	at	
baseline	 and	 during	 follow-up	 (at	 1,	 2,	 3,	 5,	 7,	 and	 10	 years)	were	 extracted	 from	 storage	 in	
January	 2012.	 Immediately	 following	 this	 procedure,	 samples	 were	 prepared	 for	 cholesterol	
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measurements	and	transported	on	dry	 ice	 to	 the	 laboratory	 facilities	of	Russells	Hall	Hospital,	
Dudley,	UK.	
Lipid	Measurements	
TC	concentrations	were	measured	enzymatically	by	means	of	the	VITROS	CHOL	slide	technique	
using	the	Triton	X-100	surfactant,	which	is	based	on	methods	described	previously.[27]	HDL-c	was	
measured	using	immunoturbidimetry.	Low-density-lipoprotein	cholesterol	(LDL-c)	was	calculated	
using	Friedewald’s	formula.[28]	
Statistical	Analysis		
The	primary	outcomes	were	systematic	differences	in	TC	and	HDL-c	levels	measured	in	the	most	
recently	stored	samples	and	measurements	from	samples	that	were	stored	 long-term	and	the	
secondary	outcome	was	the	difference	in	LDL-c	levels.	To	test	for	a	period	effect,	a	longitudinal	
regression	analysis	was	used	that	corrects	for	repeated	measurements	within	patients.	Lipid	level	
(TC	and	HDL-c)	was	the	dependent	variable	and	follow-up	time;	subcohort	(1985–1989,	1990–
1994,	 etc.)	 and	 an	 interaction	 term	 between	 follow-up	 time	 and	 subcohort	 were	 the	 main	
independent	variables.	As	the	course	of	cholesterol	levels	over	follow-up	time	was	nonlinear,	a	
quadratic	time	term	(time2)	was	included.	To	test	for	a	period	effect	in	the	course	of	cholesterol	
levels,	the	 interaction	between	subcohort	and	follow-up	time	was	evaluated.	Several	variables	
were	 considered	 as	 potential	 confounders:	 age,	 gender,	 statin	 use	 at	 baseline,	 BMI,	 smoking,	
blood	 pressure,	 28-joint	 disease	 activity	 score	 (DAS28),	 rheumatoid	 factor	 positivity,	 and	
glucocorticosteroid	use.	Variables	were	considered	confounders	if	their	addition	to	the	model	led	
to	 a	 >10%	 change	 in	 one	 of	 the	 subcohort	 follow-up	 time	 effects.	 For	 the	 development	 of	 a	
correction	factor	for	the	storage	decay	effect,	linear	mixed	models	were	used,	with	cholesterol	
level	 as	 the	dependent	variable,	 storage	 time	as	primary	 independent	 variable,	 and	 the	 same	
confounders	as	in	the	analyses	described	previously.	Storage	time	was	calculated	by	subtracting	
the	baseline	date	(date	the	blood	samples	were	first	frozen)	from	the	date	of	serum	analysis.	The	
storage	decay	correction	factor	developed	to	adjust	the	TC,	HDL-	c,	and	LDL-c	levels	was	defined	
as	the	estimated	change	in	mmol/L	cholesterol	("Chol)	per	additional	unit	of	storage	time	(years)	
multiplied	by	the	number	of	storage	years	(#)	of	a	particular	sample.	When	added	to	the	measured	
cholesterol	 level	 ("observed),	 it	 gives	 an	 estimate	 of	 the	 “original”	 cholesterol	 value	 ($).	
Therefore,	 the	 lipid	storage	decay	 factor	 is:	"observed	+	 ("Chol		#).	 In	order	 to	evaluate	 the	
clinical	effect	of	the	decay	in	CVD	risk	models,	reclassification	across	CVD	risk	groups	before	and	
after	correction	was	calculated.	The	SCORE	risk	algorithm	was	used	to	quantify	the	10-year	risk	
of	CVD	with	and	without	correction	for	the	storage	decay	effect.	The	CVD	risk	was	calculated	with	
and	without	correction	for	the	storage	decay	effect	on	lipids	for	all	1050	patients	from	the	RA	
inception	cohort.	Reclassification	of	patients	across	CVD	risk	groups	(low	<10%,	intermediate	10–
20%,	and	high	<20%)	was	calculated.	If	the	estimated	CVD	risk	of	a	patient	exceeds	10%,	primary	
prevention	 in	 the	 form	 of	 lifestyle	 changes	 or	 medical	 treatment	 is	 indicated	 according	 to	
European	guidelines	for	CV	prevention.[29]	
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RESULTS	
Patients	
One	hundred	and	fifty-two	patients	were	 included,	evenly	distributed	across	the	5	subcohorts	
(Table	1),	with	storage	 times	 ranging	 from	1	 to	26	years.	Samples	 from	the	oldest	 subcohorts	
comprised	the	longest	storage	times.	Serum	samples	from	seven	time	points	(0,	1,	2,	3,	5,	7,	and	
10	years)	were	analyzed	 if	available,	yielding	a	 total	of	971	samples.	Age,	gender,	 rheumatoid	
factor	(RF)	positivity,	DAS28,	use	of	statins	and	glucocorticosteroids	appeared	to	show	trends	over	
time	(Table	1).	
Table	1.	Patient	characteristics		
	 	 	 Subcohorts	
N=152	 1	(N=30)	
1985-1989	
2	(N=31)	
1990-1994	
3	(N=30)	
1995-1999	
4	(N=30)	
2000-2004	
5	(N=31)	
2005-2009	
Age	(years),	mean±SD	 51±14.4	 50±13.5	 52±14.5	 58±12.1	 59±12.6	
Female,	N(%)	 16	(53.3)	 19	(61.3)	 17	(56.7)	 25	(83.3)	 21	(67.7)	
RF	positive,	N(%)	 26	(86.7)	 23	(74.2)	 25	(83.3)	 23	(76.7)	 25	(80.6)	
DAS28,	mean±SD	 5.6±1.2	 5.3±1.4	 4.8±1.6	 4.9±1.0	 5.0±1.2	
BMI,	mean±SD	 26±3.8	 27.1±4.6	 25.6±3.3	 26.2±3.0	 26.6±6.8	
Smokers,	N(%)	 14	(46.7)	 6	(19.4)	 10	(33.3)	 9	(30.0)	 9	(29.0)	
Statin	use,	N(%)	 0	(0.0)	 0	(0.0)	 2	(6.7)	 2	(6.7)	 9	(29.0)	
Glucocorticosteroid	use,	N(%)	 3	(10.0)	 3	(9.7)	 5	(16.7)	 17	(56.7)	 17	(54.8)	
Baseline	lipoprotein	levels	
	TC	(mmol/L),	mean±SD	
	HDL-c	(mmol/L),	mean±SD	
	TC:HDL-c,	mean±SD	
	
4.2±1.2	
0.6±0.2	
7.2±1.9	
	
4.5±1.5	
0.9±0.3	
5.5±1.6	
	
5.4±1.0	
1.0±0.3	
5.9±1.4	
	
5.3±1.2	
1.1±0.2	
5.1±1.2	
	
5.2±1.2	
1.2±0.4	
4.5±1.2	
Treatment	during	follow-up	 	 	 	 	 	
	B-DMARDS,	N(%)	 9	(30.0)				 13	(41.9)								10	(33.3	 17	(56.7	 3	(9.7)	
I. Abbreviations:	RF,	rheumatoid	factor;	DAS28;	28-joint	disease	activity	score,	BMI:	body	
mass	index,	TC,	total	cholesterol;	HDL-c,	high-density-lipoprotein	cholesterol,	B-DMARDS;	
biological	disease	modifying	anti-rheumatic	drugs	
	
Differences	between	subcohorts	
Lipid	levels	measured	at	baseline	are	presented	in	Table	1.	Lipid	levels	tended	to	be	lowest	in	the	
subcohorts	 that	had	the	 longest	storage	time	(figure	2)	and	there	appeared	to	be	a	nonlinear	
course	 of	 lipid	 levels	 during	 storage	 time.	 The	 unadjusted	 results	 (not	 shown)	 revealed	 a	
significant	interaction	effect	between	subcohort	and	follow-up	time	for	TC	and	LDL-c	(p=0.02	and	
p=0.01,	resp.).	Overall,	the	course	of	the	various	lipoprotein	levels	over	time	was	not	significantly	
different	 between	 subcohorts	 after	 adjustment	 for	 confounders	 (age,	 gender,	 and	 BMI)	 with	
p=0.09,	p=0.05,	and	p=0.18	for	TC,	LDL-c,	and	HDL-c,	respectively.	Rheumatoid	factor	and	DAS28	
were	not	confounders	after	these	adjustments.	When	looking	specifically	at	the	oldest	and	most	
recent	cohort	(the	two	extremes	in	terms	of	storage	time),	lipid	levels	in	the	oldest	cohort	were	
systematically	 lower	 than	 lipid	 levers	 in	 the	 most	 recent	 subcohort;	 a	 statistically	 significant	
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difference	for	TC	and	LDL-c	(p=0.04	and	p=0.03)	and	a	nonsignificant	difference	for	HDL-c	(p=0.25)	
were	found	after	correction	for	confounders.	
Figure	 2.	 Lipoprotein	 levels	 measured	 in	 stored	 serum	 samples	 in	 the	 various	 subcohorts.	 Total	
cholesterol	(a)	and	HDL-c	(b)	are	depicted	on	the	$-axis.	Samples	taken	at	the	most	recent	follow-up	
moment	in	time,	time	point	“10”	on	the	%-axis,	have	the	shortest	follow-up	time	and	samples	taken	at	
baseline	(time	point	“0”)	have	been	stored	the	longest.	
	
Storage	time	
There	was	a	significant	decay	effect	of	storage	time	on	TC	and	HDL-c	levels	(p<0.001)	(Tables	2	
and	3).	No	effect	of	storage	time	was	found	for	LDL-c	levels	(p=0.83,	data	not	shown).	For	the	
analysis	for	TC	and	LDL-	c,	age,	gender,	BMI,	statin	use,	and	glucocorticosteroid	use	at	baseline	
were	confounders	and	were	adjusted	for	in	the	analysis.	For	HDL-c,	a	model	with	adjustment	for	
age	and	gender	sufficed.	As	a	significant	decay	effect	was	found	for	TC	and	HDL-c,	a	correction	
factor	was	estimated.	As	storage	time	increased,	a	decrease	(95%	CI)	was	observed,	−0.03	mmol/L	
(−0.045	to	0.015)	for	TC	and	−0.024	mmol/L	(−0.027	to	−0.021)	for	HDL-c	per	year	of	increasing	
storage	time.	The	decrease	in	HDL-c	levels	was	relatively	larger	(considering	the	range)	than	the	
decrease	in	TC	levels	at	same	length	of	storage.	The	TC:HDL-c	ratio	calculated	for	the	same	sample	
will	 therefore	 become	 higher	 as	 a	 direct	 result	 of	 increasing	 storage	 time	 and	 the	
disproportionate	decay	effect	on	TC	and	HDL-c.	This	lipid	decay	was	estimated	to	be	linear.	A	lipid	
decay	correction	factor	was	calculated	to	be	[y	=	observed	+	(Chol		t	)];	0.03	mmol/L	for	TC	and	
0.02	 mmol/L	 for	 HDL-c.	 Figure	 3	 illustrates	 the	 differences	 in	 the	 course	 of	 unadjusted	 and	
adjusted	cholesterol	levels.	
Clinical	Impact	of	the	Storage	Decay	Effect	on	Lipids		
The	storage	decay	effect	of	lipids	during	storage	affects	the	TC:HDL-c	ratio.	This	ratio	is	used	when	
calculating	 the	 10-year	 CVD	 risk	 of	 individual	 patients	 in	 a	 clinical	 setting.	 Patients	 are	 then	
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categorized	as	either	“low”	risk	(<10%	10-year	risk	of	a	CVD	event),	“intermediate”	risk	(10–20%	
10-year	risk	of	a	CVD	event),	or	“high”	risk	(>20%	10-year	risk	of	a	CVD	event).		
Table	2.	Effect	of	storage	time	(years)	on	total	cholesterol	(TC)	levels	
	 Estimate	 SE	 P-value	 95%	CI	
	 	 	 	 Lower	 Upper	
Constant	 3.41	 0.39	 <.001	 2.65	 4.17	
Storage	time	 −.03	 0.01	 <.001	 −.05	 −.02	
Time	within	patients	(follow-up)	 0.01	 0.00	 <.001	 0.00	 0.02	
Time2	(follow-up)	 −.00	 0.00	 <.001	 −.00	 −.00	
Gender	 0.02	 0.10	 0.81	 −.17	 −.21	
Age	 0.02	 0.04	 <.001	 0.09	 0.02	
Statin	use	at	baseline	 0.89	 0.19	 <.001	 0.52	 1.26	
BMI	 0.01	 0.01	 0.34	 −.01	 0.03	
Glucocorticosteroid	use	at	baseline	 0.24	 0.12	 0.04	 0.01	 0.47	
i. SE,	standard	error;	BMI,	body	mass	index;	and	95%	CI:	95%	confidence	interval.	
ii. Data	are	adjusted	for	age,	gender,	statin	use	at	baseline,	BMI,	and	glucocorticosteroid	use	
at	baseline.	
iii. Time2	is	a	quadratic	term	that	was	included	due	to	the	nonlinear	course	of	cholesterol	levels	
over	follow-up	time,	and	this	variable	also	represents	time	within	patients	(follow-up	time).	
	
Table	3.	Effect	of	storage	time	(years)	on	HDL-c	levels,	adjusted	results.	
	 Estimate	 SE	 P-value	 95%	CI	
	 	 	 	 Lower	 Upper	
Constant	 1.25	 0.06	 <.001	 1.14	 1.36	
Storage	time	 −.02	 0.00	 <.001	 −.03	 −.02	
Time	within	patients	(follow-up)	 0.00	 0.00	 <.001	 0.00	 0.00	
Time2	(follow-up)	 −.00	 0.00	 <.001	 −.00	 −.00	
Gender	 −.07	 0.02	 0.001	 -.1.2	 0.03	
Age	 <.00	 0.00	 0.001	 0.001	 0.004	
i. SE,	standard	error;	95%	CI,	95%	confidence	interval.	
ii. Data	are	adjusted	for	age,	gender,	and	time	within	patients2.	
	
As	a	result	of	the	storage	decay	effect	the	TC:HDL-c	ratio,	that	was	calculated	using	the	measured	
lipoprotein	 levels,	 increases	 as	 storage	 time	 increases.	 To	 better	 approximate	 the	 lipoprotein	
levels	 at	 the	 time	 the	 serum	 sample	 was	 taken,	 and	 the	 lipid	 decay	 correction	 factor	 was	
estimated.	Correction	 for	 the	 storage	decay	effect	will	 yield	 a	 lower	 (improved)	 TC:HDL	 ratio,	
which	reduces	the	calculated	CVD	risk.	After	applying	the	storage	correction	factor,	the	TC:HDL-c	
ratio	 decreased.	 Before	 correction,	 TC:HDL	 ratio	 was	 classified	 as	 high	 in	 75%	 of	 patients,	
compared	to	54%	after	correction	(not	shown).	After	correction,	patients	moved	to	lower	CV	risk	
groups,	as	the	TC:HDL-c	ratio	decreases	after	correction	for	the	storage	decay	effect	(Table	4).	
Before	correction,	most	patients	were	categorized	 in	 the	“low”	CVD	risk	group	(<10%)	and	53	
patients	were	reclassified	from	the	intermediate	and	high	risk	groups	to	this	group,	totaling	552	
patients	(a	relative	11%	increase)	after	correction.	The	intermediate	(10–20%)	and	high	(>20%)	
	 29	
CVD	risk	groups	decreased	 in	size	by	8%	and	11%	respectively.	Overall,	 in	 this	cohort	of	1050	
patients,	53	(5%)	patients	changed	CVD	risk	groups	according	to	SCORE	10-year	risk	predictions	
for	CVD.	
Figure	3.	Lipoprotein	levels	measured	over	time	in	the	various	subcohorts	before	and	after	correction	
with	the	lipid	decay	factor.	Mean	TC	and	HLD-c	levels	are	depicted	on	the	y-axis	and	follow-up	time	
on	the	x-axis	
	
Table	4.	Reclassification	of	the	10-year	risk	of	CVD	
10-year	risk	of	CVD		 Before	correction	for	
storage	decay	n(%)	
After	correction	for	
storage	decay	n(%)	
Reclassified	(N=53)	
Low	(<10%)		 499	(48%)	 552	(53%)	 +53	 (11%)	
Intermediate	(10-20%)	 178	(17%)	 164	(16%)	 −14	(8%)	
High	(>20%)	 373	(35%)	 334	(31%)	 -39	(11%)	
Total,	n(%)	 1050	(100%)	 1050	(100%)	 53	(5%)	
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DISCUSSION	
Our	study	is	the	first	to	investigate	the	validity	of	cholesterol	levels	obtained	in	serum	samples	
that	 have	 been	 stored	 for	 10	 years,	 and	 to	 evaluate	 if	 this	 storage	 decay	 effect	 is	 clinically	
important	for	CVD	risk	evaluation	in	RA	patients.	A	significant	but	modest	storage	decay	effect	on	
cholesterol	levels	was	found.	The	magnitude	of	this	effect	with	regards	to	CVD	risk	assessment	
appears	relatively	small.	Correction	factors	to	adjust	for	this	effect	were	calculated,	0.03	mmol/L	
for	 TC	 and	 0.02	mmol/L	 for	 HDL-c,	 per	 additional	 year	 of	 storage.	 Interestingly,	 the	 absolute	
changes	in	TC	and	HDL-c	per	additional	year	of	storage	in	this	cohort	lie	close	together.	This	means	
that	the	impact	of	this	storage	decay	effect	will	be	greater	for	HDL-c,	as	the	range	of	HDL-c	levels	
is	much	smaller	compared	to	TC	levels.	The	decay	effect	of	TC	levels	reported	in	this	study	is	less	
steep	than	the	decrease	in	HDL-c.	Therefore,	the	observed	TC:HDL-c	ratio	may	become	increased	
and	 lead	to	false-higher	CVD	risk	predictions.	 In	particular	 lipid	measurements	 in	samples	that	
have	undergone	long-term	storage	would	be	inaccurate,	which	could	eventually	lead	to	distorted	
risk	predictions	if	these	values	were	used	in	CVD	risk	assessment.	However,	clinical	impact	of	the	
storage	decay	effect	appears	to	be	minimal,	with	only	a	small	number	of	patients	(5%)	moving	
from	groups	indicated	for	primary	CVD	prevention	(either	the	intermediate	or	high	risk)	to	the	
low	risk	group	after	application	of	a	correction	factor.	Although,	on	an	individual	level,	changes	in	
absolute	 lipid	 levels	 may	 be	 relevant,	 these	 changes	 do	 not	 appear	 to	 significantly	 affect	
cardiovascular	risk	predictions	overall.	Therefore,	a	correction	factor	can	be	used	but	may	not	be	
necessary	if	samples	have	been	stored	under	stable	conditions.	Determining	whether	long-term	
storage	affects	the	integrity	of	lipid	samples	requires	analysis	of	long-term	data.	Ideally	one	would	
compare	 values	 determined	 in	 the	 past,	 directly	 after	 acquiring	 the	 blood	 sample	 (“original”	
values),	with	values	determined	 from	stored	samples	 (“observed”	values)	within	patients.	The	
differences	between	“original”	values	and	“observed”	values	provide	an	immediate	indication	of	
the	storage	effect.	Several	studies	have	used	this	approach	but	in	serum	samples	that	were	stored	
for	relatively	short	periods	of	1-2	years.[19,	20,	24,	25]	However,	measurements	of	lipids	directly	
after	blood	sampling	are	not	always	available	in	RA	cohorts.	This	may	be	due	to	the	fact	that	the	
awareness	of	the	increased	risk	of	CVD	gained	particular	interest	long	after	the	start	of	RA	cohorts.	
Hence	a	different	approach	is	required	to	assess	the	storage	decay	effect	on	lipid	levels	in	these	
cohorts.		
In	a	study	that	investigated	the	effect	of	long-term	storage	(7	years),[26]	the	group	means	of	lipids	
for	pairs	of	serial	specimens	that	were	taken	at	6-	and	12-month	intervals	were	compared.	It	was	
assumed	that	in	the	absence	of	a	storage	effect	the	variation	in	group	means	would	reflect	only	
normal	biological	variation,	which	would	not	lead	to	a	systematic	downward	or	upward	effect	in	
the	group	mean	cholesterol	levels.	Subsequently,	any	observed	changes	would	reflect	the	storage	
effect.[26]	However,	in	a	long	running	cohort	that	includes	a	lengthy	follow-up	of	more	than	10	
years,	 patients	 could	 also	 be	 systematically	 different	 between	 different	 time-periods.	 For	
example,	patients	that	were	included	more	recently	are	probably	more	likely	to	use	statins	at	the	
time	the	serum	samples	were	taken	than	patients	that	were	included	25	years	ago.	In	this	cohort,	
cholesterol	levels	from	samples	that	were	stored	the	shortest	could	therefore	be	systematically	
lower	than	samples	that	were	stored	the	longest,	without	involvement	of	a	storage	effect.	Such	
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a	period	effect	could	lead	to	biased	results.	Therefore,	we	used	a	method	in	which	the	data	were	
grouped	according	to	five	different	time-periods	for	analysis,	to	adjust	results	for	a	period	effect.	
Illustratively,	statin	use	at	baseline	increased	from	0%	in	the	first	three	subcohorts	(1985–1999)	
to	29%	in	the	last	cohort	(2005–2009).	The	percentage	of	smokers	decreased	from	47%	to	29%	
during	 that	 same	 timeframe.	 Overall,	 these	 subcohorts	 did	 not	 seem	 to	 differ	 significantly,	
excluding	 period	 effect	 as	 a	 confounder	 in	 this	 cohort.	 Consequently,	 a	 simplified	model	was	
developed.	The	methodology	used	in	this	study	can	also	be	applied	in	other	cohorts.	
This	study	has	limitations.	The	storage	effect	was	estimated	without	knowing	“original”	values	for	
comparison.	The	correction	factor	was	directly	derived	from	the	regression	coefficient	of	storage	
time.	 It	 was	 assumed	 that	 after	 correction	 for	 repeated	 measures	 and	 for	 confounders	 any	
observed	change	is	attributable	to	the	storage	effect.	Biological	variation	of	lipid	levels	within	a	
subject	could	potentially	contribute	to	the	found	decay	effect	over	time.	However,	several	(!	=	7)	
measurements	per	patient	were	included,	in	the	total	group	of	152	patients.	Serum	samples	had	
been	stored	under	similar	condition,	albeit	in	different	storage	facilities.	It	was	considered	unlikely	
that	any	variation,	either	due	to	biological	variation	within	patients	or	due	to	differing	storage	
circumstances,	would	contribute	to	an	overall,	systemic	trend.	It	has	been	previously	suggested	
that	such	variability	in	measured	cholesterol	levels	is	unpredictable	and	often	a	wide	variation	in	
both	directions	(±20%)	is	reported.[30,	31]	In	the	model	that	was	formulated,	the	most	important	
confounders	were	dealt	with,	but	the	existence	of	other	confounding	factors	cannot	be	excluded.	
Storage	conditions,	varying	temperatures	during	storage,	and	number	of	times	the	samples	were	
thawed	 are	 all	 factors	 that	 could	 have	 contributed	 in	 affecting	 serum	 cholesterol	 levels.	 As	
multiple	sets	of	samples	from	152	patients	were	used,	it	is	considered	unlikely	that	any	of	these	
highly	variable	factors	contributed	significantly	to	the	systemic	decay	effect	that	was	found.	In	
addition,	modifying	the	storage	temperature	from	−20C	to	−80C	for	all	serum	samples	in	2008	
is	 a	 limitation,	 although	 the	vast	majority	of	 the	 samples	 (1985–2007)	were	 stored	under	 the	
same	conditions.	Storage	effects	are	likely	to	be	even	smaller	with	lower	temperatures.	
In	conclusion,	the	results	of	this	study	show	that	modest	decay	of	lipid	levels	in	serum	samples	
should	be	expected	during	 long-term	(>10	years)	storage.	Using	the	method	proposed	here,	a	
correction	factor	can	be	formulated	to	adjust	for	this	storage	decay	effect.	However,	as	the	clinical	
impact	on	CV	predictions	appears	minimal,	extensive	adjustment	may	not	be	necessary	to	obtain	
valid	lipid	levels.	Hence,	stored	serum	samples,	even	when	stored	for	long	periods	of	time,	are	a	
valuable	 source	of	data.	These	data	can	be	of	particular	 importance	 for	 studies	 in	RA	cohorts	
involving	 long-term	outcomes	such	as	cardiovascular	disease.	 In	addition,	 it	may	be	 financially	
attractive	 to	minimize	 the	 analysis	 period	 by	 performing	 cholesterol	measurements	 in	 stored	
serum	samples	all	at	once	at	the	end	of	a	long-term	study	with	multiple	samples	taken	over	long	
periods	of	time.	It	is	recommended	to	employ	the	method	presented	in	this	study	in	other	long-
term	cohorts.	
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ABSTRACT		
Objective		
This	study	was	undertaken	to	assess	the	predictive	ability	of	four	established	cardiovascular	risk	
models	 for	 the	 10-year	 risk	 of	 fatal	 and	 non-fatal	 cardiovascular	 disease	 (CVD)	 in	 European	
patients	with	rheumatoid	arthritis	(RA).		
Methods		
Data	 from	 the	Nijmegen	early	 rheumatoid	 arthritis	 inception	 cohort	was	used.	Discriminatory	
ability	 for	 CVD	 risk	 prediction	 was	 estimated	 by	 the	 area	 under	 the	 receiver	 operating	
characteristic	 curve.	 Calibration	 was	 assessed	 by	 comparing	 the	 observed	 versus	 expected	
number	of	events	using	Hosmer-Lemeshow	tests	and	calibration	plots.	Sensitivity	and	speciﬁcity	
were	calculated	for	the	cut-off	values	of	10%	and	20%	predicted	10-year	risk	of	CVD.		
Results		
Areas	under	the	receiver	operating	characteristic	curve	were	0.78–0.80,	indicating	moderate	to	
good	discrimination	between	patients	with	and	without	CVD.	The	CVD	risk	models	Systematic	
Coronary	 Risk	 Evaluation	 (SCORE),	 Framingham	 risk	 score	 (FRS)	 and	Reynolds	 risk	 score	 (RRS)	
primarily	 underestimated	 CVD	 risk	 at	 low	 and	 middle	 observed	 risk	 levels,	 and	 mostly	
overestimated	 CVD	 risk	 at	 higher	 observed	 risk	 levels.	 The	 QRisk	 II	 primarily	 overestimated	
observed	 CVD	 risk.	 For	 the	 10%	 and	 20%	 cut-off	 values,	 which	 are	 used	 as	 indicators	 for	
preventive	treatment,	sensitivity	ranged	from	68–87%	and	40–65%,	respectively	and	speciﬁcity	
ranged	from	55–76%	and	77–88%,	respectively.	Depending	on	the	model,	up	to	32%	of	observed	
first	time	CVD	occurred	in	patients	with	RA	who	were	classiﬁed	as	low	risk	(<10%)	for	CVD.		
Conclusions		
Established	 risk	 models	 generally	 underestimate	 (Systematic	 Coronary	 Risk	 Evaluation	 score,	
Framingham	Risk	Score,	Reynolds	risk	score)	or	overestimate	(QRisk	II)	CVD	risk	in	patients	with	
RA.	
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INTRODUCTION	
Cardiovascular	disease	(CVD)	risk	models	are	informative	tools	guiding	preventive	or	therapeutic	
strategies	by	providing	estimations	of	CVD	risk.[1–5]	In	patients	with	rheumatoid	arthritis	(RA),	
the	 risk	 of	 CVD	 is	 increased	 and	 screening	 of	 CVD	 risk	 factors	 and	 identiﬁcation	 of	 high-risk	
patients	is	warranted.[6]	Risk	algorithms	developed	for	the	general	population	do	not	necessarily	
perform	well	 in	the	RA	population,	and	may	underestimate	the	 increased	risk	 in	RA.	The	most	
widely	used	risk	algorithms	are;	the	Framingham	risk	score	(FRS),	the	Systematic	Coronary	Risk	
Evaluation	score	(SCORE),	the	Reynolds	risk	score	(RRS)	and	the	QRisk	II	risk	score.	The	FRS	has	
been	developed	and	validated	in	American	cohorts,[7]	including	the	General	Cardiovascular	Risk	
Proﬁle	algorithm,	which	 is	 the	FRS	adjusted	to	calculate	the	10-year	risk	of	 fatal	and	non-fatal	
CVD.[2]	The	original	SCORE	was	developed	and	validated	in	12	European	cohorts	to	predict	fatal	
CVD.[1]	Country-speciﬁc	versions	of	the	SCORE	were	developed	to	optimize	prediction	of	the	10-
year	risk	of	CVD.[8,	9]	SCORE	and	FRS	are	based	on	traditional	risk	factors.	However,	in	patients	
with	RA	CVD	risk	 is	not	fully	explained	by	these	factors.[10]	 Inﬂammation	may	account	for	the	
extra	 risk.[11]	 In	 the	 general	 population,	 inﬂammation	 has	 been	 shown	 to	 be	 an	 important	
independent	 risk	 factor	 for	 CVD.[12]	 The	 RRS	 incorporates	 the	 inﬂammatory	 marker	 high-
sensitivity	C	reactive	protein	(hs-CRP)	 in	addition	to	traditional	risk	factors.[4,	5]	However,	 it	 is	
unclear	if	adding	an	inﬂammatory	marker	such	as	hs-CRP	to	a	CVD	risk	algorithm	improves	the	
predictive	performance	in	RA,	as	patients	with	RA	may	retain	high	levels	of	CRP	during	the	course	
of	the	disease.	The	European	League	Against	Rheumatism	(EULAR)	recommendations	for	CVD	risk	
management	[13]	recommend	the	use	of	a	multiplication	factor	of	1.5	to	the	risk	estimate	of	the	
SCORE	(a	modiﬁed	score,	or	M-SCORE)	when	a	patients	fulﬁls	two	out	of	three	criteria;	disease	
duration	>10	years,	rheumatoid	factor	or	anticyclic	citrullinated	peptide	positivity	and	presence	
of	 extra-articular	 manifestations.	 Recently,	 an	 updated	 version	 of	 the	 QRisk	 algorithm	 was	
developed	by	Hippisley-Cox	et	al.[3]	This	QRisk	II	algorithm	includes	RA	as	an	independent	risk	
factor.	However,	it	is	not	known	whether	the	M-SCORE,	RRS	and	QRisk	II	risk	algorithms	predict	
future	 CVD	 in	 patients	 with	 RA	 more	 accurately	 compared	 with	 the	 SCORE	 or	 the	 FRS.	 The	
predictive	performance—that	is,	the	accuracy	of	predictions	of	future	CVD	event(s)—of	these	risk	
algorithms	has	not	been	evaluated	and	compared	in	European	patients	with	RA.	Therefore,	the	
objective	 of	 this	 study	 is	 to	 assess	 the	 performance	 of	 four	 established	 CVD	 risk	 algorithms	
(SCORE,	 FRS,	 RRS	 and	 QRiskII)	 for	 predicting	 the	 10-year	 risk	 of	 fatal	 and	 non-fatal	 CVD	 in	
European	patients	with	RA.	
	
METHODS	
Study	design	and	patients	
This	retrospective	study	is	based	on	largely	prospective	collected	data	from	the	Nijmegen	early	
RA	inception	cohort.	Patients	were	included	at	diagnosis	of	RA	(baseline)	in	the	outpatient	clinic	
of	the	departments	of	rheumatology	of	the	Radboud	University	Medical	Centre	(since	1985)	or	
the	Maartenskliniek	in	Nijmegen	(since	1990).	At	inclusion,	patients	had	a	disease	duration	of	<1	
year,	were	disease	modifying	antirheumatic	drug	naive	and	fulﬁlled	the	1987	American	College	
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of	Rheumatology	(ACR)	(inclusion	before	2010)	or	ACR/EULAR	2010	criteria	(inclusion	after	2010)	
for	the	classiﬁcation	of	RA.[14]	All	patients	provided	written	informed	consent.	Patients	with	a	
history	of	CVD	before	inclusion	were	excluded	from	our	analysis.	All	four	algorithms	evaluated	in	
this	study	can	be	used	to	calculate	the	10-year	risk	of	CVD.	Predicted	risk	estimates	in	patients	
with	a	follow-up	time	<10	years	were	adjusted	proportionally,	according	to	the	length	of	actual	
follow-up	and	calculated	as	a	proportion	of	10	years.[15]	
Data	collection	
Baseline	characteristics	were	retrieved	from	the	cohort	database	including;	age	(years),	gender	
(male/female),	 rheumatoid	 factor	 positivity,	 anticyclic	 citrullinated	 peptide	 positivity,	 28-joint	
disease	 activity	 score	 and	CRP	 (mg/L).	Data	on	CVD	 risk	 factors	 at	 baseline	were	 collected	by	
medical	chart	and	electronic	patient	ﬁle	review,	including	smoking	status	(Y/N),	blood	pressure	
(mm	Hg),	use	of	statins	(Y/N)	and	antihypertensive	medication	(Y/N),	height	(m)	and	weight	(kg),	
diabetes	mellitus	 (Y/N),	 hypertension	 (Y/N)	 and	 family	 history	 of	 CVD	 (Y/N).	 Lipid	 levels	were	
measured	using	serum	from	frozen	samples	collected	at	baseline.	Non-fasting	total	cholesterol	
(TC)	and	high-density-lipoprotein	cholesterol	 (HDL-c)	 concentrations	 (mmol/L)	were	measured	
using	laboratory	facilities	of	Russells	Hall	Hospital,	Dudley	UK.	
Primary	outcome	
The	primary	outcome	is	first	time	CVD(fatal	and	non-fatal),	which	was	retrieved	from	physician	
diagnosis	 and	 extensive	 review	 of	 medical	 charts	 and	 electronic	 patient	 ﬁles.	 Included	
cardiovascular	 events	 were:	 acute/unstable	 coronary	 syndrome	 (myocardial	 infarction	 and	
unstable	 angina	 pectoris),	 stable	 angina	 pectoris,	 cerebral	 vascular	 accident	 (CVA),	 transient	
ischaemic	attack,	peripheral	vascular	disease	and	heart	failure.	Deaths	due	to	CVD	were	veriﬁed	
from	death	certiﬁcates,	provided	by	Statistics	Netherlands,[16]	including	deaths	due	to	CVD	and	
CVA	but	excluding	cerebral	hemorrhage	and	non-coronary	cardiac	death	(i.e.,	arrhythmias).	As	
every	CVD	risk	model	has	 its	own	set	of	predicted	outcomes,	four	separate	outcome	variables	
were	constructed	speciﬁcally	adjusted	to	ﬁt	the	models.	
Risk	algorithms	
All	risk	algorithms	included	gender,	smoking,	TC:HDL-c	ratio	and	systolic	blood	pressure.	The	10-
year	general	FRS	for	CVD	[2]	the	SCORE	[9]	and	RRS[4,	5]	were	calculated	using	the	published	risk	
algorithms.	The	SCORE	that	was	used	is	the	Dutch	version	adapted	to	predict	fatal	and	non-fatal	
CVD.[9,	17]	The	QRisk	II	risk	algorithm	also	includes	diabetes	(Y/N),	atrial	ﬁbrillation	(Y/N),	blood	
pressure	treatment	(Y/N),	RA	(Y/N),	body	mass	index	(weight	(kg)/height	(m)2),	family	history	of	
CVD,	chronic	kidney	disease	and	the	Townsend	deprivation	score.[3]	The	latter	was	not	available	
in	our	cohort.	Therefore,	CVD	risk	was	calculated	using	an	adjusted	QRisk	II	algorithm	excluding	
this	variable,	courtesy	of	ClinRisk.	The	M-SCORE	was	considered	but	not	included	because	in	this	
inception	cohort	it	would	apply	only	to	a	very	small	number	of	patients	(n=23).	
Statistical	analysis	
Baseline	data	were	used	to	calculate	individual	estimates	of	the	10-year	CVD	risk	for	all	four	CVD	
risk	algorithms.	Missing	values	were	imputed	using	multiple	imputations	with	ﬁve	repetitions.	The	
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discriminatory	 ability	 of	 the	 four	 algorithms	was	 estimated	using	 the	 area	 under	 the	 receiver	
operating	characteristic	(ROC)	curve,	which	is	similar	to	the	concordance-statistic	(c-statistic).[18]	
An	 area	 under	 the	 ROC	 curve	 of	 1	 signiﬁes	 perfect	 discriminatory	 ability	 and	 an	 area	 of	 0.5	
indicates	the	prediction	model	does	not	perform	better	than	a	random	guess.	Calibration	was	
assessed	by	comparing	the	agreement	between	observed	and	predicted	(calculated	by	means	of	
the	CVD	risk	algorithms)	number	of	cardiovascular	events	(%)	in	groups	of	patients	stratiﬁed	in	
deciles	of	the	predicted	risk.	Hosmer-Lemeshow	(H-L)	tests	and	calibration	plots	were	used.	In	
the	 calibration	 plots,	 a	 line	was	 ﬁtted	 between	 the	 observed	 and	 predicted	 probabilities	 of	 a	
cardiovascular	event	per	decile	of	predicted	risk	using	quadratic	spline.	Sensitivity	and	speciﬁcity	
were	calculated	for	the	cut-off	values	of	10%	and	20%	that	mark	the	difference	between	low-risk	
and	 intermediate-to-high	 risk	 and	 between	 low-intermediate	 risk	 and	 high-risk	 patients,	
respectively.	These	cut-off	points	are	 recommended	 in	guidelines	 to	be	used	as	 indicators	 for	
preventive	treatment;	lifestyle	adjustments	and	drug	therapy	interventions.	In	this	cohort,	regular	
CRP	was	measured,	but	values	<5	mg/L	were	not	quantiﬁed.	These	values	were	imputed	as	2.5	
mg/L.	A	sensitivity	analysis	was	performed	for	CRP	values	below	5	mg/L	using	either	0	or	5	as	
alternatives	for	values	<5	mg/L.	All	statistical	analyses	were	performed	using	SPSS	V.20.0.	
	
RESULTS		
Patients	
In	total,	1157	patients	were	enrolled	of	which	107	patients	experienced	a	CVD	event	prior	to	the	
diagnosis	of	RA,	leaving	1050	patients	with	9957	patient-years	for	analysis.	During	follow-up,	149	
patients	developed	a	ﬁrst	cardiovascular	event	(1.14	events	per	100	patient-years);	67	cases	of	
acute/unstable	coronary	syndrome	(myocardial	infarction	or	unstable	angina	pectoris),	24	cases	
of	stable	angina	pectoris,	26	CVAs,	10	transient	ischaemic	attacks,	18	cases	of	peripheral	vascular	
disease	and	4	cases	of	heart	failure.	Out	of	all	these	events,	15	were	fatal.	The	primary	outcome	
was	 adjusted	 to	 ﬁt	 each	 CVD	 risk	 algorithm,[2–5	 9]	 leaving	 104,	 149,	 87	 and	 126	 ﬁrst	
cardiovascular	events	for	analysis	of	SCORE,	FRS,	RRS	and	QRisk	II,	respectively.	As	the	RRS	is	not	
applicable	to	patients	with	diabetes,	these	patients	(n=44)	were	excluded,	leaving	a	total	of	1006	
patients	 for	 analysis	 of	 the	 RRS.	 Patient	 characteristics	 for	 all	 (n=1050)	 patients	 with	 RA	 are	
presented	in	table	1.	Missing	values	ranged	from	0.1%	to	10.3%	at	baseline	for	variables	included	
in	the	models.	
Discrimination	
Discriminatory	ability	was	comparable	across	 the	 four	CVD	risk	models.	Overall,	discriminative	
ability	was	good;	c-statistic	scores	of	0.78	(95%CI	0.74	to	0.82),	0.80	(95%	CI	0.77	to	0.84),	0.78	
(95%CI	 0.73	 to	 0.82)	 and	 0.79	 (95%CI	 0.75	 to	 0.83)	 for	 the	 SCORE,	 FRS,	 RRS	 and	 QRisk	 II,	
respectively.	The	corresponding	ROC	curves	are	presented	in	ﬁgure	1.	
Calibration	
Across	 deciles	 of	 predicted	 CVD	 risk	 there	 were	 discrepancies	 between	 the	 observed	 and	
predicted	(calculated	risk	scores)	number	of	cardiovascular	events	for	all	four	algorithms	(ﬁgures		
3	
Predictive	performance	of	four	CVD	risk	models	in	RA		
	 40	
Table	1.	Patient	characteristics		
	 All	patients	
(N=1050)	
No	CVD	
(N=901)	
CVD	
(N=149)	
p-value	
Age	(years),	mean±SD	 54±13.8	 53±13.9	 61±10.2	 <.001	
Female,	n(%)	 695	(66)	 616	(68)	 79	(53)	 <.001	
DAS28	at	baseline,	mean±SD	 4.9±1.3	 4.8±1.3	 5.4±1.3	 0.001	
Swollen	joint	count,	median	(	p25–p75)	 7	(5–12)	 7	(5–11)	 9	(6–14)	 0.002	
Tender	joint	count,	median	 (	p25–p75)	 5	(3–9)	 5	(3–9)	 7	(4–12)	 <.001	
ESR	 (mm/hour),	median	 (	p25–p75)	 25	(16–45)	 23	(16–44)	 34	(20–50)	 0.001	
CRP	(mg/L),	median	(	p25–p75)	 16	(3–42)	 15	(3–41)	 22	(5–47)	 0.078	
VAS	 (mm),	median	 (	p25–p75)	 41	(30–57)	 40	(29–55)	 50	(32–64)	 0.002	
Rheumatoid	 factor	 positivity,	n(%)	 777	(74)	 658	(73)	 118	(79)	 0.110	
Anti-CCP	positivity,	 n(%)	 681	(65)	 572	(64)	 91	(61)	 0.510	
Smoking	at	baseline,	n(%)	 332	(32)	 265	(29)	 60	(41)	 0.003	
BMI	 (weight(kg)/Height(m)
2
),	mean±S	 26±4.3	 26±4.4	 26±4.1	 0.038	
Systolic	blood	 pressure	 (mmHg),	mean±SD	 146±24	 145±24	 155±25	 <.001	
Diastolic	blood	pressure	 (mmHg),	mean±SD	 84±12	 83±12	 86±10	 0.004	
Total	cholesterol	 (mmol/L),	mean±SD	 5.1±1.2	 5.2±1.2	 5.3±1.4	 0.127	
HDL-cholesterol	 (mmol/L),	mean±SD	 1.3±0.3	 1.3±0.3	 1.2±0.3	 0.124	
TC:HDLc	 ratio,	mean±SD	 4.2±0.9	 4.1±1.1	 4.4±1.0	 0.010	
Diabetes	at	baseline,	n(%)	 44	(4)	 30	(3)	 14	(10)	 <.001	
Hypertension	at	baseline,	n(%)	 148	(14)	 110	(12)	 38	(26)	 <.001	
Treatment	with	antihypertensive	medication	
at	baseline,	n(%)	
	
172	(17)	
	
144	(16)	
	
37	(25)	
	
0.018	
Treatment	with	statins	at	baseline,	n(%)	 38	(4)	 28	(3)	 10	(7)	 0.061	
Family	history	 of	CVD,	n(%)	 326	(25)	 281	(31)	 53	(36)	 0.386	
SCORE	 (%),	median	 (	p25–p75)	 9	(3–28)	 7	(2–23)	 28	(11–48)	 <.001	
FRS	(%),	 median	(	p25–p75)	 13	(5–23)	 11	(5–20)	 23	(15–33)	 <.001	
RRS*	(%),	median	(	p25–p75)	 6	(2–17)	 5	(1–14)	 17	(7–30)	 <.001	
QRiskII	(%),	 median	(	p25–p75)	 14	(5–28)	 12	(4–25)	 27	(17–37)	 <.001	
I. For	RRS,	patients	with	diabetes	are	excluded;	n=1006.	
II. The	p-value	is	for	the	difference	between	patients	with	RA	with	and	without	CVD,	using	two-sample	t	test,	
two-sample	Wilcoxon	test	or	χ2	test,	as	appropriate.	
III. Anti-CCP,	anti-cyclic	citrullinated	peptide;	BMI,	body	mass	index;	CRP,	C	reactive	protein;	CVD,	cardiovascular	
disease;	DAS28,	disease	activity	score	28-joints;	ESR,	erythrocyte	sedimentation	rate;	FRS,	Framingham	risk	
score;	 HDL-cholesterol,	 high-density-lipoprotein	 cholesterol;	 RA,	 rheumatoid	 arthritis;	 RRS,	 Reynolds	 risk	
score;	SCORE,	Systematic	Coronary	Risk	Evaluation;	TC:HDL-c	ratio,	total	cholesterol:high-density	lipoprotein	
cholesterol	ratio;	VAS,	visual	analogue	scale.	
	
2	and	3).	CVD	risk	predictions	calculated	using	SCORE	appear	to	deviate	from	the	observed	CVD	
risk	in	the	middle	and	top	deciles,	particularly	when	CVD	risk	is	underestimated	(ﬁgures	2A	and	
3A).	 The	 H-L	 test	 yielded	 a	 p-value	 of	 <0.001,	 indicating	 poor	 model	 ﬁt.	 The	 number	 of	
cardiovascular	 events	 predicted	 by	 the	 FRS	 were	 similar	 to	 the	 observed	 number	 of	 events,	
showing	a	modest	difference	in	predicted	and	observed	CVD	risk	in	the	lower	and	middle	deciles.	
The	predicted	number	of	CVD	events	in	the	top	two	deciles	showed	a	more	pronounced	deviation	
from	the	observed	number	of	CVD,	under-	and	overestimating	CVD	risk.	The	H-L	test	indicated	
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poor	model	ﬁt	with	a	p	value	of	0.024	(ﬁgures	2B	and	3B).	Overall,	the	CVD	risk	as	predicted	by	
the	RRS	is	not	in	concurrence	with	the	observed	CVD	risk,	underestimating	the	number	of	events	
(ﬁgures	2C	and	3C),	with	an	overall	p-value	of	0.020	of	the	H-L	test	indicating	poor	model	ﬁt.	The	
QRisk	II	mainly	overestimated	observed	CVD	risk.	The	H-L	test	result	indicated	moderate	model	
ﬁt	with	a	p	value	of	0.20	(ﬁgures	2D	and	3D).	Overall,	the	number	of	CV	events	that	were	expected	
based	on	the	risk	calculated	by	these	algorithms	appeared	to	be	an	inaccurate	estimate	of	the	
observed	number	of	CVD	events	in	patients	with	RA.	
	
Figure	1.	Receiver	 operating	characteristic	(ROC)-curves	for	the	different	 risk	algorithms.	 Area	under	the	curve	
(AUC)-values	(95%	CI)	are	0.78	(0.74	to	0.82),	0.80	(0.77	to	0.84),	0.78	(0.73	to	0.82)	and	0.79	(0.75	to	0.83)	
for	the	Systematic	Coronary	 Risk	Evaluation	(A),	Framingham	risk	score	(B),	Reynolds	 risk	 score	(C)	and	QRisk	II	 (D),	
respectively.	
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Figure	2.	Observed	 (closed	 bars)	versus	 predicted	 (open	bars)	cardiovascular	 (CV)	 events	(%)	in	deciles	 of	
predicted	 risk,	for	the	Systematic	Coronary	Risk	Evaluation	(A),	Framingham	risk	score	(B),	Reynolds	(C)	
and	QRisk	II	(D)	risk	algorithm.		
	
Sensitivity	and	speciﬁcity	
Sensitivity	and	speciﬁcity	of	the	10%	and	20%	cut-off	points	for	CVD	risk	are	presented	in	table	2.	
Also	shown	in	this	table,	are	the	positive	and	negative	predictive	values.	The	negative	predictive	
value	ranges	from	92%	to	97%	depending	on	the	model	and	the	cut-off	point,	which	indicates	
that	 out	 of	 all	 patients	 classiﬁed	 as	 being	 ‘low	 risk’,	 a	 relatively	 small	 number	 of	 patients	 did	
develop	CVD.	When	considering	the	total	number	of	CVD	events,	varying	from	87–149	depending	
on	the	model,	up	to	24%	(SCORE)	and	32%	(RRS)	of	ﬁrst	CVD	events	occurred	in	patients	with	RA	
who	were	classiﬁed	as	‘low	risk’	(<10%).	
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Table	2.	Sensitivity	and	specificity	of	cut-off	points	in	CV	risk	scores	
	 True	
case	
(n)	
Positive	
test		
(n)	
True	
positive	
(n)	
False	
positive	
(n)	
False	
negative	
(n)	
True	
negative	
(n)	
Total	
(%)		
SENS	
(%)	
SPEC	
(%)		
PPV	
(%)	
NPV	
(%)	
SCORE	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 104	 410	 79	 331	 25	 615	 1050	 76	 65	 19	 96	
	>20%	 104	 247	 63	 184	 41	 762	 1050	 61	 80	 26	 95	
FRS	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 149	 487	 130	 357	 19	 544	 1050	 87	 60	 27	 97	
	>20%	 149	 144	 88	 161	 61	 740	 1050	 59	 82	 35	 92	
RRS	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 87	 284	 59	 255	 28	 694	 1006	 68	 76	 21	 96	
	>20%	 87	 144	 33	 111	 54	 808	 1006	 40	 88	 23	 94	
QRisk	II	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 126	 516	 106	 410	 20	 514	 1050	 84	 55	 21	 96	
	>20%	 126	 298	 82	 216	 44	 708	 1050	 65	 77	 28	 94	
i. True	cases	represent	all	CV	events	that	occurred,	using	the	criteria	for	each	individual	risk	score.		
ii. The	number	of	positive	tests	are	the	number	of	patients	who	are	classified	as	being	at	intermediate-high	or	
high	risk	(a	risk	score	of	>10%	or	>20%,	respectively)	for	CVD,	out	of	the	total	number	of	patients	with	RA.	
iii. 	As	the	RRS	is	not	applicable	to	patients	with	diabetes,	these	patients	(n=44)	are	excluded,	leaving	a	total	of	
1006	patients	for	analysis.		
iv. Sensitivity	 is	 calculated	 as	 the	 proportion	 of	 correctly	 classified	 patients	 given	 a	 positive	 result	 on	 the	
outcome	variable,	that	is,	proportion	of	patients	with	a	predicted	risk	>10%	or	>20%	out	of	all	the	patients	
who	experienced	an	event	(true	positive).	Specificity	 is	calculated	as	the	proportion	of	correctly	classified	
patients	given	a	negative	result	on	the	outcome	variable,	that	is,	proportion	of	patients	with	a	predicted	risk	
<10%	or	<20%	out	of	all	the	patients	who	did	not	have	an	event	(true	negative).	
v. 	CV,	cardiovascular;	CVD,	cardiovascular	disease;	FRS,	Framingham	risk	score;	NPV,	negative	predicting	value;	
PPV,	 positive	 predicting	 value;	 RA,	 rheumatoid	 arthritis;	 RRS,	 Reynolds	 risk	 score;	 SEN,	 sensitivity;	 SPEC,	
specificity;	SCORE,	Systematic	Coronary	Risk	Evaluation.	
	
	
DISCUSSION	
The	risk	estimations	from	the	four	evaluated	CVD	risk	algorithms	deviate	from	the	observed	risk;	
mainly	 overestimating	 (QRisk	 II)	 and	 underestimating	 (SCORE,	 FRS,	 RRS)	 the	 risk	 of	 future	 CV	
events	in	European	patients	with	RA.	This	underestimation	was	most	pronounced	in	the	lower	
two-thirds	 of	 predicted	 CVD	 risk,	 in	 line	with	 the	 underestimation	 of	 CVD	 by	 FRS	 and	 RRS	 in	
patients	with	RA	from	northern	America.[15]	Moreover,	the	low-to-intermediate	range	of	CVD	
risk	is	most	clinically	relevant,	as	preventive	interventions	are	recommended	if	CVD	risk	exceeds	
10%	or	20%.	The	risk	models	discriminated	relatively	well,	with	areas	under	 the	ROC	curve	of	
0.78–0.80,	indicating	moderate	to	good	discrimination	between	patients	with	and	without	CVD.	
Calibration	of	all	four	algorithms	was	poor	to	moderate,	particularly	in	the	clinically	relevant	low	
and	intermediate	ranges	of	risk.	Out	of	all	‘low	risk’	patients	a	relatively	small	number	of	patients	
developed	CVD.	However,	these	patients	still	accounted	for	up	to	32%	(RRS)	of	all	CVD	events	and	
as	these	patients	were	classiﬁed	as	‘low	risk’	(underestimation)	it	 is	unlikely	that	they	received	
sufficient	 preventative	 treatment.	 When	 comparing	 the	 predictive	 performance	 of	 the	 four	
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algorithms	 in	 patients	 with	 RA	 with	 the	 predictive	 performance	 reported	 in	 the	 general	
population,	discriminative	ability	appears	comparable.[3,	5,	9,	19]	However,	in	the	RA	population	
these	 models	 appear	 to	 perform	 less	 well	 in	 terms	 of	 calibration,	 considering	 the	 large	
discrepancy	between	observed	and	predicted	CVD	number	of	events	observed	in	this	study.	In	
the	Netherlands,	assessment	of	the	SCORE	risk	model	for	the	prediction	of	10-year	CVD	mortality	
and	morbidity	showed	a	slight	overestimation	of	CVD	risk	and	relatively	good	discriminative	ability	
with	a	 c-statistic	 score	of	0.75	 in	men	and	0.71	 in	women.[9]	 In	an	American	cohort,	 the	FRS	
showed	 relatively	 high	 discriminative	 ability	 (c-statistic	 score	 of	 0.76	 and	 0.79	 for	 men	 and	
women,	respectively)	and	good	calibration	(H-L	test	p	value	of	0.14)	indicating	moderate	model	
ﬁt.[2]	The	RRS	showed	good	discrimination	and	calibration	in	the	general	population	as	well,	with	
a	c-statistic	score	of	0.81	and	H-L	test	p-value	of	0.61.[4]	The	QRisk	II	algorithm	generated	similar	
results	 in	 a	 large	 British	 cohort	 with	 a	 c-statistic	 of	 0.79	 and	 0.82	 for	 men	 and	 women,	
respectively,	and	good	calibration.[3]	These	results	were	not	achieved	in	the	RA	population	of	this	
study.	This	is	in	concurrence	with	a	recent	study	by	Crowson	et	al,[15]	evaluating	the	RRS	and	FRS	
in	525	North	American	patients	with	RA	without	prior	CVD	reporting	that	both	risk	algorithms	
underestimated	CVD	risk.	The	relative	 importance	of	traditional	CVD	risk	factors	that	form	the	
foundation	of	these	algorithms	may	be	different	in	patients	with	RA.	The	selection	of	risk	factors	
and	the	relative	weight	of	each	factor	in	these	risk	algorithms	may	not	be	a	good	representation	
of	the	contributing	risk	factors	for	CVD	in	patients	with	RA.		
In	order	to	better	identify	patients	at	risk,	different	approaches	have	been	proposed.	First,	the	
cut-off	points	in	CVD	risk	used	as	indications	for	primary	prevention	could	be	adjusted.	However,	
this	could	also	lead	to	overtreatment	as	the	majority	of	patients	in	the	lower	risk	group	do	not	
develop	CVD.	Alternatively,	a	correction	factor	could	be	used	to	adjust	the	CVD	risk	in	patients	
with	RA,	as	was	suggested	by	the	EULAR	recommendations	for	CVD	risk	management.[13]	Few	
patients	in	this	cohort	fulﬁlled	two	out	of	the	three	criteria	(n=23)	as	none	of	the	patients	had	a	
disease	duration	>10	years	at	baseline,	and	this	model	was	therefore	not	regarded	for	analysis.	
Interestingly,	recent	data	suggests	that	patients	with	RA	may	have	similar	chances	to	develop	CVD	
early	and	late	in	their	disease	course.[20,	21]	Another	approach	is	the	addition	of	RA-speciﬁc	risk	
factors	to	the	risk	algorithm.	The	RRS	includes	CRP,	a	variable	indicative	for	disease	activity	in	RA.	
CRP	has	been	associated	with	atherosclerosis	and	CVD	in	the	general	population	and	in	the	RA	
population.[22–27]	Adding	this	variable	to	a	CVD	risk	model	could	therefore	improve	predictive	
performance.	However,	results	of	this	study	showed	that	the	RRS	provided	similar	or	slightly	less	
accurate	CVD	risk	predictions	in	patients	with	RA,	compared	with	other	models	that	do	not	include	
CRP.	 Regular	 CRP	 was	 used	 to	 calculate	 CVD	 risk	 with	 the	 RRS	 algorithm	 whereas	 hs-CRP	 is	
indicated,[4,	 5]	 which	 could	 have	 affected	 the	 predicted	 probabilities.	 However,	 sensitivity	
analysis	for	CRP	values	<5	mg/L	showed	no	different	outcomes	when	setting	these	values	at	either	
0	mg/L	or	5	mg/L	 (not	 shown).	 Future	 research	 is	necessary	 to	determine	whether	other	RA-
speciﬁc	baseline	 components	 that	better	 reﬂect	 future	disease	 activity	may	 improve	CVD	 risk	
prediction.	However,	simply	adding	disease	speciﬁc	parameters	may	not	be	sufﬁcient	to	boost	
model	 performance	without	 further	 adjusting	 the	 risk	 algorithm	 and	 its	 predictors	 to	 the	 RA	
population.	Interestingly,	the	FRS	which	was	developed	in	the	US	population,	appears	to	perform	
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better	than	SCORE	in	this	cohort	of	European	patients,	with	the	lowest	number	of	patients	falsely	
classiﬁed	as	being	‘low-risk’.	Whereas	the	included	risk	factors	and	predicted	outcomes	are	quite	
similar	between	the	SCORE	and	FRS,	the	relative	weights	attributed	to	the	different	risk	factors	
do	 differ	 between	 both	 risk	models.	 An	 explanation	 for	 these	 results	may	 be	 that	 the	 Dutch	
patients	with	RA	bear	a	better	resemblance	to	the	US	general	population	(with	an	increased	CVD	
burden	compared	with	the	Dutch)	than	to	the	Dutch	general	population,	in	terms	of	their	CVD	
risk	proﬁle.		
Several	strengths	and	weaknesses	of	this	study	should	be	considered.	The	hs-CRP	measurements	
were	 not	 available	 in	 this	 cohort	 which	 could	 have	 affected	 RRS	 performance.	 However,	 as	
described	in	the	previous	paragraph	regarding	the	sensitivity	analysis,	this	is	unlikely.	It	was	not	
possible	to	directly	compare	model	performance	between	this	RA	cohort	and	a	cohort	of	age-
matched	and	gender-matched	healthy	controls.	Further,	these	results	may	not	be	generalizable	
to	patients	with	long-standing	disease	as	an	inception	cohort	was	used.	Also,	the	adjustment	of	
risk	scores	in	patients	with	a	follow-up	<10	years,	may	provide	an	inaccurate	estimation	if	CV	risk	
changes	during	the	course	of	RA.	However,	evidence	from	our	cohort	suggests	the	risk	is	equal	
across	the	10	years.[28]	A	strength	of	this	study	is	the	prospective	data	collection	with	minimal	
missing	data.	This	study	compares	a	large	number	of	algorithms,	all	in	the	same	RA	cohort,	which	
provides	a	comprehensive	overview	of	CVD	risk	model	performance	in	patients	with	RA.		
In	 conclusion,	 the	 SCORE,	 RRS,	 FRS	 and	 QRisk	 II	 algorithms	 tend	 to	mainly	 underestimate	 or	
overestimate	 CVD	 risk	 in	 a	 large	 portion	 of	 the	 RA	 population	 and	 provide	 less	 accurate	
predictions	 of	 CVD	 risk	 in	 the	 RA	 population,	 compared	with	 results	 reported	 in	 the	 general	
population.	Underestimating	CVD	risk	may	lead	to	insufﬁcient	treatment	of	(traditional)	CVD	risk	
factors.	Perhaps,	a	RA-speciﬁc	CVD	risk	model	could	improve	CVD	risk	prediction	in	patients	with	
RA.	The	performance	of	a	RA-speciﬁc	CVD	risk	model	should	be	compared	to	the	performance	of	
the	current	risk	algorithms.	
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CHAPTER	4	
High-density	lipoprotein	cholesterol	subfractions	HDL2	and	HDL3	
are	reduced	in	women	with	rheumatoid	arthritis	and	may	
augment	the	cardiovascular	risk	of	women	with	RA:	a	cross-
sectional	study		
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ABSTRACT	
Introduction	
Higher	levels	of	high	density	lipoprotein	cholesterol	(HDL-c)	subfractions	HDL3-c	and	particularly	
HDL2-c	protect	against	cardiovascular	disease	(CVD),	but	inflammation	reduces	the	HDL-c	level	
and	may	 impair	 its	anti-atherogenic	effect.	Changed	HDL-c	composition	through	the	 impact	of	
inflammation	 on	 HDL-c	 subfractions	may	 contribute	 to	 the	 excess	 risk	 of	 CVD	 in	 rheumatoid	
arthritis	 (RA).	 In	 this	 study,	we	 investigated	whether	HDL2-c	and	HDL3-c	concentrations	differ	
between	RA	patients	and	healthy	controls,	and	whether	these	levels	are	related	to	the	level	of	RA	
disease	activity.	
Methods	
Non-fasting	blood	samples	were	collected	from	45	RA	patients	and	45	healthy	controls.	None	of	
the	participants	had	a	history	of	CVD,	diabetes,	or	used	lipid-lowering	drugs.	HDL2-c	and	HDL3-c	
concentrations	were	obtained	by	ultracentrifugation.	Regression	modeling	was	used	to	compare	
HDL-c	subfraction	levels	between	RA	patients	and	healthy	controls,	and	to	analyze	the	effect	of	
disease	activity	on	HDL2-c	and	HDL3-c.	
Results	
HDL2-c	and	HDL3-c	were	significantly	lower	in	RA	patients	compared	to	healthy	controls	(P	=	0.01,	
P	=	0.005,	respectively).	The	HDL2-c:HDL3-c	ratio	was	significantly	lower	in	patients	compared	to	
controls	 (P	 =	 0.04).	 Reduced	 HDL2-c	 and	 HDL3-c	 levels	 were	 primarily	 present	 in	 female	 RA	
patients	 and	 not	 in	male	 RA	 patients.	 A	modest	 effect	 of	 the	 28-joint	 disease	 activity	 score	 (	
DAS28)	 on	 HDL2-c	 concentrations	 was	 found,	 after	 correction	 for	 disease	 duration,	
glucocorticosteroid	use	and	body	mass	index	(BMI),	with	a	0.06	mmol/L	decrease	with	every	point	
increase	in	DAS28	(P	=	0.05).	DAS28	did	not	significantly	affect	HDL3-c	concentrations	(P	=	0.186).	
Conclusions	
	Both	HDL-c	subfractions	but	particularly	HDL2-c	concentrations	were	decreased	in	RA,	primarily	
in	women.	 This	 seems	 to	 be	 associated	with	 disease	 activity	 and	 is	 of	 clinical	 relevance.	 The	
reduction	of	the	HDL-c	subfraction	concentrations,	particularly	the	supposedly	beneficial	HDL2-
c,	may	negatively	impact	the	cardiovascular	risk	profile	of	women	with	RA.	
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INTRODUCTION	
Cardiovascular	 morbidity	 and	 mortality	 are	 increased	 in	 the	 rheumatoid	 arthritis	 (RA)	
population.[1-3]	The	risk	of	cardiovascular	disease	(CVD)	in	RA	is	approximately	two-	to	three-fold	
greater	than	in	the	general	population,	comparable	to	the	risk	of	patients	with	type	2	diabetes	
mellitus.[4]	As	traditional	risk	factors	do	not	fully	account	for	the	increased	CVD	risk	in	RA,	it	is	
suggested	 that	 inflammation	plays	an	 important	 role	 in	mediating	 cardiovascular	 risk	 in	 these	
patients.[5,6]	In	RA,	it	has	been	shown	that	inflammation	affects	the	lipid	profile	and	accelerates	
atherosclerosis.[7,8]	 However,	 it	 appears	 that	 there	 is	 no	 difference	 in	 risk	 of	 CVD	 between	
patients	with	low	or	high	disease	activity.[9]	Apparently,	low	levels	of	inflammation	are	sufficient	
to	increase	CVD	risk	in	RA.	In	the	general	population,	increased	levels	of	total	cholesterol	(TC),	
low-density-lipoprotein	cholesterol	(LDL-c)	and	triglycerides,	and	decreased	levels	of	high-	density	
lipoprotein	cholesterol	 (HDL-c)	or	a	pro-atherogenic	 lipid	profile,	are	 important	risk	factors	for	
CVD.[10]	In	the	general	population,	HDL-c	is	regarded	as	the	main	anti-atherogenic	lipoprotein	
and	increased	levels	of	HDL-c	have	been	associated	with	a	protective	effect	against	cardiovascular	
mortality	and	morbidity.[11,12]	The	beneficial	effect	of	HDL-c	appears	 to	be	 the	strongest	 for	
women.[12]	This	advantageous	effect	of	HDL-c	is	supposed	to	be	accomplished	primarily	through	
the	 reverse	 cholesterol	 transport	 (RCT)	 and	 the	 neutralization	 of	 oxidized	 lipids.[13]	 In	 RA	
patients,	 however,	 the	 effect	 of	 changes	 in	 lipid	 concentrations	 on	 CVD	 risk	 is	 less	 straight	
forward.[8]	Lipoprotein	and	apolipoprotein	levels	are	known	to	fluctuate	during	the	course	of	RA,	
possibly	 under	 the	 influence	 of	 inflammation	 and	 anti-inflammatory	 treatment,	 including	 oral	
steroids	and	biologic	therapies.[14-17]	During	active	disease,	increased	levels	of	TC,	triglycerides	
(TG)	and	apolipoprotein	B	(ApoB),	and	reduced	concentrations	of	HDL-c	have	been	reported.[14]	
Other	aspects	of	the	lipid	profile	may	be	of	importance.	The	inflammatory	response	in	RA	patients	
may	compromise	the	beneficial	anti-atherogenic	effect	of	HDL-c	on	CVD	risk.	In	addition	to	lower	
levels	 of	 HDL-c,[14,18,19]	 inflammation	 may	 reduce	 the	 anti-oxidative	 capacity,	 impair	 RCT	
capacity	of	HDL-c	in	RA	patients,	and	even	lead	to	HDL-c	becoming	pro-atherogenic.[20-23]	The	
functionality	of	HDL-c	is	partially	dependent	on	HDL-c	composition.	Based	on	its	density	HDL-c	
can	 be	 divided	 into	 two	main	 subfractions:	 HDL2-cholesterol	 (HDL2-c)	 and	 the	 smaller	 HDL3-
cholesterol	 (HDL3-c).	HDL2-c	has	been	suggested	 to	be	 the	more	variable	component	of	 total	
HDL,	while	primarily	higher	levels	of	the	HDL2-c	subfraction	contribute	to	the	anti-atherogenic	
effect	of	HDL-c.[24-26]	 For	 that	 reason,	decreased	 levels	 of	HDL-c	 subfractions	 and	particular	
HDL2-c	could	contribute	to	the	risk	of	CVD	in	RA.	However,	it	is	currently	unclear	whether	HDL2-
c	and	HDL3-c	concentrations	are	actually	decreased	in	RA,	and	whether	their	levels	are	associated	
with	the	level	of	disease	activity.	Therefore,	the	objective	of	this	study	was	to	investigate	whether	
HDL2-c	 and	 HDL3-c	 concentrations	 differ	 between	 RA	 patients	 and	 healthy	 controls,	 and	 to	
investigate	whether	HDL2-c	and	HDL3-c	concentrations	are	associated	with	the	level	of	RA	disease	
activity.	
	
4		
High-density	lipoprotein	cholesterol	subfractions	in	RA	
	 52	
METHODS	
Patients	and	controls	
This	 is	 a	 cross-sectional	 study	 comparing	 a	 group	 of	 45	 consecutive	 patients	with	 RA,	with	 a	
control	group	of	45	consecutive	healthy	individuals.	RA	patients	were	included	in	the	study	if	they	
fulfilled	 the	1987	American	College	of	Rheumatology	 classification	 criteria	 for	RA,	did	not	use	
lipid-lowering	drugs,	had	no	cardiovascular	comorbidity	(hypertension	was	allowed)	or	diabetes.	
Disease	activity	scores	(DAS28)	were	registered.	The	controls	were	consecutively	recruited	from	
healthy	blood-donors	who	came	to	the	regional	blood	bank	for	a	donation	and	were	matched	for	
gender.	The	donors	did	not	suffer	from	any	inflammatory	or	auto-immune	disorders	and	did	not	
use	lipid-lowering	drugs,	and	were	free	of	cardiovascular	comorbidity	and	diabetes.	All	patients	
and	controls	who	were	entered	in	the	study	provided	their	informed	consent.	The	Medical	Ethical	
Committee	 Arnhem-Nijmegen	 approved	 the	 study.	 An	 a	 priori	 sample	 size	 calculation	 was	
deemed	inappropriate,	as	evidence	regarding	HDL2-c	and	HDL3-c	concentrations	is	limited	and	
no	studies	have	been	performed	investigating	these	concentrations	in	RA	patients.	
Lipoprotein	measurements	
In	both	patients	and	controls,	non-fasting	blood	samples	(30	ml)	were	collected,	using	vacutainer	
tubes	 (Beckton	 Dickinson,	 Rutherford,	 New	 Jersey,	 USA)	 containing	 K3-	
ethylenediaminetetraacetic	 acid	 (EDTA)	 (1	mg/ml),	 and	a	 sample	was	 taken	 in	a	 tube	without	
anticoagulant	to	obtain	serum.	Tubes	were	centrifuged	at	3,600	rpm	for	10	minutes	at	23°C,	and	
frozen	at	-80°C	until	assay.	Levels	of	plasma	TC,	TG	and	HDL-c	were	determined	enzymatically	on	
an	Eroset	Hitachi	747	analyzer	which	was	validated	for	these	particular	measurements.	During	
each	 run,	 samples	 from	both	 patients	 and	 controls	were	 analyzed	 to	 prevent	 any	within	 and	
between	 run	 variability	 to	 affect	 group	 differences	 in	 HDL-c	 subfraction	 levels.	 Low-density	
lipoprotein	(LDL)	cholesterol	levels	were	calculated	according	to	the	Friedewald	formula,	which	
provides	reliable	values	up	to	a	TG	concentration	of	4.0	mmol/L.	ApoB	and	ApoA-I	levels	(mg/L)	
were	 determined	 by	 immunonephelometry.	 HDL-c	 subfractions	 were	 isolated	 by	 means	 of	
ultracentrifugation.[27]	In	short,	2	ml	plasma	was	introduced	in	MSE	(Measuring	and	Scientific	
Equipment)	tubes	of	the	ultracentrifuge	(Beckman	L7-55).	KBr	and	CBBR	(Coomassie	Brilliant	Blue	
R)	(1.5%	solution)	was	added	and	the	tubes	were	centrifuged	at	44,000	rpm	for	22	hours	at	15°C.	
HDL2-c	 (density	 1.08	 g/ml)	 and	 HDL3-c	 (density	 1.149	 g/ml)	 were	 separated	 and	 their	
concentrations	were	measured	as	previously	described	for	total	HDL-c,	correcting	for	density	and	
volume	(2	ml).	
Statistical	analyses	
The	primary	outcome	was	the	difference	in	the	concentration	of	HDL2-c	(mmol/L)	between	RA	
patients	and	the	control	group.	Secondary	outcomes	were	between-group	differences	in	HDL3-c	
(mmol/L),	HDL2-c:HDL3-c	ratio,	TC,	TG,	HDL-c,	LDL-c	(mmol/L),	ApoA-I	and	ApoB	(mg/L)	 levels.	
The	differences	in	HDL2-c	and	HDL3-c	concentrations	and	lipoprotein	levels	(TC,	TG,	LDL-c,	HDL-
c,	ApoA-I	and	ApoB)	between	RA	patients	and	healthy	controls	were	analyzed	using	independent-
sample	t-tests,	with	α =	0.05.	To	analyze	the	influence	of	age	and	gender	on	HDL2-c	and	HDL3-c	
concentrations,	analysis	of	covariance	was	used	with	HDL2-c	or	HDL3-c	concentrations	(mmol/L)	
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as	the	dependent	variable,	RA	(patient	or	control)	as	independent	variable,	and	gender	and	age	
as	covariates	and	by	including	an	interaction	term	for	gender	and	presence	of	RA.	To	analyze	the	
effect	of	disease	activity	on	the	HDL2-c	and	HDL3-c	concentrations,	regression	analysis	was	used	
with	 HDL2-c	 or	 HDL3-c	 concentrations	 as	 the	 dependent	 variable,	 disease	 activity	 as	 the	
independent	variable,	and	age,	gender,	smoking,	BMI,	rheumatoid	factor	positivity	and	disease	
duration	as	potential	confounders.	Additional	analyses	were	performed	to	investigate	the	effect	
of	 the	 inflammatory	 markers	 erythrocyte	 sedimentation	 rate	 (ESR;	 mm/hour)	 and	 C-reactive	
protein	(CRP;	mg/L)	included	in	the	DAS28.	Measured	values	of	CRP	levels	<5	mg/L	were	set	at	0	
mg/L.	Potential	confounders	were	added	stepwise	to	the	model,	with	a	change	in	the	regression	
coefficient	of	disease	activity	of	at	least	10%	as	the	selection	criterion.	Mean	HDL2-c	and	HDL3-c	
levels	 were	 determined	 for	 patients	 treated	 with	 glucocorticosteroids,	 methotrexate	 and	
biologicals	separately	and	compared	by	means	of	nonparametric	statistics. 
	
RESULTS	
Patients	and	controls	
A	total	of	13	men	and	32	women	with	RA	were	included	with	a	mean	±	standard	deviation	(SD)	
age	of	58±10	years	and	60±11	years,	respectively.	The	same	number	of	healthy	controls	(n	=	45)	
were	 included,	 13	men	 and	 32	 women	 with	 a	 mean±SD	 age	 of	 54±6	 years	 and	 55±8	 years,	
respectively.	The	participants	 in	 the	control	 group	were	on	average	5	years	 younger	 than	 the	
patients	in	the	RA	group	(Table	1).	Patient	characteristics	are	presented	in	Table	1.	
Table	1.	Patient	characteristics		
	 RA	patients	(n	=	45)	 Healthy	 controls	(n	=	45)	
Age,	mean±SD	 (years)	 60±10.1	 55±7.8	
Female,	n(%)	 32	(71)	 32	(71)	
Rheumatoid	factor	positive,	n(%)	 40	(89)	 N/A	
DAS28,	mean±SD	 3.1±1.7	 N/A	
ESR,	median	 (P25	 to	P75)	 14	(5	to	28.5)	 N/A	
CRP,	median	 (P25	to	P75)	 0	(0	to	12)	 N/A	
Smoking,	n(%)	 16	(32)	 –	
BMI,	mean±SD	 25±(3.3)	 –	
Anti-rheumatic	medication,	n(%)	 15	(33)	 N/A	
Methotrexate	 22	(49)	 N/A	
Other	DMARD	 11	(24)	 N.A	
Biological	DMARD	 15	(33)	 N/A	
Oral	glucocorticoids,	n(%)	 8	(18)	 N/A	
i. BMI,	body	mass	index;	CRP,	C-reactive	protein;	DAS28,	disease	activity	score	(28	joints);	DMARD,	disease	
modifying	anti-rheumatic	drugs;	ESR,	erythrocyte	sedimentation	rate;	n,	number.	
	
Lipid	and	lipoprotein	patterns	in	RA	and	controls	
HDL-c	subfractions	HDL2-c	and	HDL3-c,	and	other	 lipid	and	 lipoprotein	 levels,	were	compared	
between	the	RA	and	healthy	control	group.	Results	are	presented	in	Table	2.	The	recovery	of	HDL-
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c	after	separation	into	subfractions	averaged	95%.	The	results	show	that	TC	and	LDL-c	levels	did	
not	differ	significantly,	while	TG	and	Apo	B	levels	were	significantly	higher	in	RA,	and	HDL-c	and	
Apo	A-1	 levels	were	 lower	 (Table	2).	Notably,	both	HDL-c	 sub	 fractions	HDL2-c	 (P	=	0.01)	and	
HDL3-c	(P	=	0.005)	were	significantly	reduced	in	RA	patients	(Figure	1).	Results	regarding	HDL2-c	
concentrations	demonstrated	a	larger	difference	between	RA	patients	and	controls,	compared	to	
HDL3-c,	 and	 consequently	 the	HDL2-c:HDL3-c	 ratio	 also	was	 significantly	 lower	 in	RA	patients	
(Table	2).	
Table	2.	Results	from	the	independent-sample	t-test	of	lipid	and	lipoprotein	levels	in	RA	patients	and	
healthy	controls.		
	 RA	Patients	(n=45)	 Healthy	controls	(n=45)	 P-value	
Lipids	(mmol/L),	mean±SD		 	 	 	
TC,	mean±SD	 5.7±1.1	 5.7±0.8	 0.72	
TG,	mean±SD	 2.1±1.2	 1.6±0.8	 0.04	
HDL-c,	mean±SD	 1.3±0.3	 1.6±0.3	 <.001	
			HDL2-c	 0.5±0.3	 0.7±0.4	 0.01	
			HDL3-c	 0.8±0.2	 0.9±0.2	 0.005	
			HDL2-c:HDL3-c	 0.5±0.3	 0.7±0.4	 0.04	
LDL-c,	mean±SD	 3.5±0.9	 3.3±0.7	 0.41	
Apolipoproteins	(mg/L)		 	 	 	
Apo	A-1,	mean±SD	 1517.2±242.2	 1710±217.2	 <.001	
Apo	B,	mean±SD	 987.5±220.3	 862.2±188.8	 0.005	
i. Apo,	apolipoprotein;	HDL,	high	 density	 lipoprotein;	 LDL,	 low	density	lipoprotein;	 n,	
number;	RA,	 rheumatoid	arthritis;	SD,	 standard	deviation;	 TC,	total	 cholesterol;	TG,	
triglycerides.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	HDL2-c	and	HDL3-c	subfractions	in	RA	patients	(RA)	and	healthy	controls(HC)	
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Influence	of	age	and	gender	on	HDL2-c	and	HDL3-c	concentrations.		
There	appeared	to	be	no	association	between	age	and	each	of	the	HDL-c	subfractions	HDL2-c	and	
HDL3-c	(not	shown).	In	healthy	controls,	both	HDL2-c	(P	<	0.001)	and	HDL3-c	(P	<	0.001)	levels	
were	significantly	higher	in	women.	In	RA	patients,	these	levels	were	not	different	between	men	
and	women	 (P	 =	 0.13	 and	 P	 =	 0.20,	 respectively).	 Therefore,	 the	 difference	 between	 RA	 and	
healthy	controls	was	analyzed	for	men	and	women	separately.	In	men,	the	differences	between	
RA	and	healthy	controls	in	HDL2-c	(0.011	mmol/L,	95%	confidence	interval	(CI)	-0.17	to	0.15)	and	
HDL3-c	 (0.007	 mmol/L,	 95%CI	 -0.16	 to	 0.18)	 were	 not	 significant	 (P	 =	 0.89	 and	 P	 =	 0.93,	
respectively)	(figure	2).	For	women,	these	differences	between	RA	patients	and	controls	in	HDL2-
c	 (0.27	 mmol/L,	 95%CI	 0.10	 to	 0.45)	 and	 HDL3-c	 (0.16	 mmol/L,	 95%CI	 0.08	 to	 0.23)	 were	
significant	 (P	 =	 0.003	 and	 P	 <	 0.001,	 respectively).	 After	 repeating	 the	 analyses	 using	 linear	
regression	with	an	interaction	term	for	group	and	gender	(see	methods),	it	appeared	that	there	
were	interactions	regarding	gender	and	presence	of	RA	for	HDL2-c	(P	=	0.055),	as	well	as	for	HDL3-
c	 (P	 =	 0.063).	 In	women,	 the	HDL2-c:HDL3-c	 ratio	was	 significantly	 different	 between	RA	 and	
controls,	 with	 a	mean	 difference	 of	 0.2	 (95%	 CI	 0.04	 to	 0.40,	 P=	 0.02)	 compared	 to	 a	mean	
difference	of	0.01	(95%	CI	-0.2	to	0.1,	P	=	0.9)	in	men.	These	findings	are	mirrored	in	TG,	Apo	A-I	
and	Apo	B	concentrations.	TG	and	Apo	B	 levels	were	significantly	 increased	only	 in	 female	RA	
patients	compared	to	female	controls	(P	=	0.002	and	P	=	0.005,	respectively).	Apo	A-1	levels	were	
found	to	be	significantly	lower	in	female	RA	patients	with	a	mean	difference	of	229.8	mg/L	(P	<	
0.001)	and	similar	in	men	with	a	mean	difference	of	88.6	mg/L	(P	=	0.379).		
Figure	2.	HDL2-c	and	HDL3-c	subfractions	in	male	and	female	RA	patients	(RA)	and	healthy	controls	
(HC).		
	
HDL2-c,	HDL3-c	and	disease	activity	in	RA	
Figure	3	shows	that,	in	RA	patients	the	HDL2-c	and	HDL3-c	concentrations	were	similar	across	all	
categories	of	the	DAS28	(low	<3.2;	n	=	31,	medium	3.2	to	5.1;	n	=	6,	and	high	>5.1;	n	=	8).	The	
effect	of	disease	activity,	as	a	continuous	measure,	on	HDL2-c	concentrations	was	estimated	using	
regression	 analysis,	 with	 gender,	 age,	 disease	 duration	 and	 use	 of	 glucocorticosteroids	 as	
covariates,	 while	 smoking,	 BMI	 and	 rheumatoid	 factor	 were	 not	 acting	 as	 confounders.	 A	
statistically	 small	 effect	 of	 DAS28	 on	 HDL2-c	 was	 found	 (Figure	 3).	 HDL2-c	 concentration	
HDL2-chol and HDL3-chol concentrations. The mean ±
SD HDL2-chol and HDL3-chol levels in users and non-
users of methotrexate, biologicals and glucocorticoster-
oids are presented in Table 3. The subanalysis of HDL2-
chol and HDL3-chol levels in non-users and users of
glucocorticosteroids (at the time of the study) showed
moderately lower mean concentrations of HDL2-chol
and moderately higher HDL3-chol levels in users (Table
3), without reaching statistical significance. Glucocorti-
costeroid use and mean prescribed dosage was similar
in men and women (not shown). Disease duration was
considered a confounder as well. In patients with a
longer disease duration (≥10 years) versus patients with
a shorter disease duration (<10 years), higher levels of
both HDL2-chol (mean ± SD 0.6 ± 0.4 versus 0.3 ± 0.1)
and HDL3-chol (mean ± SD 0.9 ± 0.1 versus 0.7 ± 0.2)
concentrations were found. Interestingly, in this study,
women had a longer mean ± SD disease duration (18 ±
11 years versus 8 ± 7 years in men) and a higher mean
± SD DAS28 score (3.4 ± 1.8 versus 2.4 ± 1.2).
Discussion
This study is the first to investigate the distribution of
HDL subfractions in RA patients. According to our
results, both HDL subfractions but particularly HDL2-
chol concentrations were decreased in RA, leading to a
decreased HDL2:HDL3 ratio in these patients. Intrigu-
ingly, the differences in HDL subfractions between RA
and controls were most evident in women, whereas simi-
lar levels of HDL2-chol and HDL3-chol have been
observed in men. Disease activity was not strongly related
to the level of HDL2-chol or HDL3-chol. Finally, our
results suggest that the low HDL2-chol concentration
might contribute to the previously reported increased
cardiovascular risk in RA women.
Results from previous studies investigating HDL and its
anti-atherogenic properties in inflammatory conditions
such as RA, indicate that HDL function deteriorates and
may even become pro-atherogenic in these patients
[20-23]. An inverse relation between HDL3-chol and risk
of CVD has been previously reported [28,29]. When
comparing HDL subfraction levels in cases with CVD
and controls the largest differences were found in HDL2-
chol concentrations, and often stronger inverse associa-
tions between HDL2-chol and CVD were reported
[24-26,30]. This is in accordance with our results; the lar-
gest difference between RA patients and controls was
found in HDL2-chol concentrations, and, consequently,
the HDL2:HDL3 ratio was lower in this group. This fact
might translate into an impaired RCT, one of the crucial
anti-atherogenic mechanisms involving HDL. The RCT
relies on the quantity of both HDL2-chol and HDL3-
chol. Several enzymes, including cholesterylester transfer
protein (CETP) may affect HDL2-chol and HDL3-chol
Figure 2 HDL2-chol and HDL3-chol subfractions in male and female RA patients (RA) and healthy controls (HC). The observed
differences in mean HDL3-chol and particularly HDL2-chol levels (mmol/L) between RA patients and controls were primarily present in women,
not men. In women, the differences between RA patients and healthy controls in HDL2-chol and HDL3-chol were larger; 0.27 mmol/L (95%CI
0.09 to 0.45) for HDL2-chol, and 0.16 mmol/L, (95% CI 0.08 to 0.23) for HDL3-chol. CI, confidence interval; HDL, high density lipoprotein; RA,
rheumatoid arthritis.
Figure 3 HDL2-chol and HDL3-chol concentrations in a group
of RA patients with low, moderate and high disease activity
levels. HDL2-chol and HDL3-chol concentrations were similar across
all categories of the DAS28 (low <3.2; n = 31, medium 3.2 to 5.1; n
= 6, and high >5.1; n = 8). The results of the regression analysis
showed a small effect of DAS28 on HDL2-chol; a decrease in HDL2-
chol of 0.06 mmol/L with every point increase in DAS28 (P = 0.05).
Disease activity did not significantly relate to HDL3-chol, which
decreased by 0.02 mmol/L with every point increase in DAS28 (P =
0.19). DAS28, disease activity score (28 joints); HDL, high density
lipoprotein; n, number; RA, rheumatoid arthritis.
Arts et al. Arthritis Research & Therapy 2012, 14:R116
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decreased	by	0.06	mmol/L	with	every	point	 increase	 in	DAS28	 (P	=	0.05),	while	correcting	 for	
gender,	age,	disease	duration	and	use	of	glucocorticosteroids.	Disease	activity	did	not	significantly	
relate	to	HDL3-c,	which	decreased	by	0.02	mmol/L	with	every	point	increase	in	DAS28	(P	=	0.19),	
while	 correcting	 for	 gender,	 age,	 disease	 duration	 and	 use	 of	 glucocorticosteroids.	 The	
inflammatory	marker	ESR	was	significantly	associated	with	HDL2-c	(P	=	0.046)	and	HDL3-c	(P	=	
0.006),	while	correcting	for	gender,	age,	disease	duration	and	use	of	glucocorticosteroids.	(CRP	
did	 not	 have	 a	 significant	 effect	 on	 either	 HDL2-c	 or	 HDL3-c	 levels	 (P	 =	 0.51	 and	 P	 =	 0.21,	
respectively).	The	effect	on	HDL2-c	and	HDL3-c	for	every	point	increase	in	ESR	(mm/hour)	and	
CRP	(mg/L)	was	small;	a	decrease	of	0.006	mmol/L	and	0.002	mmol/L,	respectively,	 in	HDL2-c,	
and	a	decrease	of	0.004	mmol/L	and	0.002	mmol/L,	respectively,	in	HDL3-c.	
	
Figure	3.	HDL2-c	and	HDL3-c	concentrations	in	a	group	of	RA	patients	with	low,	moderate	and	high	
disease	activity	levels.		
	
HDL2-c,	HDL3-c	in	relation	to	treatment	and	disease	duration	in	RA	
Use	of	(oral)	glucocorticosteroids	was	included	as	a	confounder	in	the	analysis	of	the	effect	of	
disease	activity	on	HDL2-c	and	HDL3-c	concentrations.	The	mean±SD	HDL2-c	and	HDL3-c	levels	in	
users	and	non-users	of	methotrexate,	biologicals	and	glucocorticosteroids	are	presented	in	Table	
3.	The	subanalysis	of	HDL2-c	and	HDL3-c	levels	in	non-users	and	users	of	glucocorticosteroids	(at	
the	time	of	the	study)	showed	moderately	lower	mean	concentrations	of	HDL2-c	and	moderately	
higher	 HDL3-c	 levels	 in	 users	 (Table	 3),	 without	 reaching	 statistical	 significance.	
Glucocorticosteroid	use	and	mean	prescribed	dosage	was	similar	in	men	and	women	(not	shown).	
In	 patients	 with	 a	 longer	 disease	 duration	 (≥10	 years)	 versus	 patients	 with	 a	 shorter	 disease	
duration	(<10	years),	higher	levels	of	both	HDL2-c	(mean±SD	0.6±0.4	versus	0.3±0.1)	and	HDL3-c	
(mean±SD	0.9±0.1	versus	0.7±0.2)	concentrations	were	found.	Interestingly,	in	this	study,	women	
had	 a	 longer	mean±SD	disease	 duration	 (18±11	 years	 versus	 8±7	 years	 in	men)	 and	 a	 higher	
mean±SD	DAS28	score	(3.4±1.8	versus	2.4±1.2).	
HDL2-chol and HDL3-chol concentrations. The mean ±
SD HDL2-chol and HDL3-chol levels in users and non-
users of methotrexate, biologicals and glucocorticoster-
oids are presented in Table 3. The subanalysis of HDL2-
chol and HDL3-chol levels in non-users and users of
glucocorticosteroids (at the time of the study) showed
moderately lower mean concentrations of HDL2-chol
and moderately higher HDL3-chol levels in users (Table
3), without reaching statistical significance. Glucocorti-
costeroid use and mean prescribed dosage was similar
in men and women (not shown). Disease duration was
considered a co founder as well. In patients with a
longer disease duration (≥10 years) versus patients with
a shorter disease dur tion (<10 years), higher levels of
both HDL2-chol (mean ± SD 0.6 ± 0.4 versus 0.3 ± 0.1)
and HDL3-ch l (me ± SD 0.9 ± 0.1 versus 0.7 ± 0.2)
concentrations were found. Interestingly, in this study,
women had a longer mean ± SD disease duration (18 ±
11 years versus 8 ± 7 years in men) and a higher mean
± SD DAS28 score (3.4 ± 1.8 versus 2.4 ± 1.2).
Discussion
This study is the first to investigate the distribution of
HDL subfractions in RA patients. According to our
results, both HDL subfractions but particularly HDL2-
chol concentrations were decreased in RA, leading to a
decreased HDL2:HDL3 ratio in these patients. Intrigu-
ingly, the differences in HDL subfractions between RA
and controls were most evident in women, whereas simi-
lar levels of HDL2-chol and HDL3-chol have been
observed in men. Disease activity was not strongly related
to the level of HDL2-chol or HDL3-chol. Finally, our
results suggest that the low HDL2-chol concentration
might contribute to the previously reported increased
cardiovascular risk in RA women.
Results from previous studies investigating HDL and its
anti-atherogenic properties in inflammatory conditions
such as RA, indicate that HDL function deteriorates and
may even become pro-atherogenic in these patients
[20-23]. An inverse relation between HDL3-chol and risk
of CVD has been previously reported [28,29]. When
comparing HDL subfraction levels in cases with CVD
and controls the largest differences were found in HDL2-
chol concentrations, and often stronger inverse associa-
tions between HDL2-chol and CVD were reported
[24-26,30]. This is in accordance with our results; the lar-
gest difference between RA patients and controls was
found in HDL2-chol concentrations, and, consequently,
the HDL2:HDL3 ratio was lower in this group. This fact
might translate into an impaired RCT, one of the crucial
anti-atherogenic mechanisms involving HDL. The RCT
relies on the quantity of both HDL2-chol and HDL3-
chol. Several enzymes, including cholesterylester transfer
protein (CETP) may affect HDL2-chol and HDL3-chol
Figure 2 HDL2-chol and HDL3-chol subfractions in male and female RA patients (RA) and healthy controls (HC). The observed
differences in mean HDL3-chol and particularly HDL2-chol levels (mmol/L) between RA patients and controls were primarily present in women,
not men. In women, the differences between RA patients and healthy controls in HDL2-chol and HDL3-chol were larger; 0.27 mmol/L (95%CI
0.09 to 0.45) for HDL2-chol, and 0.16 mmol/L, (95% CI 0.08 to 0.23) for HDL3-chol. CI, confidence interval; HDL, high density lipoprotein; RA,
rheumatoid arthritis.
Figure 3 HDL2-ch l and HDL3-chol conc trati ns in a group
of RA patients with low, moderate and high disease activity
levels. HDL2-chol and HDL3-chol concentrations were similar across
all categories of the DAS28 (low <3.2; n = 31, medium 3.2 to 5.1; n
= 6, and high >5.1; n = 8). The results of the regression analysis
showed a small ffect of DAS28 on HDL2-chol; a decr as i HDL2-
chol of 0.06 mmol/L with every point increase in DAS28 (P = 0.05).
Disease activity did not significantly relate to HDL3-chol, which
decreased by 0.02 mmol/L with every point increase in DAS28 (P =
0.19). DAS28, disease activity score (28 joints); HDL, high density
lip protein; n, number; RA, r eumatoid arthritis.
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Table	2.	Results	from	the	independent-sample	t-test	of	lipid	and	lipoprotein	levels	in	RA	patients	and	
healthy	controls.	
i. high	 density	 lipoprotein;	 RA,	 rheumatoid	arthritis;	SD,	 standard	deviation.	
	
	
DISCUSSION	
This	study	is	the	first	to	investigate	the	distribution	of	HDL-c	subfractions	in	RA	patients.	According	
to	our	results,	both	HDL-c	subfractions	but	particularly	HDL2-	c	concentrations	were	decreased	in	
RA,	leading	to	a	decreased	HDL2-c:HDL3-c	ratio	in	these	patients.	Intriguingly,	the	differences	in	
HDL-c	subfractions	between	RA	and	controls	were	most	evident	in	women,	whereas	similar	levels	
of	HDL2-c	and	HDL3-c	were	observed	in	men.	Disease	activity	was	not	strongly	related	to	the	level	
of	 HDL2-c	 or	 HDL3-c.	 Finally,	 our	 results	 suggest	 that	 the	 low	 HDL2-c	 concentration	 might	
contribute	to	the	previously	reported	increased	cardiovascular	risk	 in	RA	women.	Results	from	
previous	 studies	 investigating	 HDL-c	 and	 its	 anti-atherogenic	 properties	 in	 inflammatory	
conditions	 such	 as	 RA,	 indicate	 that	 HDL-c	 function	 deteriorates	 and	may	 even	 become	 pro-
atherogenic	 in	 these	patients.[20-23]	An	 inverse	relation	between	HDL3-c	and	risk	of	CVD	has	
been	previously	reported.[28,29]	When	comparing	HDL-c	subfraction	levels	in	cases	with	CVD	and	
controls	the	largest	differences	were	found	in	HDL2-c	concentrations,	and	often	stronger	inverse	
associations	between	HDL2-c	and	CVD	were	reported.[24-26,30]	This	is	in	accordance	with	our	
results;	 the	 largest	 difference	 between	 RA	 patients	 and	 controls	 was	 found	 in	 HDL2-c	
concentrations,	and,	 consequently,	 the	HDL2-c:HDL3-c	 ratio	was	 lower	 in	 this	group.	This	 fact	
might	translate	into	an	impaired	RCT,	one	of	the	crucial	anti-atherogenic	mechanisms	involving	
HDL-c.	The	RCT	 relies	on	 the	quantity	of	both	HDL2-c	and	HDL3-c.	Several	enzymes,	 including	
cholesterylester	 transfer	 protein	 (CETP)	 may	 affect	 HDL2-c	 and	 HDL3-c	 concentrations,	 by	
lowering	them.[13]	Interestingly,	higher	CETP	concentrations	have	been	previously	indicated	in	
RA	patients	providing	 a	possible	 explanation	 for	 the	decreased	HDL2-c	 levels	 observed	 in	our	
study.[31]	 Lower	HDL2-c	 levels	may	 impair	 RCT	 in	 these	 patients,	 contributing	 to	 accelerated	
atherosclerosis.	 Nevertheless,	 future	 research	 is	 necessary	 to	 clarify	 the	 exact	 mechanisms	
responsible	for	the	differences	in	HDL-c	subfractions	between	RA	patients	and	controls.	 In	our	
study,	HDL2-c	and	HDL3-c	concentrations	were	lower	in	men	compared	to	women	in	both	groups	
investigated.	This	is	in	accordance	with	previous	findings	in	the	general	population.	Interestingly,	
the	 differences	 in	 subfraction	 levels	 that	 were	 found	 between	 the	 RA	 patients	 and	 healthy	
individuals	were	only	apparent	in	women,	whereas	no	such	differences	between	male	RA	patients	
	
	
Methotrexate	 Biologicals	 Glucocorticosteroids	
	 Yes	 No		 p-value	Yes		 No	 p-value	 Yes	 No	 p-value	
HDL2-c,	
(mmol/L)	
mean±SD		
0.47	±	0.4	 0.46	±	0.3	 0.70	 0.42	±	0.2	 0.49	±	0.4	 0.83	 0.43	±	0.2	0.48	±	0.4	 0.87	
HDL3-c,	
(mmol/L)	
mean±SD		
	
		
0.82	±	0.2	 0.83	±	0.2	 0.94	 0.82	±	0.2	 0.84	±	0.2	 0.36	 0.86	±	0.1	0.81	±	0.2	 0.34	
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and	healthy	controls	were	seen.	It	has	been	previously	suggested	that	the	excess	risk	of	CVD	in	
RA	is	primarily	attributable	to	female	RA	patients.[32,33]	Compared	to	the	general	population,	
the	mortality	rate	in	RA	is	increased	in	both	men	and	women,	but	mortality	from	all	cardiac	causes	
is	larger	in	women	than	in	men.[34]	Hence,	it	is	tempting	to	speculate	that	the	excess	CVD	risk	in	
RA	women	might	be	partly	due	to	the	relative	reduction	in	the	beneficial	HDL	subfraction	HDL2-	
c.	This	is	supported	by	previous	findings	that	show	a	decrease	in	HDL-c	and	HDL2-c	concentrations	
in	postmenopausal	women	compared	to	premenopausal	women,[35]	a	transition	that	is	reported	
to	 induce	 an	 increase	 in	 the	 risk	 of	 CVD,	 although	modest,	 supposedly	 due	 to	 a	 decrease	 in	
endogenous	 estrogen.[36-38]	 Nevertheless,	 it	 is	 unlikely	 that	 serum	 estrogen	 decisively	
contributed	 to	 the	 differences	 in	 HDL2-c	 observed	 in	 the	 present	 study,	 as	 it	 has	 been	
demonstrated	to	be	unaltered	 in	RA	women.[39]	Alternatively,	some	differences	 in	RA-related	
parameters	between	men	and	women	may	have	contributed	to	this	result.	In	line	with	that,	we	
observed	 that	 RA	women	 in	 this	 study	 had	 longer	 disease	 duration	 and	 higher	mean	 disease	
activity.	 However,	 there	 is	 inconsistent	 evidence	 of	 a	 certain	 influence	 of	 cumulative	 disease	
activity	on	the	lipid	profile	in	RA	patients.	We	have	previously	shown	that	disease	duration	is	not	
strongly	 associated	with	 cardiovascular	 risk.[9,40]	Others,	 in	 turn,	 have	 indicated	 that	disease	
duration	is	associated	with	accelerated	atherogenesis	and	evidence	of	increased	carotid	intima-
media	wall	thickness	[41]	or	presence	of	carotid	plaques.[42]	Further	research	is	needed	in	order	
to	shed	more	light	into	this	 interesting	issue.	Our	results	show	that	in	the	RA	group,	there	is	a	
modest	 association	 between	 DAS28	 and	 HDL2-c	 concentration	 and	 no	 apparent	 relationship	
between	 DAS28	 and	 HDL3-c	 concentrations.	 For	 each	 1.0	 increment	 of	 the	 DAS28,	 HDL2-c	
decreased	by	0.06	mmol/L.	 If	disease	activity	 in	a	patient	 increases	 from	a	very	 low	 to	a	high	
DAS28	 score	 by	 3.1	 points,	 from	 2.0	 to	 5.1,	 theoretically	 the	 HDL2-c	 concentration	 would	
decrease	 0.19	mmol/	 L.	 Although	 on	 a	 statistical	 level	 these	 differences	 did	 not	 prove	 to	 be	
significant,	it	is	likely	that	such	an	effect,	if	sustained	for	a	longer	period	of	time,	would	become	
clinically	relevant.[43]	Hence,	successful	suppression	of	disease	activity	by	means	of	treatment	
may	also	have	a	clinically	relevant	effect	on	risk	of	CVD	by	augmenting	HDL2-c	and	HDL3-clevels.	
Due	 to	 the	 limited	 number	 of	 RA	 patients	 who	 were	 investigated,	 we	 were	 unable	 to	 find	
consistent	differences	between	the	various	treatment	strategies	regarding	HDL	subfraction	levels.	
This	is	an	interesting	issue	to	pursue	in	future	research.		
There	are	several	 limitations	of	 this	 study	 that	 require	consideration.	Data	 regarding	variables	
that	could	be	possible	confounders	in	the	analysis	of	lipid	concentrations,	such	as	smoking	and	
BMI	were	not	available	for	the	healthy	controls	and	were,	therefore,	not	included	in	the	analysis.	
Although	it	is	unlikely	that	differences	in	these	variables	between	RA	patients	and	controls	are	of	
sufficient	size	to	yield	biased	results,	patients	and	controls	were	matched	on	age	and	gender	and	
randomly	selected	to	prevent	selection	bias.	Also,	this	is	a	cross-sectional	study	and,	therefore,	
no	 long-term	 effects	 are	 reported.	 Hence,	 prolonged	 exposure	 to	 high	 disease	 activity	 or	
remission	over	time	and	the	possible	effect	on	HDL-c	composition	as	well	as	possible	changes	in	
HDL-c	composition	before	and	during	the	course	of	RA	require	 further	research.	Further,	 lipid	
measurements	were	performed	using	non-fasting	blood	samples,	possibly	affecting	cholesterol	
levels.	However,	HDL-c	concentrations	are	less	likely	to	be	affected.[44,45]	
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In	 conclusion,	 levels	 of	 HDL-c	 and	 both	 HDL2-c	 and	 HDL3-c	 but	 particularly	 HDL2-c,	 were	
decreased	in	female	RA	patients	but	not	in	male	patients,	compared	to	healthy	controls.	This	also	
affected	the	HDL2:HDL3	ratio,	which	decreased	in	RA.	Disease	activity	level	seems	to	be	related	
to	the	level	of	HDL2-c	and	HDL3-c	albeit	in	a	modest	association.	This	abnormal	HDL-c	subfraction	
pattern	 may	 negatively	 impact	 the	 risk	 of	 CVD	 in	 RA	 patients,	 particularly	 women.	 Larger	
prospective	studies	would	be	further	necessary	in	order	to	test	this	hypothesis.	
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CHAPTER	5	
Atherogenic	index	and	high-density	lipoprotein	cholesterol	as	
cardiovascular	risk	determinants	in	rheumatoid	arthritis:	the	
impact	of	therapy	with	biologicals	
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ABSTRACT	
Cardiovascular	diseases	(CVD)are	a	serious	concern	in	rheumatoid	arthritis	(RA),	accounting	for	
approximately	one-third	to	one-half	of	all	RA-related	deaths.	Besides	the	attempts	to	identify	new	
risk	factors,	the	proper	management	of	traditional	CVD	risk	factors	such	as	dyslipidemia	should	
become	a	priority	 in	 the	periodic	evaluation	of	 every	RA	patient.	Atherogenic	 index	has	been	
suggested	to	be	less	susceptible	to	disease	activity	variation	during	large	periods	of	time,	making	
him	more	attractive	to	be	used	in	CVD	risk	prediction	in	this	group	of	patients	as	compared	to	
individual	 lipids	 concentrations.	 Nevertheless,	 inflammation	 may	 negatively	 impact	 the	 anti-
atherogenic	 properties	 of	 high-density	 lipoprotein	 cholesterol	 (HDL-c),	 suggesting	 that	 HDL-c	
function	assessment	is	of	particular	importance	when	predicting	CVD	risk	in	these	patients.	Tight	
control	of	 inflammation	becomes	therefore	crucial	for	a	successful	CVD	risk	management.	The	
present	paper	debates	these	hypotheses	focusing	on	the	eﬀects	of	therapy	with	biologicals	on	
the	above-mentioned	parameters.	
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INTRODUCTION	
Cardiovascular	disease	(CVD)	is	a	serious	concern	in	patients	with	chronic	inflammatory	diseases.	
For	patients	with	rheumatoid	arthritis	(RA),	it	represents	the	leading	cause	of	death,	accounting	
for	approximately	one	third	to	one	half	of	all	RA-related	deaths.[1,	2]	In	order	to	decrease	this	
incidence,	risk	factors	need	to	be	identified.	Intriguingly,	previous	studies	have	suggested	that	the	
augmented	CVD	burden	found	in	RA	patients	is	not	fully	explained	by	traditional	CVD	risk	factors,	
such	 as	 dyslipidemia,	 hypertension,	 smoking,	 and	 physical	 inactivity.[3]	 Consequently,	 factors	
leading	or	deriving	 from	chronic	 inflammation	have	been	 suggested	 to	be	 responsible	 for	 the	
augmented	 CVD	 risk.[4–6]	 However,	 no	 such	 factor	 is	 proved	 to	 definitively	 confirm	 this	
hypothesis.	Recently,	several	studies	have	suggested	that	CVD	risk	assessment	in	RA	patients	can	
be	 improved	 solely	 by	 focusing	 on	 the	 traditional	 risk	 factors.	 Impaired	during	 the	periods	 of	
active	 disease,	 physical	 activity	 could	 be	 significantly	 improved	 by	 better	 disease	 control	 as	
suggested	in	the	recent	international	guidelines.[7]	Using	diﬀerent	methods	to	assess	the	risk	of	
developing	CVD,	Toms	et	al.	have	recently	reported	that	between	2%	and	25%	of	RA	patients	who	
should	receive	a	lipid	lowering	drug	(statin)	according	to	their	calculated	risk	do	not	actually	use	
this	medication.[8]	The	percentages	may	even	increase	from	7%	to	30%	if	the	1.5	multiplier	factor	
is	 applied	 as	 recently	 recommended.[9]	 Despite	 its	 limitations,	 the	 study	 emphasizes	 the	
possibility	of	suboptimal	therapy	of	traditional	risk	factors	in	RA	patients,	providing	a	means	of	
reducing	 CVD	 risk	 in	 RA.	 Furthermore,	 inflammation	 may	 alter	 traditional	 CVD	 risk	 factors	
including	 the	 lipid	 pattern,	 by	 augmenting	 concentration	 and	 composition	 level.[10,	 11]	 This	
observation	has	recently	led	to	the	concept	of	“smaller	slice	of	a	bigger	pie,”	which	emphasizes	
that	due	to	the	presence	of	chronic	 inflammation,	the	relative	contribution	of	these	factors	to	
overall	 CVD	 risk	 in	 RA	 is	 diﬀerent	 than	 in	 the	 general	 population.	 All	 these	 data	 suggest	 that	
despite	the	progresses	made	in	the	past	years,	traditional	CVD	risk	factors	such	as	dyslipidemia	
are	not	yet	entirely	understood	and	appropriately	managed	in	patients	with	RA.	Traditionally,	the	
atherogenic	 lipid	profile	 is	made	up	of	 increased	total	cholesterol	(TC),	 low-density	 lipoprotein	
cholesterol	(LDL-c),	triglycerides	(TG),	and	decreased	high-density	lipoprotein	cholesterol	(HDL-
c).	In	chronic	inflammatory	diseases,	such	as	RA,	however,	diﬀerent	concentrations	of	lipids	can	
be	found	throughout	diﬀerent	stages	of	the	disease:	increased	TC	and	LDL-c	in	the	years	prior	to	
disease	onset,	reduced	levels	of	TC	and	HDL-c	during	early	active	disease,	and	diﬀerent	patterns	
in	 established	 RA.[12,	 13]	 Hence,	 due	 to	 the	 variable	 degree	 of	 chronic	 inflammation,	 the	
individual	lipid	concentrations	may	frequently	fluctuate	during	the	course	of	disease	making	the	
impact	of	such	changes	on	CVD	risk	less	clear.	Nevertheless,	the	diﬀerent	cholesterol	fractions	
seem	to	fluctuate	together	in	the	same	direction.	In	line	with	this,	recent	studies	have	suggested	
that	 the	 atherogenic	 index	 (AI—the	 ratio	 TC:HDL-c)	 is	 less	 susceptible	 to	 disease	 activity	
fluctuations	in	RA.	Therefore,	one	can	hypothesize	that	AI	may	be	more	appropriate	to	be	used	
in	CVD	risk	assessment	in	RA	patients	than	individual	cholesterol	fractions	measurements.	Finally,	
inflammation	may	not	only	modulate	lipid	levels	but	also	change	the	composition	of	lipoproteins.	
In	line	with	this,	our	group	and	others	have	shown	that	HDL-c	becomes	less	anti-atherogenic	in	
RA	patients,	and	this	is	associated	with	inflammatory	status.[10,	11]	Therefore,	we	suggest	that	
in	 chronic	 inflammatory	 conditions,	 HDL-c	 anti-atherogenic	 properties	 (i.e.,	 antioxidant,	
cholesterol	 reverse	 transport)	 may	 prove	 to	 be	 a	 valuable	 alternative	 marker	 to	 predict	 the	
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development	 of	 atherosclerosis	 and	 CVD	 in	 RA	 patients.	 Recent	 recommendations	 for	 the	
treatment	of	RA	propose	a	tight	control	of	disease	activity	to	achieve	rapid	remission	in	the	early	
disease	stage.	Controlling	the	inflammatory	process	is	likely	to	favorably	impact	CVD	risk.	In	line	
with	 this,	 new	 therapeutic	 strategies	 have	 been	 recently	 elaborated,	 encouraging	 the	 use	 of	
aggressive	 anti-rheumatics,	 including	 biologicals,	 earlier	 in	 the	 course	 of	 disease.[7]	 The	
consequence	will	be	that	an	increasing	number	of	RA	patients	will	be	treated	in	the	future	with	
these	drugs.	Appropriate	knowledge	about	their	eﬀects	on	cardiovascular	risk	factors,	including	
lipid	 pattern,	 would	 therefore	 be	 of	 great	 importance.	 Several	 previous	 publications	 have	
addressed	 the	 eﬀects	 of	 biologicals	 on	 the	 lipid	 profile,	 concentrating	 on	 individual	 lipid	
levels/changes.	However,	important	questions	regarding	the	overall	atherogenic	capacity	of	the	
lipid	profile	and	the	subsequent	 impact	on	the	cardiovascular	 risk	remain	 largely	unanswered.	
The	present	paper	focuses	on	the	relation	between	the	therapy	with	biologicals	and	atherogenic	
index	as	a	more	suitable	parameter	in	RA	to	address	CVD	risk	in	this	population.	In	addition,	data	
on	HDL-c	function	in	the	same	context	will	be	discussed.	
	
Methods	
Literature	Search	and	Study	Selection	
We	conducted	a	literature	search	in	Medline	via	PubMed	for	articles	published	up	to	May	2012.	
The	MeSH	terms	used	were	anti-TNF,	infliximab,	adalimumab,	etanercept,	tocilizumab,	rituximab,	
and	rheumatoid	arthritis	(MeSH).	These	were	combined	with	cholesterol	(MeSH),	lipids,	HDL,	and	
atherogenic	index.	Articles	were	selected	if	they	met	all	of	the	following	criteria:	(a)	clinical	trial	
or	observational	study	that	included	≥10	patients	with	rheumatoid	arthritis	(except	for	rituximab	
studies),	(b)	treatment	with	infliximab,	adalimumab,	etanercept,	tocilizumab,	or	rituximab,	and	
(c)	 values	 of	 total	 cholesterol	 (TC),	 HDL-c,	 and	 atherogenic	 ratio’s	 taken	 before	 and	 after	
treatment.	The	search	was	further	restricted	to	English	language	full-text	articles.	Studies	were	
manually	selected	by	two	authors	(CP,	EA)	by	screening	the	title,	keywords,	and	abstract,	using	
the	eligibility	 criteria.	 If	possibly	eligible,	 full-text	 articles	were	 retrieved	and	 judged	using	 the	
eligibility	criteria.	The	inclusion	of	articles	was	determined	by	consensus.	
Data	Presentation.		
Due	 to	 the	 heterogeneity	 of	 study	 populations,	 type	 of	 treatment,	 dosages,	 follow-up	 time,	
outcome	 measures,	 and	 statistical	 analysis,	 a	 meta-analysis	 was	 not	 performed.	 Hence,	 a	
narrative	summary	of	the	results	is	provided.	The	primary	summary	measure	used	to	compare	
results	was	 the	diﬀerence	 in	AI	 for	 short-term	 studies	 (<6	months)	 and	 long-term	 studies	 (>6	
months).	 Results	 regarding	 anti-TNFα,	 anti-IL-6R,	 and	 anti-CD20	 therapy	 are	 discussed.	 No	
additional	quality	assessments	were	performed.	Sample	size,	diﬀerences	in	type	of	treatment	and	
dosages,	and	study	duration	were	taken	into	consideration	when	comparing	results.	
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RESULTS	&	DISCUSSION	
In	 total,	 there	were	105	 records	 identified.	Of	 them,	4	were	excluded	because	 they	were	not	
written	 in	 English,	 5	were	 case	 reports,	 56	were	 oﬀ	 topic,	 3	were	 themselves	 reviews,	 and	 4	
studies	investigated	less	than	ten	RA	patients	(see	inclusion	criteria).	At	the	end	of	the	selection	
procedure,	 33	 full-text	 articles	met	 the	 eligibility	 criteria	 and	were	 considered	 for	 this	 paper	
(figure	 1).	 Of	 the	 33	 studies,	 the	 vast	 majority	 concerned	 anti-TNF	 users,	 usually	 infliximab,	
adalimumab,	 and	 etanercept,[11,	 14–32]	 8	 studies	 concerned	 tocilizumab	 (including	 three	
randomized	 clinical	 trials),[21,	 33–39]	 and	 5	 studies	 investigated	 rituximab	 eﬀects	 on	 lipids	
pattern.[14,	 40–43]	 Data	 on	 other	 biologicals,	 including	 abatacept,	 anakinra,	 golimumab,	 or	
certolizumab	have	not	been	addressed	here	due	to	their	very	limited	and	preliminary	character.	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	Flowchart		
	
Anti-TNF	Agents	
TNF-α	is	a	pro-inflammatory	cytokine	which	plays	a	pivotal	role	in	both	RA	and	atherosclerosis	
pathogenesis.	A	beneficial	eﬀect	of	anti-TNF	treatment	on	CVD	morbidity	and	mortality	in	RA	has	
been	demonstrated.[44]	Many	studies	have	investigated	the	eﬀects	of	anti-TNF	medication	on	
the	lipid	profile,	yet	the	majority	of	studies	comprise	small	groups	of	patients	with	a	short	follow-
up.	This	paper	will	further	focus	on	studies	concerning	infliximab,	adalimumab,	and	etanercept.	
As	previously	mentioned,	it	will	separately	address	the	short	and	long-term	eﬀects,	respectively,	
for	all	three	drugs	taken	together.	Finally,	the	eﬀects	on	HDL-c	function	will	be	summarized.		
Short-term	studies	
Short-term	studies	demonstrate	primarily	significant	anti-atherogenic	changes,	particularly	in	TC	
and	HDL-c	 levels,	whereas	TG	and	LDL-c	concentrations	often	remain	unchanged.	 Interestingly	
and	of	importance	for	our	present	paper,	changes	in	the	atherogenic	index	(TC:HDL-c)	and	other	
ratios	(LDL-c:HDL-c,	ApoB:ApoA-1)	have	also	been	noticed.	Our	group	found	a	significant	decrease	
of	approximately	8%	in	both	LDL-c:HDL-c	and	the	TC:HDL-c	ratio	after	two	weeks	of	treatment	
with	adalimumab	in	a	group	of	33	RA	patients	as	compared	to	placebo.[24]	Our	results	have	been	
further	 confirmed	by	a	 recent	 study	 in	50	RA	patients	 receiving	adalimumab:	AI	baseline—16	
Mediators of Inflammation 3
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• 56 out-off topic
• 3 reviews
• 5 case reports
• 4 not English
• 4 (N < 10)
Figure 1: Flowchart.
3.1.1. Short-Term Studies. Short-term studies demonstrate
primarily significant antiatherogenic changes, particularly in
TC and HDL levels, whereas TG and LDL oncentrations
often remain unchang d. Interestingly and f importance
for our present paper, changes in the atherogenic index
(TC :HDL) and other ratios (LDL :HDL, ApoB : ApoA-1)
have also been noticed. Our group found a significant
decrease of approximately 8% in both LDL :HDL and
the TC :HDL ratio after two weeks of treatment with
adalimumab in a group of 33 RA patients as compared to
placebo [24]. Our results have been further confirmed by
a recent study in 50 RA patients receiving adalimumab: AI
baseline—16 weeks was 3.33 (0.93) versus 3.15 (0.85), P =
0.034 [32]. A significant decrease in the apoB : apoA-1 ratio
has been also reported (P = 0.014). A trend towards a
more pronounced eﬀect on HDL in the responders group
has been noticed together with an association with disease
activity changes (r = −0.31, P = 0.03). Similar results have
been reported by Jamnitski et al., who found a significant
decrease in the ApoB : ApoA-1 ratio over a period of 3
months [19] in 292 RA patients receiving TNF blockade.
Interestingly, this change has been found only in good and
moderate EULAR responders. Nevertheless, some further
studies reported opposite results (Table 1). Following 45 RA
patients treated with infliximab during a period of almost
6 months, our group reported a significant increase in the
TC :HDL ratio [11] at the end of this period. These findings
were supported by Dahlqvist et al. [17], who reported an
increase of 8% and 9% in the LDL :HDL and TC :HDL ratio,
over the same time period in 52 RA patients treated with
infliximab. Other studies did not indicate any change in the
atherogenic index or other ratios within a period of 3 or
6 months of anti-TNF therapy [14, 16, 18, 21, 25, 26, 28,
30, 31], although individual lipid levels were often found to
increase in the initial months of treatment [25, 26, 30, 31].
Studying 56 patients with RA receiving infliximab for 30
weeks, Allanore et al. found no changes in the atherogenic
index despite a significant stable increase of HDL and TC.
They also noticed no relations between response to therapy
and lipid pattern modifications [15]. Similar findings have
been reported by Seriolo et al. in 34 consecutive RA patients
treated with various TNF blockers (n = 16 for etanercept,
n = 14 for infliximab, and n = 4 for adalimumab) for
24 weeks [26]. The authors reported however on a relation
between changes in HDL and disease activity (DAS28) by the
end of the study (r = −0.52, P < 0.01), without making
any reference to response rate. These findings are in line
with those from a previous study, indicating a correlation
between the decrease in disease activity and the increase in
HDL 6 weeks after therapy with infliximab has been initiated
[31]. This association remained after adjusting for changes in
prednisone dose, age, gender, and disease duration. Although
the mean atherogenic index did not change, changes in
DAS28 were significantly associated with changes in the
atherogenic index in the period 0 to 2 weeks. However, this
association disappeared when the whole study period (6
weeks) has been considered.
A few more studies should be mentioned, which did
investigate the eﬀects of TNF blockade on lipids pattern
in RA patients, however, without entirely fulfilling our
inclusion criteria. Several investigators pulled together data
fr m patients with RA and other inflammatory conditions
such as ankylosing spondylitis [20]. In this setting, they
found no changes in AI after 6 months of therapy with
infliximab. Other studies provided data only on individual
lipids without atherogenic index or other ratios [22, 27,
29]. Finally, in an elegant study, Gonzalez-Juanatey et al.
investigated endothelial function and atherogenic index in
a small group (N = 8) of RA patients who failed on
infliximab and were now treated with adalimumab. Besides
rapid improvement of endothelial function, a significant
decrease of the atherogenic index was observed at week 2
(3.30 ± 0.55) and at week 12 (3.28 ± 0.48) when compared
with baseline atherogenic index result (3.52± 0.50) (P value
for both comparisons = 0.012). This was associated with a
decrease in disease activity and inflammation status [45].
The apparent heterogeneity of these results may be due
to several factors. Firstly, it mostly concerns small-group
studies enrolling RA patients from diverse countries with a
distinctive health care system and lifestyle habits, including
physical activity (biking for the Dutch population) [11, 23–
25, 31, 32] and alimentation (fish-reach diet in Northern
Europe, Mediterranean diet in the Southern Europe) [14,
15, 17, 18, 20, 26, 28]. Secondly, a diﬀerence between the
anti-TNF agents may be present, leading to a more pro-
atherogenic profile in the case of infliximab [11, 17], with
milder eﬀects for adalimumab and etanercept [19, 24, 32].
Thirdly, gendermay also contribute to this heterogeneity, our
group reporting a more pronounced eﬀect on lipid pattern
in male RA patients. Accordingly, total cholesterol and HDL
increased more markedly 6 months after starting infliximab
(P < 0.04), translating into a tendency to increase of the
atherogenic index [25]. Finally, the response rate and the
degree of response to anti-TNF therapy is likely to impact
the changes in lipid profile. Though several studies have
addressed the association between changes in disease activity
or inflammatory status and changes in lipids concentrations,
only a few investigated the association between the latter
and response according to established criteria (EULAR/ACR)
[19, 25, 32]. These studies suggest that the atherogenic index
tends to increase more in nonresponders as compared to
responders [25], or to decrease only in responders [19, 32].
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weeks	was	3.33	(0.93)	versus	3.15	(0.85),	P	=	0.034.[32]	A	significant	decrease	in	the	ApoB:ApoA-
1	ratio	has	been	also	reported	(P	=	0.014).	A	trend	towards	a	more	pronounced	eﬀect	on	HDL-c	
in	 the	 responders	 group	 has	 been	 noticed	 together	 with	 an	 association	 with	 disease	 activity	
changes	(r	=	−0.31,	P	=	0.03).	Similar	results	have	been	reported	by	Jamnitski	et	al.,	who	found	a	
significant	decrease	in	the	ApoB:ApoA-1	ratio	over	a	period	of	3	months	[19]	in	292	RA	patients	
receiving	TNF	blockade.	 Interestingly,	 this	 change	has	been	 found	only	 in	good	and	moderate	
EULAR	 responders.	 Nevertheless,	 some	 further	 studies	 reported	 opposite	 results	 (Table	 1).	
Following	45	RA	patients	treated	with	infliximab	during	a	period	of	almost	6	months,	our	group	
reported	a	significant	increase	in	the	TC:HDL-c	ratio	[11]	at	the	end	of	this	period.	These	findings	
were	supported	by	Dahlqvist	et	al.[17],	who	reported	an	increase	of	8%	and	9%	in	the	LDL-c:HDL-
c	and	TC:HDL-c	ratio,	over	the	same	time	period	in	52	RA	patients	treated	with	infliximab.	Other	
studies	did	not	indicate	any	change	in	the	AI	or	other	ratios	within	a	period	of	3	or	6	months	of	
anti-TNF	therapy,[14,	16,	18,	21,	25,	26,	28,	30,	31]	although	 individual	 lipid	 levels	were	often	
found	to	increase	in	the	initial	months	of	treatment.[25,	26,	30,	31]	Studying	56	patients	with	RA	
receiving	infliximab	for	30	weeks,	Allanore	et	al.	found	no	changes	in	the	AI	despite	a	significant	
stable	increase	of	HDL-c	and	TC.	They	also	noticed	no	relations	between	response	to	therapy	and	
lipid	 pattern	 modifications.[15]	 Similar	 findings	 have	 been	 reported	 by	 Seriolo	 et	 al.	 in	 34	
consecutive	 RA	patients	 treated	with	 various	 TNF	blockers	 (n	 =	 16	 for	 etanercept,	 n	 =	 14	 for	
infliximab,	 and	 n	 =	 4	 for	 adalimumab)	 for	 24	weeks.[26]	 The	 authors	 reported	 however	 on	 a	
relation	between	changes	in	HDL-c	and	disease	activity	(DAS28)	by	the	end	of	the	study	(r	=	-0.52,	
P	<	0.01),	without	making	any	reference	to	response	rate.	These	findings	are	in	line	with	those	
from	a	previous	study,	indicating	a	correlation	between	the	decrease	in	disease	activity	and	the	
increases	in	HDL-c	6	weeks	after	therapy	with	infliximab	has	been	initiated.[31]	This	association	
remained	 after	 adjusting	 for	 changes	 in	 prednisone	 dose,	 age,	 gender,	 and	 disease	 duration.	
Although	 the	 mean	 AI	 did	 not	 change,	 changes	 in	 DAS28	 were	 significantly	 associated	 with	
changes	in	the	AI	in	the	period	0	to	2	weeks.	However,	this	association	disappeared	at	the	end	of	
the	study	period	(6	weeks).	
A	few	more	studies	should	be	mentioned,	which	did	investigate	the	eﬀects	of	TNF	blockade	on	
lipids	 pattern	 in	RA	patients,	 however,	without	 entirely	 fulfilling	our	 inclusion	 criteria.	 Several	
investigators	pulled	together	data	from	patients	with	RA	and	other	inflammatory	conditions	such	
as	ankylosing	spondylitis.[20]	In	this	setting,	they	found	no	changes	in	AI	after	6	months	of	therapy	
with	infliximab.	Other	studies	provided	data	only	on	individual	lipids	without	AI	or	other	ratios.[22,	
27,	29]	Finally,	in	an	elegant	study,	Gonzalez-Juanatey	et	al.	investigated	endothelial	function	and	
AI	 in	 a	 small	 group	 (n=8)	 of	 RA	patients	who	 failed	 on	 infliximab	 and	were	 now	 treated	with	
adalimumab.	Besides	rapid	improvement	of	endothelial	function,	a	significant	decrease	of	the	AI	
was	observed	at	week	2	(3.30	±	0.55)	and	at	week	12	(3.28	±	0.48)	when	compared	with	baseline	
AI	result	(3.52	±	0.50)	(P	value	for	both	comparisons	=	0.012).	This	was	associated	with	a	decrease	
in	disease	activity	and	inflammation	status.[45]	The	apparent	heterogeneity	of	these	results	may	
be	due	to	several	factors.	Firstly,	it	mostly	concerns	small-group	studies	enrolling	RA	patients	from	
diverse	 countries	with	 a	 distinctive	 health	 care	 system	 and	 lifestyle	 habits,	 including	 physical	
activity[11,	23–25,	31,	32]	and	alimentation	 (fish-rich	diet	 in	Northern	Europe,	Mediterranean	
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diet	in	the	Southern	Europe).[1	4,	15,	17,	18,	20,	26,	28]	Secondly,	a	diﬀerence	between	the	anti-
TNF	 agents	 may	 be	 present,	 leading	 to	 a	 more	 pro-atherogenic	 profile	 in	 the	 case	 of	
infliximab,[11,	17]	with	milder	eﬀects	for	adalimumab	and	etanercept.[19,	24,	32]	Thirdly,	gender	
may	also	contribute	to	this	heterogeneity,	our	group	reporting	a	more	pronounced	eﬀect	on	lipid	
pattern	in	male	RA	patients.	Accordingly,	total	cholesterol	and	HDL-c	increased	more	markedly	6	
months	after	starting	infliximab	(P	<	0.04),	translating	into	a	tendency	of	the	AI	to	increase.[25]	
Finally,	the	response	rate	and	the	degree	of	response	to	anti-TNF	therapy	is	likely	to	impact	the	
changes	in	lipid	profile.	Though	several	studies	have	addressed	the	association	between	changes	
in	 disease	 activity	 or	 inflammatory	 status	 and	 changes	 in	 lipids	 concentrations,	 only	 a	 few	
investigated	 the	association	between	the	 latter	and	response	according	 to	established	criteria	
(EULAR/ACR).[19,	 25,	 32]	 These	 studies	 suggest	 that	 the	 AI	 tends	 to	 increase	 more	 in	 non-
responders	as	compared	to	responders,[25]	or	to	decrease	only	in	responders.[19,	32]	
Table	1.	Short-term	effects	of	anti-TNF	drugs	on	AI	and	other	ratios.		
Study		 Drug	 No	of	patients	 Duration		 Effect	
	 	 	 	 AI	 Other	ratios	
Popa	et	al.[24]	 ADA	 33	 	2	wk	 L	 LDL-c:HDL-c	
Wijbrandts	et	al.[32]	 ADA	 8	 16	wk	 L		 ApoB:ApoA-1	
Gonzalez-Juanatey	et	al.[45]	 ADA	 8		 12	wk	 L	 -	
Kume	et	al.[21]		 ADA/ETN	 42	 24	wk	 N	 -		
Seriolo	et	al.[26]	 ADA/ETN/IFX	 34	 24	wk	 N	 -		
Soubrier	et	al.[28]	 ADA/ETN/IFX	 29	 14	wk	 N	 ApoB:ApoA-1	
Jamnitski	et	al.[19]	 ETN	 292	 16	wk	 L	 ApoB:ApoA-1	
Allanore	et	al.[15]	 IFX	 56	 30	wk	 N	 LDL-c:HDL-c	
Popa	et	al.[1]	 IFX	 45	 24	wk	 H	 -	
Dahlqvist	et	al.[17]	 IFX	 52	 24	wk	 H	 -		
Popa	et	al.[25]	 IFX	 55	 24	wk	 H	 -	
Tam	et	al.[30]	 IFX	 19	 14	wk	 N	 LDL-c:HDL-c	
Vis	et	al.[31]	 IFX	 69	 6	wk	 N	 -	
Engvall	et	al.[18]	 IFX	 40	 14	wk	 -	 ApoB:ApoA-1	
Ajeganova	et	al.[14]	 ADA/ETN/IFX	 162	 24	wk	 -	 ApoB:ApoA-1	
Curtis	et	al.[16]	 Not	specified	 289	 8	wk	 L	 -	
i. ETN;	etanercept,	ADA;	 adalimumab,	 IFX;	 infliximab,	AI;	 atherogenic	 index,	wk;	 	weeks,	 L;	
lower,	N;	neutral,	H;	higher	
	
Long-Term	Studies.		
During	the	first	year	of	treatment	with	anti-TNF	agents,	lipid	concentrations	tend	to	increase,	with	
some	reporting	a	return	to	baseline	levels	after	an	initial	increase.[23]	Despite	a	constant	dosage	
of	the	anti-TNF	drug,	changes	in	AI	reported	by	short-term	studies	are	often	not	sustained	over	
longer	periods	of	time.	Using	etanercept	in	a	group	of	292	RA	patients,	Jamnitski	et	al.	found	a	
more	pronounced	decrease	of	ApoB:ApoA-1	ratio	4	months	after	therapy	has	been	initiated	as	
compared	 to	one	year	 time	point,	whereas	TC:HDL-c	 ratio	 remained	 similar	 throughout	 study	
period.[19]	The	authors	have	also	performed	an	analysis	in	patients	who	responded	and	patients	
who	did	not	respond	to	the	therapy	according	to	the	EULAR	response	criteria.	There	was	a	trend	
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towards	a	lower	AI	both	at	4	months	and	at	one	year	after	starting	etanercept	in	the	responder’s	
subgroup	 compared	 to	 the	non-responders,	 reaching	 significance	 in	 the	 case	of	ApoB:ApoA-1	
ratio	 (P	 =	 0.005).	 Wijbrandts	 et	 al.	 also	 reported	 an	 improvement	 of	 the	 AI	 52	 weeks	 after	
adalimumab	has	been	started	in	a	group	of	44	RA	patients,[32]	with	ApoB:ApoA-1	ratio	decreasing	
with	7%	(P	=	0.05)	and	TC:HDL-c	ratio	with	4%	(P	=	0.27).	Of	note,	both	ratios	reached	statistical	
significance	16	weeks	after	starting	adalimumab	(P	=	0.014	and	P	=	0.034,	resp.).[32]	In	contrast,	
in	a	case-control	study	of	52	established	RA	patients	and	70	early	RA	patients,	Dahlqvist	et	al.	
reported	that	the	LDL-c:HDL-c	and	TC:HDL-c	ratios	significantly	worsened	one	year	and	even	two	
years	after	infliximab	was	started:	9.2%	and	10.4%,	respectively.[17]	In	line	with	this,	our	group	
found	 a	 significant	 increase	 in	 the	 TC:HDL-c	 ratio	 in	 a	 group	 of	 55	 RA	 patients	 treated	 with	
infliximab:	9%	after	6	months	(P	=	0.02)	and	4%	after	12	months	(P	=	0.05).[25]	In	the	same	study,	
LDL-c:HDL-c	ratio	did	not	significantly	changed	over	time.	Peters	et	al.	 found	no	change	in	the	
ApoB:ApoA-1	 ratio	and	TC:HDL-c	 ratio,	 respectively,	 in	a	group	of	80	RA	patients	 treated	with	
infliximab	for	a	period	of	48	weeks.[23]	Interestingly,	they	observed	that	changes	in	prednisone	
dose	were	related	to	changes	in	HDL-c	and	TC,	with	a	relatively	greater	impact	on	HDL-c,	resulting	
in	 an	 inverse	 association	 between	 prednisone	 dose	 and	 AI	 (TC:HDL-c	 and	 ApoB:ApoA-1).[23]	
Finally,	 in	 a	 large	 study	 involving	 diﬀerent	 anti-TNF	 agents	 (infliximab,	 adalimumab,	 and	
etanercept),	 Ajeganova	 et	 al.	 found	 no	 changes	 in	 ApoB:ApoA-1	 ratio	 in	 all	 three	 subgroups	
according	to	the	drug,	12	months	after	therapy	has	been	initiated.[14]	Similar	results	have	been	
previously	reported	by	Engvall	et	al.,	who	observed	no	change	in	ApoB:ApoA-1	ratio	between	3	
months	and	2	years	of	 follow-up.[18]	Both	 studies	 report	no	data	on	TC:HDL-c	 index.	Despite	
apparent	discrepancy,	some	trends	maybe	depicted	when	analyzing	these	long-term	eﬀects	of	
anti-TNF	drugs	on	lipids	in	patients	with	RA.	These	trends	become	clearer	when	focusing	on	AI,	
which	demonstrates	 therefore	 to	be	 superior	 to	 individual	 lipid	 concentrations	 in	 this	 respect	
(Table	 2).	 Therapy	 with	 etanercept	 or	 adalimumab	 seems	 to	 have	 a	 positive	 impact	 on	 AI,	
although	this	improvement	does	not	always	reach	statistical	significance.[19,	32]	In	contrast,	the	
use	of	infliximab	may	worsen	lipid	ratios	on	the	long	term,[17,	25]	though	some	report	a	neutral	
eﬀect.[23]	 Nevertheless,	 a	 rapid	 and	 sustained	 control	 of	 disease	 activity	 as	 in	 the	 case	 of	
responders	would	be	associated	with	better	ratios	compared	to	non-responders,	even	in	those	
patients	 treated	 with	 infliximab.[23]	 Alternatively,	 the	 concomitant	 use	 of	 prednisone	 may	
influence	 AI.	 Given	 the	 prognostic	 value	 of	 these	 ratios	 for	 future	 CVD,	 it	 is	 likely	 that	 these	
changes	 are	 clinically	 relevant	 and	may	 contribute	 to	 the	 decreased	 incidence	 of	myocardial	
infarction	and	other	CVD	events	observed	with	anti-TNFα	treatment	in	RA.	
Anti-TNF	therapy	and	HDL-c	function	
The	 link	 between	 HDL-c	 and	 cardiovascular	 disease	 risk	 is	 far	 more	 complex	 than	 originally	
thought.	 This	may	 be	 explained	 by	 the	 inherent	 heterogeneity	 of	 HDL-c	 particles	 in	 terms	 of	
composition,	 structure,	 and	 biological	 function.	 Emerging	 evidence	 suggests	 that	 for	 instance	
small	 dense	 protein-rich	HDL3-c	 particles	 are	 less	 capable	 of	 protecting	 LDL	 against	 oxidative	
modification.[46]	This	has	led	some	to	propose	that	the	functionality	of	HDL-c	may	be	as	relevant	
as	plasma	levels	of	HDL-c	to	CVD	risk	assessment.[47,	48]	In	the	same	context,	a	number	of	studies	
have	 demonstrated	 that	 inflammation	 is	 able	 to	 negatively	 impact	 the	 anti-atherogenic	
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properties	of	HDL-c.[49]	The	issue	becomes	of	interest	thus	in	the	case	of	patients	suﬀering	from	
chronic	 inflammatory	diseases,	 such	as	RA.	 In	 a	 study	on	48	RA	patients,	which	also	 included	
patients	 with	 SLE	 and	 healthy	 controls,	McMahon	 et	 al.	 demonstrated	 for	 the	 first	 time	 the	
presence	of	a	pro-inflammatory	HDL-c	 in	this	group	of	patients.[10]	About	20%	of	RA	patients	
were	likely	to	have	such	an	HDL-c,	as	compared	to	4%	of	healthy	controls.	HDL-c	function	tended	
to	correlate	with	ox-LDL	concentrations	(r	=	0.355).	Inflammatory	markers	and	prednisone	dosage	
have	been	shown	to	be	associated	with	a	pro-inflammatory	HDL-.	Interestingly,	the	authors	found	
no	 association	 between	 HDL-c	 function	 (pro-inflammatory)	 and	 HDL-c	 concentrations,	 an	
observation	which	has	been	recently	confirmed	by	an	elegant	study	in	the	general	population.[47]	
Statins	may	reverse	the	pro-inflammatory	HDL-c	as	was	observed	in	a	small	group	of	RA	patients	
during	a	period	of	12	weeks.[50]	This	improvement	was	not	entirely	contributed	to	a	decrease	in	
inflammatory	state.	It	was	further	indicated	that	the	pro-inflammatory	function	of	HDL-c	in	RA	
might	be	due	to	a	diﬀerent	composition	as	compared	with	anti-inflammatory	HDL-c,(51)	including	
a	lower	LCAT	activity	and	higher	MPO	activity.	Nevertheless,	the	study	does	not	provide	suﬃcient	
evidence	to	support	the	standard	use	of	statins	in	patients	with	RA.	Our	group	has	investigated	
for	the	first	time	the	eﬀects	of	anti-TNF	therapy	on	HDL-c	anti-atherogenic	function.	We	found	
that	 infliximab	 is	able	to	 improve	HDL-c	anti-oxidative	capacity,	an	eﬀect	that	was	sustained	6	
months	after	anti-TNF	therapy	has	been	initiated.[11]	It	is	still	unclear	how	stable	these	eﬀects	
are	further	in	the	course	of	therapy	and	whether	they	are	solely	due	to	TNF	blockade	or	more	
likely	 to	 reflect	 the	overall	 inflammatory	 suppression	achieved	 in	 these	patients.	Recently,	we	
observed	 that	 HDL-c	 subfractions	 are	 modified	 in	 RA	 patients,	 especially	 in	 women,[51]	
reinforcing	again	the	importance	and	in	the	same	time	the	complexity	of	HDL-c	status	in	these	
patients	 with	 respect	 to	 their	 CVD	 risk.	 Whether	 anti-TNF	 drugs	 are	 able	 to	 restore	 this	
detrimental	HDL-c	profile	remains	a	subject	for	further	investigations.	
Table	2.	Long-term	effects	of	anti-TNF	drugs	on	AI	and	other	ratios.		
Study	 Drug	 No	of	patients	 Duration	 Effect	
	 	 	 	 AI	 Other	ratios	
Jamnitski	et	al.[19]	 ETN	 292	 1	year	 N	 ApoB:ApoA-1	
Wijbrandts	et	al.[32]	 ADA	 50	 1	year	 N	 ApoB:ApoA-1	
Dahlqvist	et	al.[17]	 IFX	 51	 2	years	 H	 -	
Popa	et	al.[25]	 IFX	 55	 1	year	 H	 LDL-c:HDL-c	
Peters	et	al.[23]	 IFX	 80	 1	year	 N	 ApoB:ApoA-1	
Ajeganova	et	al[14]	 ETN/ADA/IFX	 162	 1	year	 -	 ApoB:ApoA-1	
Engvall	et	al.[18]	 IFX	 18	 2	years	 -	 ApoB:ApoA-1	
i. ETN;	 etanercept,	 ADA;	 adalimumab,	 IFX;	 infliximab,	 AI;	 atherogenic	 index,	 N;	 neutral,	 H;	
higher	
	
Anti-IL6	agents	
Interleukin	 (IL6)	 is	 another	 cytokine	 that	 plays	 a	 key	 role	 in	 the	 pathogenesis	 of	 chronic	
inflammatory	diseases.	Recently,	 the	therapeutic	blockade	of	 its	 receptor	proved	to	eﬃciently	
suppress	disease	activity	in	patients	with	RA.[33–35,	37,	39]	Owing	to	the	increased	CVD	risk	and	
anti-TNF	 experience,	 trials	 investigating	 the	 eﬀects	 of	 the	 IL-6	 receptor	 (IL-6R)	 antagonist	
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tocilizumab	(TCZ)	in	patients	with	RA	have	included	for	the	first	time	the	impact	of	the	therapy	on	
the	 lipid	 pattern	 as	 part	 of	 the	 safety	 analysis	 of	 the	 drug.	 An	 increase	 of	 individual	 lipid	
concentrations	 has	 been	 constantly	 reported	with	 TCZ.[37,	 38]	 Nevertheless,	 detailed	 results	
regarding	the	eﬀect	of	treatment	on	the	AI	could	not	be	derived	from	all	of	the	studies	(Table	3).	
Maini	et	al.	reported	that	lipids	levels	increased	initially	and	then	stabilized	and	did	not	continue	
to	increase	during	the	treatment	period,	which	is	comparable	to	the	eﬀects	reported	in	anti-TNF	
studies.	Importantly,	the	mean	AI	remained	largely	unchanged	and	was	reduced	to	below	its	initial	
level	by	the	20-week	follow-up	visit	in	the	groups	receiving	8	mg/kg	of	TCZ.[37]	In	another	trial	by	
Emery	et	al.,	20-week	therapy	with	TCZ	resulted	in	higher	rate	of	more	than	30%	increase	in	LDL-
c:HDL-c	 ratio	 in	 patients	 receiving	 the	 drug	 compared	 to	 controls:	 22.2%	 (TCZ	 8	 mg/kg),	
19.1%(TCZ4	mg/kg),	and	10,1%	(controls),	respectively.[33]	In	contrast,	comparable	proportions	
of	patients	had	greater	than	30%	increase	in	the	ApoB:ApoA-1	ratio:	11.6%	(TCZ	8	mg/kg),	9.4%	
(TCZ	4	mg/kg),	and	9.7%	(controls),	respectively.	No	acute	CVD	event	has	been	reported	during	
the	study	period.	In	the	OPTION	study	comparing	two	TCZ	regimens	with	placebo,	Smolen	et	al.	
report	similar	results.[39]	Increases	in	the	TC:HDL-c	ratio	of	more	than	30%	above	baseline	were	
observed	in	17%	of	patients	treated	with	TCZ	8	mg/kg,	8%	of	patients	receiving	TCZ4	mg/kg	and	
5%	 in	 the	 placebo	 group.	 A	 comparable	 ApoB:ApoA-1	 ratio	 between	 the	 groups	 have	 been	
reported	 however.	 One	 last	 trial	 adds	 to	 strengthen	 the	 previous	 presented	 data	 (TOWARD	
study).[34]	In	this	study	patients	receiving	TCZ	8mg/kg	and	a	DMARD	were	compared	to	patients	
receiving	a	DMARD	and	placebo.	The	authors	indicate	increases	of	more	than	30%	in	the	TC:HDL-
c	ratio	in	12%	and	7%	of	patients	in	the	TCZ	and	control	group,	respectively,	and	increases	of	more	
than	30%	in	the	LDL-c:HDL-c	ratio	in	20%	and	12%	of	patients,	respectively.	Again,	no	significant	
changes	in	the	ApoB:ApoA-1	ratio	have	been	noticed	in	both	groups.	Finally,	Jones	et	al.	compared	
the	monotherapy	with	TCZ	and	methotrexate	in	a	group	of	673	RA	patients	(AMBITION	study).[35]	
They	report	no	data	on	AI	during	the	24	weeks	of	therapy.	It	was	however	noted	that	TCZ	is	more	
prone	to	disturb	lipid	pattern	compared	to	methotrexate	and	leads	to	LDL-c	and	TG	elevations.	In	
an	observational	 study,	Kawashiri	et	al.	noticed	no	changes	 in	 the	ApoB:ApoA-1	and	TC:HDL-c	
ratio	despite	an	increase	of	individual	lipids	in	a	small	group	of	RA	patients	treated	with	TCZ	for	
12	weeks.[36]	 Similar	 findings	 have	 been	 reported	 by	 Kume	 et	 al.,	 who	 found	 no	 changes	 in	
TC:HDL-c	ratio	24	weeks	after	starting	tocilizumab	in	22	RA	patients,	despite	sustained	increase	
of	both	TC	and	HDL-c	alone.[21]	Interestingly,	the	authors	noticed	that	the	increase	in	TC	in	the	
TCZ	group	has	been	higher	than	 in	the	patients	receiving	adalimumab	or	etanercept,	reaching	
statistical	significance	(TCZ	versus	ETN	P	=	0.024,	TCZ	versus	ADA	P	=	0.032).	Although	the	first	of	
its	kind	by	directly	comparing	three	diﬀerent	biologicals	with	respect	to	endothelial	dysfunction	
and	lipid	pattern,	the	results	of	the	study	should	be	interpreted	with	caution	given	the	relative	
low	 number	 of	 patients	 enrolled	 in	 each	 group	 (approximately	 20).	 Overall,	 the	 present	
experience	with	 tocilizumab	appears	 to	 suggest	 a	 certain	detrimental	 eﬀect	on	 lipids	pattern,	
translated	into	a	higher	percentage	of	patients	with	a	significant	increase	in	the	AI—TC:HDL-c	and	
LDL-c:HDL-c,[33,	34,	39]	whereas	ApoB:ApoA-1	ratio	remains	stable	throughout	the	therapy.[33,	
36,	39]	These	lipid	modifications	led	in	several	cases	to	the	start	of	therapy	with	lipid-lowering	
agents.	It	is	still	unclear	if	long-term	treatment	with	TCZ	would	reverse	these	detrimental	eﬀects	
and	achieve	sustained	improvements	in	AI.	To	our	knowledge,	no	studies	have	investigated	the	
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eﬀect	of	TCZ	on	the	HDL-c	cholesterol	function.	Given	the	emerging	importance	of	this	factor	in	
CVD	risk	assessment,	future	studies	on	this	issue	are	warranted.	
Table	3.	Effects	of	tocilizumab	on	atherogenic	index	and	other	lipid	ratios.		
Atherogenic	index	 Study	[reference],	patients	(n),	lipid	ratio’s		
Higher	 Emery	et	al.[33],	(n	=	338),	LDL-c:HDL-c	
Genovese	et	al.[34],	(n	=	803),	TC:HDL-c,	LDL-c:HDL-c	
Smolen	et	al.[39],	(n	=	418),	TC:HDL-c	
Neutral	 Kume	et	al.[21],	(n	=	22),	TC:HDL-c	
Kawashiri	et	al.[36],	(n	=	19),	TC:HDL-c,	ApoB:ApoA-1	
Maini	et	al.[37],	(n	>	50),	TC:HDL-c	
Not	assessed		 Jones	et	al.[35],	Schultz	et	al.[38]	
	
Rituximab	
There	 were	 few	 studies	 investigating	 the	 eﬀects	 of	 newer	 biologicals	 on	 lipids	 pattern	 in	 RA	
patients.	Rituximab,	a	B-cell	depletion	drug,	targeting	the	CD20	positive	B	lymphocytes,	has	been	
so	 far	been	scarcely	 investigated	with	regards	to	 its	eﬀects	on	AI	and	HDL-c	composition.	 In	a	
small	group	of	RA	patients,	Gonzalez-Juanatey	et	al.	investigated	for	the	first	time	the	eﬀects	of	
rituximab	on	 lipid	parameters.[40].	The	authors	have	 found	a	slight,	nonsignificant	 increase	 in	
HDL-c	 levels	 both	 at	 2	weeks	 (56	±	 11	mg/dl)	 and	 at	 6	months	 (57	±	 15	mg/dl)	 compared	 to	
baseline	levels	(52	±	11	mg/dl),	whereas	TC	increased	only	2	weeks	after	starting	rituximab	(211±	
42	mg/dl	versus	191	±	37	mg/dl).	No	direct	information	on	AI	has	been	provided.	In	another	study,	
Kerekes	et	al.	found	an	increase	in	HDL-c	levels	with	14.3%,	33.1%,	and	35.4%	as	compared	to	
baseline,	at	2,	6,	and	16	weeks,	respectively,	after	rituximab	had	been	initiated.[41]	At	sixteen-
week	 time-point,	 the	 diﬀerence	 reached	 significance	 (P	 =	 0.035).	 Interestingly,	 TC	 tended	 to	
decrease	without	significance,	throughout	study	period.	This	may	suggest	a	decrease	in	the	AI.	
The	results	are	in	line	with	the	previous	ones,	yet	the	limited	number	of	patients	investigated	(n	
=	5)	makes	their	 interpretation	diﬃcult.	The	first	 larger	study	comes	from	Ajeganova	et	al.[14]	
The	 Swedish	 group	 investigated	 the	 eﬀects	 of	 various	 biologicals	 on	 lipids	 pattern	 in	 215	 RA	
patients	receiving	therapy	with	various	biologicals,	focusing	on	apolipoproteins	(ApoA	and	ApoB)	
and	their	ratio.	The	investigators	found	that	in	the	rituximab-treated	group	(n	=	53)	apoA-1	levels	
increased	throughout	the	study	with	0.09	±	0.32	g/L	(P	=0.022,	follow-up	of	6	months)	and	0.09	
±	 0.32	 g/L	 (P=0.06,	 follow-up	 of	 12	 months),	 respectively.	 The	 ratio	 ApoB:ApoA-1	 remained	
relatively	stable	and	did	not	change	significantly	over	the	study	period.	The	TC,	HDL-c,	and	their	
ratio	 (AI)	 have	 been	 not	 assessed.	 Interestingly,	 the	 authors	 found	 no	 associations	 between	
ApoB:ApoA-1	 ratios	 and	markers	 of	 disease	 activity,	 therefore	 sustaining	 our	 hypothesis	 that	
ratios	are	less	susceptible	to	changes	in	disease	activity	and	thus	they	are	probably	better	suited	
to	 predict	 CVD	 risk	 in	 these	 patients.	 Finally,	 two	more	 studies	 should	 be	mentioned,	 which	
further	 investigated	the	interplay	between	rituximab	and	lipids	 in	RA	patients	by	assessing	the	
eﬀects	of	this	drug	on	HDL-c	anti-atherogenic	function.[42,	43]	In	the	first	one,	49	RA	patients	
have	been	followed	6	months	after	receiving	rituximab.[43]	As	previously	suggested,	rituximab	
modestly	increased	HDL-c	and	ApoA-1	levels	and	significantly	improved	AI(P	<	0.05).	A	subanalysis	
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revealed	 that	 these	 changes	 were	 only	 present	 in	 the	 subgroup	 of	 responders.	 There	 is	 no	
association	 found	 with	 the	 use	 of	 prednisone.	 HDL-c	 composition	 changed	 upon	 rituximab	
therapy,	becoming	depleted	in	SAA-1	in	patients	who	have	demonstrated	a	good	response	to	the	
therapy,	rendering	the	molecule	to	be	anti-atherogenic.	This	observation	further	substantiates	
the	importance	of	HDL-c	function	assessment	in	patients	with	RA	and	other	chronic	inflammatory	
conditions	in	order	to	get	a	proper	picture	of	their	CV	risk.	In	the	second	study,	Mathieu	et	al.	
presented	data	on	33	RA	patients	treated	with	rituximab.[42]	AI	remained	stable,	although	TC	
significantly	increased	both	at	6	and	at	12	months	after	rituximab	(P	<	0.001).	The	study	enrolled	
RA	patients	with	longer	disease	duration	(mean	17.6	years)	who	had	already	failed	to	respond	to	
two	different	types	of	anti-TNF	drugs.	
	
CONCLUSION	
The	available	literature	shows	that	anti-TNF	drugs,	IL-6R	antagonists,	and	anti-CD20	antibodies	
are	able	to	modulate	the	lipid	profile	in	RA.	Interestingly,	when	considering	their	eﬀects	on	the	AI	
and	other	lipoproteins	ratio,	it	becomes	evident	that	changes	in	individual	lipid	levels	often	do	
not	translate	in	to	a	change	in	AI,	or	are	not	sustained	long	enough	to	significantly	aﬀect	the	AI.	
Therapy	 with	 etanercept,	 adalimumab,	 or	 rituximab	 seems	 to	 have	 a	 positive	 impact	 on	 AI,	
although	this	improvement	does	not	always	reach	statistical	significance	and	sometimes	an	initial	
gain	is	lost	over	time.	In	contrast,	the	use	of	infliximab	may	worsen	lipid	ratios	on	the	long	term,	
though	some	report	a	neutral	eﬀect.	Similarly,	tocilizumab	is	likely	to	worsen	lipid	ratios	in	the	
first	months	after	therapy	has	been	initiated,	while	the	longer-term	eﬀects	remain	still	unknown.	
Nevertheless,	controlling	disease	activity	and	achieving	remission	seem	to	beneficially	impact	the	
lipid	 pattern,	 as	 suggested	 by	 the	 positive	 eﬀects	 seen	 in	 responders.	 Finally,	 the	 form	 and	
function	of	HDL-c	appear	to	be	compliant	to	changes	in	inflammation.	Treatment	with	anti-TNF	
agents	and	rituximab	results	in	improvements	of	the	HDL-c	anti-atherogenic	capacity.	It	is	unclear	
whether	these	changes	progress	over	time	and	to	what	extent	they	decrease	CVD	risk.	No	data	
on	 the	 eﬀects	 of	 tocilizumab	 on	 HDL-c	 function	 are	 available.	 The	 interpretation	 of	 our	
conclusions	should	not	be	without	caution.	It	is	still	unclear	to	what	extent	these	changes	actually	
lead	to	a	change	in	the	CVD	risk.	Moreover,	some	suggest	that	even	if	changes	occur,	they	might	
have	a	milder	impact	on	CVD	risk	compared	to	the	general	population.[52]	The	follow-up	period	
of	 these	 studies	 is	 often	 too	 short	 to	 include	 CVD	 events.	 Sometimes	 possible	 confounding	
variables	were	not	properly	accounted	 for	as	changes	 in	 lipid	 levels	often	were	not	a	primary	
outcome,	for	instance	in	the	majority	of	tocilizumab	studies.		
In	conclusion,	we	suggest	that	AI	and	HDL-c	function	are	more	suitable	parameters	of	lipid	profile	
as	 determinants	 of	 CVD	 risk	 in	 patients	with	RA,	 and	perhaps	 for	 other	 chronic	 inflammatory	
diseases	including	lupus,	psoriatic	arthritis,	and	ankylosing	spondylitis.	The	eﬀects	of	biologicals	
on	 these	 parameters	 depend	 on	 the	 response	 rate,	 concomitant	 prednisone	 use,	 duration	 of	
therapy,	 and	 the	 biological	 self.	 If	 CVD	 risk	 management	 becomes	 an	 integrated	 part	 of	
therapeutic	strategies	in	RA	and	given	the	increasing	importance	of	personalized	medicine,	the	
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choice	of	biological	might	become	partially	dependent	on	the	impact	on	CVD	risk	profile.	Future	
studies	with	clinical	CVD	endpoints	would	have	to	address	the	value	of	monitoring	AI	and	HDL-c	
function	during	therapy	with	biologicals	in	order	to	establish	their	real	impact	on	CVD	risk	in	these	
patients.	
	 	
Impact	of	therapy	with	biologicals	on	the	atherogenic	index	and	HDL-c	in	RA	
	
5		
	 78	
REFERENCES	
1. Gabriel	SE,	Crowson	CS,	Kremers	HM,	et	al.	Survival	in	rheumatoid	arthritis:	a	population-based	
analysis	of	trends	over	40	years.	Arthritis	Rheum.	2003;	48:	p	54–58	
2. Pincus	 T,	 Sokka	 T,	 and	Wolfe	 F.	 Premature	mortality	 in	 patients	 with	 rheumatoid	 arthritis:	
evolving	concepts.	Arthritis	Rheum.	2001;	44:	p	1234–1236	
3. Del	Rincon	I,	Williams	K,	Stern	MP,	et	al.	High	incidence	of	cardiovascular	events	in	a	rheumatoid	
arthritis	cohort	not	explained	by	traditional	cardiac	risk	factors.	Arthritis	Rheum.	2001;	44:	p	
2737–2745.	
4. Ross	R.	Atherosclerosis—an	inflammatory	disease.	The	New	England	Journal	of	Medicine.	1999;	
340:	p	115–12	
5. Sattar	N,	McCarey	W,	Capell	H.	Explaining	how	“high-grade”	systemic	inflammation	accelerates	
vascular	risk	in	rheumatoid	arthritis.	Circulation.	2003;	108:	p	2957–2963	
6. Van	Doornum	S,	McColl	G,	Wicks	IP.	Accelerated	atherosclerosis:	an	extra-articular	feature	of	
rheumatoid	arthritis?	Arthritis	Rheum.	2002;	46:	p	862–873	
7. Smolen	JS,	Landewe	R,	Breedveld	FC,	et	al.	EULAR	recommendations	for	the	management	of	
rheumatoid	arthritis	with	synthetic	and	biological	disease-modifying	antirheumatic	drugs.	Ann	
Rheum	Dis.	2010;	69:	p	964–975	
8. Toms	TE,	Panoulas	VF,	Douglas	KMJ,	et	al.	Statin	use	in	rheumatoid	arthritis	in	relation	to	actual	
cardiovascular	risk:	evidence	for	substantial	undertreatment	of	lipid-associated	cardiovascular	
risk?	Ann	Rheum	Dis.	2010;	69:	p	683–688	
9. Peters	MJL,	 Symmons	DPM,	McCarey	D,	 et	 al.	 EULAR	evidence-based	 recommendations	 for	
cardiovascular	 risk	 management	 in	 patients	 with	 rheumatoid	 arthritis	 and	 other	 forms	 of	
inflammatory	arthritis.	Ann	Rheum	Dis.	2010;	69:	p	325–331		
10. McMahon	M,	Grossman	 J,	 FitzGerald	 J,	 et	 al.	 Proinflammatory	 high-density	 lipoprotein	 as	 a	
biomarker	for	atherosclerosis	in	patients	with	systemic	lupus	erythematosus	and	rheumatoid	
arthritis,”	Arthritis	Rheum.	2006;	54:	p	2541–2549	
11. Popa	C,	Van	Tits	LJH,	Barrera	P,	et	al.	Anti-inflammatory	therapy	with	tumour	necrosis	factor	
alpha	 inhibitors	 improves	 high-density	 lipoprotein	 cholesterol	 antioxidative	 capacity	 in	
rheumatoid	arthritis	patients.	Ann	Rheum	Dis.	2009;	68:	p	868–872	
12. Park	YB,	Lee	SK,	Lee	WK,	et	al.	Lipid	profiles	in	untreated	patients	with	rheumatoid	arthritis.	J	
Rheum.	1999;	26:	p	1701–1704	
13. Van	 Halm	 VP,	 Nielen	 MMJ,	 Nurmohamed	 MT	 et	 al.	 Lipids	 and	 inflammation:	 serial	
measurements	of	the	lipid	profile	of	blood	donors	who	later	developed	rheumatoid	arthritis.	
Ann	Rheum	Dis.	2007;	66:	p	184–188	
14. Ajeganova	 S,	 Fiskesund	 R,	 De	 Faire	 U,	 et	 al.	 Eﬀect	 of	 biological	 therapy	 on	 levels	 of	
atheroprotective	 antibodies	 against	 phosphorylcholine	 and	 apolipoproteins	 in	 rheumatoid	
arthritis—a	one	year	study.	Clin	Exp	Rheum.	2011;	29:	p	942–950	
15. Allanore	Y,	Kahan	A,	Sellam	J,	et	al.	Eﬀects	of	repeated	infliximab	therapy	on	serum	lipid	profile	
in	patients	with	refractory	rheumatoid	arthritis.	Clin	Chim	Acta.	2006;	365:	p	143–148	
16. Curtis	JR,	John	A,	Baser	O.	Dyslipidemia	and	changes	in	lipid	profiles	associated	with	rheumatoid	
arthritis	and	initiation	of	anti-TNF	therapy.	Arthritis	Care	Res.	2012;	64:	p	1251–1282	
17. Dahlqvist	SR,	Engstrand	S,	Berglin	E,	et	al.	Conversion	towards	an	atherogenic	 lipid	profile	 in	
rheumatoid	arthritis	patients	during	long-term	infliximab	therapy.	Scand	J	of	Rheumatol.	2006;	
35:	p	107–111	
18. Engvall	 IL,	Tengstrand	B,	Brismar	K,	et	al.	 Infliximab	therapy	 increases	body	fat	mass	 in	early	
rheumatoid	 arthritis	 independently	 of	 changes	 in	 disease	 activity	 and	 levels	 of	 leptin	 and	
adiponectin:	a	randomised	study	over	21	months.	Arthritis	Res	Ther.	2010;	12;	R197	
	 79	
19. Jamnitski	A,	Visman	IM,	Peters	MJL,	et	al.	Beneficial	eﬀect	of	1-year	etanercept	treatment	on	
the	lipid	profile	in	responding	patients	with	rheumatoid	arthritis:	the	ETRA	study.	Ann	Rheum	
Dis.	2010;	69:	p	1929–1933	
20. Kiortsis	 DN,	Mavridis	 AK,	 Filippatos	 TD,	 et	 al.	 Eﬀects	 of	 infliximab	 treatment	 on	 lipoprotein	
profile	 in	patients	with	rheumatoid	arthritis	and	ankylosing	spondylitis.	J	Rheum.	2006;	33:	p	
921–923	
21. Kume	 K,	 Amano	 K,	 Yamada	 S,	 et	 al.	 Tocilizumab	 monotherapy	 reduces	 arterial	 stiﬀness	 as	
eﬀectively	as	etanercept	or	adalimumab	monotherapy	in	rheumatoid	arthritis:	an	open-label	
randomized	controlled	trial.	J	Rheum.	2011;	38:	p	2169–2171	
22. Nishida	K,	Okada	Y,	Nawata	M,	et	al.	 Induction	of	hyperadiponectinemia	following	long-term	
treatment	 of	 patients	 with	 rheumatoid	 arthritis	 with	 infliximab	 (IFX),	 an	 anti-TNF-alpha	
antibody.	Endocr	J.	2008;	55:	p	213–216	
23. Peters	 MJL,	 Vis	 M,	 Van	 Halm	 VP,	 et	 al.	 Changes	 in	 lipid	 profile	 during	 infliximab	 and	
corticosteroid	treatment	in	rheumatoid	arthritis.	Ann	Rheum	Dis.	2007;	66:	p	958–961		
24. Popa	 C,	 Netea	 MG,	 Radstake	 T,	 et	 al.	 Influence	 of	 anti-tumour	 necrosis	 factor	 therapy	 on	
cardiovascular	risk	factors	in	patients	with	active	rheumatoid	arthritis.	Ann	Rheum	Dis.	2005;	
64:	p	303–305	
25. Popa	 C,	 Van	 den	 Hoogen	 FHJ,	 Radstake	 TRDJ,	 et	 al.	 Modulation	 of	 lipoprotein	 plasma	
concentrations	during	long-term	anti-TNF	therapy	in	patients	with	active	rheumatoid	arthritis.	
Ann	Rheum	Dis.	2007;	66:	p	1503–1507	
26. Seriolo	B,	Paolino	S,	Sulli	A.	Eﬀects	of	anti-TNF-α	treatment	on	lipid	profile	in	patients	with	active	
rheumatoid	arthritis.	Ann	N	Y	Acad	Sci.	2006;	1069:	p	414–419	
27. Seriolo	B,	Paolino	S,	Ferrone	C.	Eﬀects	of	etanercept	or	infliximab	treatment	on	lipid	profile	and	
insulin	 resistance	 in	 patients	 with	 refractory	 rheumatoid	 arthritis.	 Clin	 Rheum.	 2007;	 26:	 p	
1799–1800	
28. Soubrier	M,	Jouanel	P,	Mathieu	S,	et	al.	Eﬀects	of	anti-tumor	necrosis	factor	therapy	on	lipid	
profile	in	patients	with	rheumatoid	arthritis.	2008.	Joint	Bone	Spine.	2008;	75:	p	22–24	
29. Spanakis	 E,	 Sidiropoulos	 P,	 Papadakis	 J,	 et	 al.	Modest	 but	 sustained	 increase	 of	 serum	high	
density	 lipoprotein	 cholesterol	 levels	 in	 patients	 with	 inflammatory	 arthritis	 treated	 with	
infliximab.	J	Rheum.	2006;	33:	p	2440–2446	
30. Tam	LS,	Tomlinson	B,	Chu	TT,	et	al.	Impact	of	TNF	inhibition	on	insulin	resistance	and	lipids	levels	
in	patients	with	rheumatoid	arthritis.	Clin	Rheum.	2007;	26:	p	1495–1498	
31. Vis	M,	Nurmohamed	MT,	Wolbink	G,	et	al.	Short	term	eﬀects	of	infliximab	on	the	lipid	profile	in	
patients	with	rheumatoid	arthritis.	J	Rheum.	2005;	32:	p	252–255	
32. Wijbrandts	 CA,	 Van	 Leuven	 SI,	 Boom	 HD,	 et	 al.	 Sustained	 changes	 in	 lipid	 profile	 and	
macrophage	 migration	 inhibitory	 factor	 levels	 after	 anti-tumour	 necrosis	 factor	 therapy	 in	
rheumatoid	arthritis.	Ann	Rheum	Dis.	2009;	68:	p	1316–1321	
33. Emery	 P,	 Keystone	 E,	 Tony	 HP,	 et	 al.	 IL-6	 receptor	 inhibition	 with	 tocilizumab	 improves	
treatment	outcomes	 in	patients	with	rheumatoid	arthritis	 refractory	to	anti-tumour	necrosis	
factor	biologicals:	results	from	a	24-week	multicenter	randomised	placebo-controlled	trial.	Ann	
Rheum	Dis.	2008;	67:	p	1516–152.	
34. Genovese	MC,	McKay	JD,	Nasonov	EL,	et	al.	Interleukin-6	receptor	inhibition	with	tocilizumab	
reduces	disease	activity	in	rheumatoid	arthritis	with	inadequate	response	to	disease-modifying	
antirheumatic	 drugs:	 the	 tocilizumab	 in	 combination	 with	 traditional	 disease-modifying	
antirheumatic	drug	therapy	study.	Arthritis	Rheum.	2008;	58:	p	2968–2980	
35. Jones	G,	Sebba	A,	Gu	 J,	et	al.	Comparison	of	 tocilizumab	monotherapy	versus	methotrexate	
monotherapy	in	patients	with	moderate	to	severe	rheumatoid	arthritis:	the	AMBITION	study.	
Ann	Rheum	Dis.	2010;	69:	p	88–96	
5		
Impact	of	therapy	with	biologicals	on	the	atherogenic	index	and	HDL-c	in	RA	
	
	 80	
36. Kawashiri	A.	Kawakami,	S.	Yamasaki	et	al.	Eﬀects	of	the	anti-interleukin-6	receptor	antibody,	
tocilizumab,	on	serum	lipid	levels	 in	patients	with	rheumatoid	arthritis.	Rheumatol	Int.	2011;	
31:	p	451–456	
37. Maini	RN,	Taylor	PC,	Szechinski	J,	et	al.	Double-blind	randomized	controlled	clinical	trial	of	the	
interleukin-6	receptor	antagonist,	tocilizumab,	in	European	patients	with	rheumatoid	arthritis	
who	had	an	incomplete	response	to	methotrexate.	Arthritis	Rheum.	2006;	54:	p	2817–2829	
38. Schultz	O,	Oberhauser	F,	Saech	J,	et	al.	Eﬀects	of	inhibition	of	interleukin-6	signaling	on	insulin	
sensitivity	and	 lipoprotein	(A)	 levels	 in	human	subjects	with	rheumatoid	diseases.	PLoS	ONE.	
2010;	5:	e14328	
39. Smolen	 JS,	Beaulieu	A,	Rubbert-Roth	A,	et	al.	 Eﬀect	of	 interleukin-6	 receptor	 inhibition	with	
tocilizumab	 in	 patients	 with	 rheumatoid	 arthritis	 (OPTION	 study):	 a	 double-blind,	 placebo-
controlled,	randomised	trial.	The	Lancet.	2008;	371:	p	987–997		
40. Gonzalez-Juanatey	 C,	 Llorca	 J,	 Vazquez-Rodriguez	 TR,	 et	 al.	 Short-term	 improvement	 of	
endothelial	 function	 in	 rituximab-treated	 rheumatoid	 arthritis	 patients	 refractory	 to	 tumor	
necrosis	factor	α	blocker	therapy.	Arthritis	Rheum.	2008;	59:	p	1821–1824	
41. Kerekes	G,	Soltész	P,	Dér	H,	et	al.	Eﬀects	of	rituximab	treatment	on	endothelial	dysfunction,	
carotid	atherosclerosis,	and	 lipid	profile	 in	 rheumatoid	arthritis.	Clin	Rheumatol.	2009;	28:	p	
705–710,	2009	
42. Mathieu	S,	Pereira	B,	Dubost	JJ,	et	al.	No	significant	change	 in	arterial	stiﬀness	 in	RA	after	6	
months	and	1	year	of	rituximab	treatment.	Rheumatology	(Oxford).	2012;	51:	p	1107–1111	
43. Raterman	HG,	Levels	H,	Voskuyl	AE.	HDL	protein	composition	alters	from	proatherogenic	into	
less	atherogenic	and	proinflammatory	in	rheumatoid	arthritis	patients	responding	to	rituximab.	
Ann	Rheum	Dis.	2013;	72:	560-5	
44. Dixon	WG,	Watson	KD,	 Lunt	M,	et	al.	Reduction	 in	 the	 incidence	of	myocardial	 infarction	 in	
patients	with	rheumatoid	arthritis	who	respond	to	anti-tumor	necrosis	factor	α	therapy:	Results	
from	the	British	Society	for	Rheumatology	Biologics	Register.	Arthritis	Rheum.	2007;	56:	p	2905–
2912	
45. Gonzalez-Juanatey	 C,	 Llorca	 J,	 Sanchez	 Andrade	 A,	 et	 al.	 Short-	 term	 adalimumab	 therapy	
improves	endothelial	function	in	patients	with	rheumatoid	arthritis	refractory	to	infliximab.	Clin	
Exp	Rheumatol.	2006;	24:	p	309–312	
46. Kontush	A,	Chapman	MJ.	Antiatherogenic	 function	of	HDL	particle	 subpopulations:	 focus	on	
antioxidative	activities.	Curr	Opin	Lipidol.	2010;	21:	p	312–318	
47. Khera	 AV,	 Cuchel	 M,	 De	 La	 Llera-Moya	 M,	 et	 al.	 Cholesterol	 eﬄux	 capacity,	 high-density	
lipoprotein	function,	and	atherosclerosis.	N	Engl	J	Med.	2011;	364:	p	127–135	
48. Stock	J.	 Importance	of	HDL	functionality	 to	cardiovascular	risk.	Atherosclerosis.	2011;	218:	p	
19–20	
49. Ansell	BJ,	Fonarow	GC,	Fogelman	AM.	The	paradox	of	dysfunctional	high-density	 lipoprotein.	
Curr	Opin	Lipidol.	2007;	18:	p	427–434	
50. Charles-Schoeman	 C,	 Khanna	 D,	 Furst	 DE,	 et	 al.	 Eﬀects	 of	 high-dose	 atorvastatin	 on	 anti-
inflammatory	properties	of	high	density	lipoprotein	in	patients	with	rheumatoid	arthritis:	a	pilot	
study.	J	Rheum.	2007;	34:	p	1459–1464	
51. Arts	EEA,	Fransen	J,	Lemmers	H,	et	al.	High-density	lipoprotein	cholesterol	subfractions	HDL2	
and	HDL3	are	reduced	in	women	with	rheumatoid	arthritis	and	may	augment	the	cardiovascular	
risk	of	women	with	RA:	a	cross-sectional	study.	Arthritis	Res	Ther.	2012;	14:	R116	
52. Symmons	DPM,	Gabriel	SE.	Epidemiology	of	CVD	in	rheumatic	disease,	with	a	focus	on	RA	and	
SLE.	Nat	Rev	Rheumatol.	2011;	7:	p	399–408	
	 81	
	 	
5		
Impact	of	therapy	with	biologicals	on	the	atherogenic	index	and	HDL-c	in	RA	
	
	 82	
	 	
		
	
	
CHAPTER	6	
The	effect	of	disease	duration	and	disease	activity	on	the	risk	of	
cardiovascular	disease	in	rheumatoid	arthritis	patients	
	
	
	
	
	
	
	
E.E.A.	Arts	
J.	Fransen	
A.A.	Den	Broeder	
C.	Popa	
P.L.C.M.	Van	Riel	
	
	
	
	
Annals	of	Rheumatic	Diseases	
2015;	74:	p	998-1003	
	 84	
ABSTRACT		
Objective		
Disease	duration	and	disease	activity	may	be	associated	with	an	increased	risk	of	cardiovascular	
disease	(CVD)	in	rheumatoid	arthritis	(RA).	The	objectives	of	this	study	were	to		investigate	(1)	the	
relationship	 between	 duration	 of	 inﬂammation	 and	 the	 development	 of	 CVD	 and	 (2)	 the	
relationship	between	RA	disease	activity	over	time	and	CVD	in	patients	with	RA.	
Methods		
RA	patients	with	a	follow-up	of	≥6	months	 in	the	Nijmegen	early	RA	cohort	without	prior	CVD	
were	included.	Disease	activity	over	time	was	calculated	using	the	time-averaged	28	joint	disease	
activity	 score	 (DAS28)	 for	 each	 patient.	 Kaplan–Meier	 survival	 analysis	 and	 Cox	 proportional	
hazards	regression	were	used	for	the	analyses.	
Results		
During	follow-up	of	the	855	patients	that	were	included,	154	CV	events	occurred.	The	course	of	
hazards	over	 time	did	not	 indicate	a	change	 in	 the	risk	of	CVD	over	 the	course	of	RA	 (disease	
duration),	which	is	also	reﬂected	by	the	absence	of	a	deﬂection	in	the	survival	curves.	The	survival	
distributions	did	not	differ	between	patients	with	a	disease	duration	of	<10	years	or	>10	years	
(Log-rank	test:	p	=	0.82).	Time-averaged	DAS28	was	signiﬁcantly	associated	with	CVD	(p	=	0.002)	
after	correction	for	confounders.	
Conclusions		
Disease	duration	does	not	appear	to	independently	affect	the	risk	of	CVD.	The	risk	of	CVD	in	RA	
patients	was	not	increased	after	10	years	of	disease	duration	compared	with	the	ﬁrst	10	years.	
Disease	activity	over	time	may	contribute	to	the	risk	of	CVD.		
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INTRODUCTION	
Rheumatoid	arthritis	(RA)	is	a	chronic	systemic	inﬂammatory	disease	of	multifactorial	aetiology.	
Despite	important	advances	in	treatment	strategies,	RA	is	still	associated	with	excess	mortality	
rates	 of	 approximately	 25%.[1]	 Cardiovascular	 disease	 (CVD)	 represents	 the	 leading	 cause	 of	
death	in	RA,	accounting	for	approximately	50%	of	all	excess	mortality.[2]	The	excess	risk	of	CVD	
cannot	be	completely	explained	by	traditional	risk	factors	alone.[3]	Growing	evidence	supports	
the	 notion	 that	 inﬂammatory	 and	 immune	 mechanisms	 underline	 atherosclerosis.[4,	 5]	 It	 is	
hypothesized	that	chronic	systemic	inﬂammation	in	RA	represents	a	disease	related	risk	factor,	
accounting	for	extra	cardiovascular	(CV)	risk.[6]	Recent	studies	have	investigated	the	link	between	
the	 presence	 of	 inﬂammatory	 markers	 used	 to	 determine	 disease	 activity	 in	 RA,	 such	 as	
erythrocyte	sedimentation	rate	(ESR)	and	C-reactive	protein	(CRP),	and	the	development	of	CVD.	
CRP	has	been	indicated	as	a	predictor	for	(accelerated)	atherosclerosis.[7,	8]	ESR	and	CRP	have	
also	 been	 associated	 with	 CVD	 in	 RA	 and	 polyarthritis.[9–12]	 Atherosclerotic	 plaques	 in	 the	
carotid	 artery	 appear	 more	 severe	 and	 prevalent	 in	 RA	 patients	 compared	 with	 the	 general	
population.[13–16]	In	comparison	to	healthy	controls	and	RA	patients	in	remission,	RA	patients	
with	active	disease	seem	to	have	less	stable	plaques,	more	vulnerable	to	rupture,	increasing	the	
probability	of	an	acute	CVD	event.[17]	Additionally,	inﬂammation	is	likely	to	modulate	traditional	
CVD	risk	factors,	including	lipids,	endothelial	function	and	insulin	sensitivity.[18,	19]	This	led	to	
the	 ‘smaller	 slice	 of	 a	 larger	 pie’	 concept	 in	which	 traditional	 CVD	 risk	 factors	 have	 a	 smaller	
contribution	to	CVD	risk	 in	RA	patients	 than	 in	 the	general	population.[6]	The	genotype	of	RA	
patients	 may	 also	 be	 of	 interest,	 potentially	 contributing	 to	 unfavourable	 lipid	 patterns	 and	
accelerated	 atherosclerosis.[20,	 21]	 Although	 a	 growing	 body	 of	 pathophysiological	 evidence	
supports	 the	 hypothesis	 that	 inﬂammation	 contributes	 to	 the	 development	 of	 CVD,	 clinical	
research	has	yet	to	clearly	demonstrate	the	relationship	between	RA	disease	activity	and	CVD.	In	
addition	to	disease	activity,	perhaps	the	time	spent	by	a	patient	in	an	inﬂammatory	state	would	
be	crucial	for	the	chance	to	develop	CVD.	Long-standing	disease	elongates	a	patient’s	exposure	
to	chronic	inﬂammation,	and	it	has	been	suggested	that	this	prolonged	exposure	has	a	cumulative	
effect	and	disease	duration	may	therefore	act	as	a	separate	CVD	risk	factor.[22]	Disease	duration	
over	 10	 years	 has	 been	 indicated	 as	 a	 risk	 factor	 for	 CVD	 in	 the	 European	 League	 Against	
Rheumatism	 (EULAR)	 recommendations	 for	 CVD	 risk	 management	 in	 RA	 patients,[23]	 even	
though	some	studies	have	shown	that	the	risk	of	CVD	is	already	increased	in	the	early,	sometimes	
preclinical	stages	of	RA	compared	with	the	general	population.[24–26]	However,	the	excess	risk	
of	CVD	reported	in	early	RA	may	still	continue	to	increase	as	the	disease	progresses	over	time.	
Therefore,	 the	objectives	of	 the	present	 study	are	 (1)	 to	 investigate	 the	 relationship	between	
duration	 of	 inﬂammation	 and	 CVD	 risk	 corrected	 for	 the	 level	 of	 inﬂammation	 and	 (2)	 to	
investigate	the	relationship	between	RA	disease	activity	and	CV	risk	in	patients	with	RA.		
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METHODS	
Study	design	and	patients	
This	study	is	based	on	mainly	prospectively	collected	data	from	the	Nijmegen	early	RA	inception	
cohort.	 Patients	 were	 included	 at	 diagnosis	 of	 RA	 (baseline)	 in	 the	 outpatient	 clinic	 of	 the	
departments	 of	 rheumatology	 of	 the	 Radboud	 University	Medical	 Centre	 (since	 1985)	 or	 the	
Maartenskliniek	(since	1990)	in	Nijmegen,	The	Netherlands.	At	inclusion,	patients	had	a	disease	
duration	of	<1	year,	were	disease-modifying	anti-rheumatic	drug	(DMARD)-naive	and	fulﬁlled	the	
1987	ACR	criteria	for	the	classiﬁcation	of	RA.	All	patients	provided	written	informed	consent,	and	
this	project	was	approved	by	the	medical	ethical	committee,	CMO	Arnhem	Nijmegen.	Patients	
were	 included	 if	 follow-up	 time	was	>6	months	and	 if	 they	had	no	history	of	CVD	prior	 to	RA	
diagnosis.	The	total	cohort	included	1018	patients	at	the	time	of	analysis.	The	77	patients	who	
had	a	history	of	CVD	prior	to	inclusion	were	excluded,	as	well	as	86	patients	who	had	a	follow-up	
of	less	than	6	months.	In	total,	855	patients	were	included	for	analysis.	
Primary	and	secondary	outcomes	
The	primary	outcome	in	this	study	was	the	occurrence	of	a	first	CVD	event	by	physician	diagnosis,	
which	was	retrieved	by	extensive	review	of	medical	charts	and	electronic	patient	ﬁles.	Included	
events	were	acute	coronary	syndrome	comprising	both	myocardial	infarction	(MI)	and	unstable	
angina	pectoris,	angina	pectoris,	cerebrovascular	event	or	stroke,	transient	ischemic	attack	(TIA),	
peripheral	artery	disease	(PAD)	and	revascularisation	procedures	including	coronary	artery	bypass	
surgery,	 percutaneous	 coronary	 intervention	 and	 percutaneous	 transluminal	 coronary	
angioplasty.	Both	fatal	and	non-fatal	events	were	included.	Deaths	due	to	CVD	were	veriﬁed	from	
death	 certiﬁcates,	 provided	by	 Statistics	Netherlands.[27]	Heart	 failure,	 cerebral	 haemorrhage	
and	non-coronary	cardiac	death	(i.e.,	arrhythmias)	were	not	included	for	the	purpose	of	this	study.	
Assessments	
Baseline	patient	characteristics	were	retrieved	from	the	RA	inception	cohort	database,	including	
age,	sex,	rheumatoid	factor	(RF)	status,	disease	activity	(28	joint	disease	activity	score	(DAS28)),	
initial	 anti-rheumatic	 treatment	 and	 treatment	 with	 biological	 DMARDs.	 The	 time-averaged	
DAS28	score	was	calculated	by	taking	the	area	under	the	curve	of	the	DAS28	score	of	the	total	
follow-up	period	divided	by	the	follow-up	period.	Baseline	data	regarding	CVD	risk	factors	were	
collected	 by	 review	 of	 patients’	 charts	 and	 electronic	 patient	 ﬁles,	 including	 smoking	 status	
(yes/no	(Y/N)),	blood	pressure,	use	of	medication	preventative	for	CVD,	body	mass	index	(BMI)	
and	diabetes	mellitus.	Non-fasting	blood	samples	were	used	to	measure	total	cholesterol	(TC),	
high-density	lipoprotein	cholesterol	(HDL-c).	
Statistical	analysis	
The	cut-off	point	of	10	years	was	used	to	differentiate	between	patients	with	and	without	‘long-
standing’	disease,	in	reference	to	the	EULAR	recommendations	that	indicate	disease	duration	>10	
years	as	a	risk	factor	for	CVD.	Differences	in	baseline	variables	between	patients	who	had	a	CVD	
before	10	years	of	disease	duration	and	patients	who	developed	CVD	after	10	years	were	tested	
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using	 independent	samples	 t-test,	Wilcoxon	test	or	χ2	 test,	as	appropriate.	The	effect	of	both	
disease	duration	and	disease	activity	on	the	risk	of	CVD	was	analysed	by	Kaplan-Meier	survival	
analysis	and	Cox	proportional	hazards	regression	analysis.	Survival	and	hazard	curves	were	used	
to	visualise	the	risk	of	CVD	over	time	and	estimate	the	effect	of	disease	duration	on	CVD	risk.	Sex,	
age,	smoking	(Y/N),	BMI	(weight	(kg)/height(m)2),	systolic	blood	pressure	(mm	Hg),	TC	(mmol/L),	
HDL-c	(mmol/L),	DAS28,	ESR	(mm/h),	CRP	(mg/L),	swollen	and	tender	joints,	visual	analogue	scale	
(VAS,	 mm)	 and	 diabetes	 at	 baseline	 (Y/N),	 treatment	 for	 CVD	 risk	 factors	 (Y/N),	 initial	 anti-
rheumatic	 treatment	 (methotrexate,	 sulfasalazine	or	other),	 (MTX)	ever	 (Y/N),	 treatment	with	
biological	ever	(Y/N)	and	RF	status	(positive/negative)	were	considered	as	possible	confounders.	
The	risk	of	a	CVD	event	during	the	ﬁrst	10	years	of	the	disease	was	compared	with	the	risk	of	a	
CVD	event	after	10	years	of	disease	duration	(up	to	25	years)	by	means	of	log-rank	testing	and	
Kaplan-Meier	survival	analysis.	For	this	purpose,	survival	experience	was	grouped	into	two.	For	
the	ﬁrst	group	(group	1)	patients	were	selected	who	were	at	risk	for	a	ﬁrst	CVD	event	in	the	ﬁrst	
10	years	of	disease	duration,	that	 is,	all	patients	who	were	included	in	this	study.	Patient	time	
stopped	at	 the	 time	of	event,	or	was	censored	after	at	 the	 latest	after	10	years	of	event-free	
follow-up.	For	the	second	group	(group	2),	patients	were	selected	(again)	if	they	had	a	follow-up	
>10	years	and	were	free	of	CVD	up	until	that	point.	Patient	time	stopped	at	the	time	of	event	or	
was	 censored	 at	 the	 latest	 at	 the	 censoring	 date	 30-09-2011.	 The	 effect	 of	 the	 level	 of	
inﬂammation	over	time	(time-averaged	DAS28	and	time-averaged	ESR)	was	analysed	using	Cox	
proportional	hazard	regression	with	time-averaged	DAS28	as	the	main	independent	variable.	Age,	
sex,	smoking	(Y/N),	BMI	(weight	(kg)/height(m)2),	systolic	blood	pressure	(mm	Hg),	TC	(mmol/L),	
HDL-c	(mmol/L),	DAS28	and	diabetes	at	baseline	(Y/N),	RF	status	(positive/negative)	and	 initial	
anti-rheumatic	treatment	(methotrexate,	sulfasalazine	or	other),	treatment	with	methotrexate	
ever	(Y/N),	treatment	with	biological	ever	(Y/N)	were	considered	as	possible	confounders.	Missing	
values	on	variables	were	imputed	using	multiple	imputation	analysis	with	five	repetitions.	
	
RESULTS	
Patient	characteristics	and	CV	events	
In	 total,	 855	patients	were	 included,	 comprising	 9959	patient	 years.	 Patients	 had	 a	mean±SD	
disease	duration	of	11.7±6.1	years.	Patient	characteristics	at	baseline	are	presented	in	table	1	for	
the	whole	group	and	separately	for	patients	with	a	CVD	event	within	the	first	10	years	following	
disease	onset	and	with	a	CVD	event	after	more	than	10	years.	In	group	1,	76%	of	patients	were	
treated	with	MTX	compared	with	73%	in	group	2,	and	30%	were	treated	with	a	biological	in	group	
1	versus	33%	 in	group	2.	A	 total	of	154	CVD	events,	of	which	16	were	 fatal,	were	 registered,	
including	64	cases	of	acute	coronary	syndrome,	19	cases	of	stable	angina	pectoris,	30	cases	of	
strokes,	 15	 cases	of	 TIAs,	 21	 cases	of	PAD	and	5	 revascularisation	procedures.	Missing	 values	
ranged	from	0.1%	for	RF	to	10.3%	for	smoking	at	baseline.	
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Disease	duration	and	the	risk	of	CVD	
The	linearity	of	both	the	survival	and	the	proportional	hazard	curve	shows	that	the	cumulative	
risk	increased	with	a	similar	rate	as	disease	duration	increased	and	that	the	risk	per	year	remained	
constant	 (figure	1A);	 also,	 the	hazard	 for	CVD	 remained	 similar	 as	 disease	duration	 increased	
(figure	1B).		
Table	1.	Patient	characteristics	
	 All		
(n=855)	
Event	<10	yrs	
(n=113)	
Event	≥	10yrs	
(n	=	41)	
p-value	
Age	(years),	mean±SD	 54±13.8	 62±9.7	 55±8.7	 <.001	
Sex	(female),	N(%)	 571	(67)		 63	(56)	 23	(56)	 0.97	
DAS28	 5.0±1.3	 5.4±1.3	 5.5±1.3	 0.83	
			SJC,	median	(P25-P75)	 9	(5–13)	 10	(6–15)	 11	(6–15)		 0.60	
			TJC,	median	(P25-P75)	 6	(2–11)	 8	(3–13)	 8	(3–13)	 0.97	
			ESR	(mm/h),	median	(P25-P75)	 30	(16–49)	 35	(18–48)	 39	(15–60)	 0.45	
			VAS	(mm),	median	(P25-P75)	 46	(27–59)	 50	(31–65)	 47	(31–60)	 0.37	
Rheumatoid	factor	(positivity),	N(%)	 664	(78)		 93(82)		 35	(85)		 0.65	
Initial	anti-rheumatic	treatment	 	 	 	 	
			Methotrexate,	N(%)	 135	(16)	 28	(25)	 3	(7)	 <.001	
			Sulfasalazine,	N(%)	 525	(61)	 69	(61)	 31	(76)	 0.09	
			Other,	N(%)	 195	(23)	 29	(26)	 7	(17)	 0.27	
Smoking,	N(%)	 256	(30)	 45	(40)	 16	(39)	 0.93	
BMI	(weight[kg]/height[m]2),	mean±SD	 23.7±6.8	 27±4.0	 25±3.3	 0.10	
Diabetes,	N(%)	 29	(3.4)	 11	(10)	 1	(2)	 0.14	
SBP	(mmHg),	mean±SD	 145±25	 155±24	 148±20	 0.10	
TC	(mmol/L),	mean±SD	 5.9±2.4	 5.2±1.4	 5.5±1.4	 0.27	
HDL-c	(mmol/L),	mean±SD	 1.5±0.6	 1.2±0.3	 1.4±0.4	 <.001	
TC:HDL-c	ratio	(mmol/L),	mean±SD	 4.2±0.9	 4.5±1.2	 4.0±0.8	 0.01	
CVD	prevention,	N(%)†	 129	(15.1)	 30	(27)	 11	(27)	 0.97	
i. P-value	for	the	difference	between	RA	patients	with	a	CVD	event	before	and	after	10	years	of	
disease	duration.	
ii. †CVD	 prevention	 represents	 medication	 use	 for	 primary	 prevention	 of	 CVD,	 including	
anticoagulants,	ACE	or	angiotensin	 II	 inhibitors,	β-blockers,	diuretics,	calcium	antagonists	and	
statins	or	fibrates.		
iii. DAS28;	28-joint	disease	activity	score,	SJC;	swollen	joint	count	(number	of	swollen	joints	out	of	
28),	TJC;	tender	joint	count	(number	of	tender	joints	out	of	28),	ESR;	erythrocyte	sedimentation	
rate,	VAS;	visual	analogue	scale,	BMI;	body	mass	index,	SBP;	systolic	blood	pressure,	TC;	total	
cholesterol,	HDL-c;	high-density	lipoprotein	cholesterol,	CVD;	cardiovascular	disease.	
	
If	 the	 risk	 of	 CVD	 would	 increase	 as	 disease	 duration	 increases,	 the	 cumulative	 survival	 and	
(expected)	 hazard	 lines	would	 show	a	 curve	 upwards	 as	 time	progresses.	 After	 correction	 for	
confounders	(table	2),	the	curves	did	not	change	(not	shown).	The	results	from	the	Kaplan-Meier	
survival	analysis	in	which	the	risk	of	CVD	during	the	first	10	years	of	disease	duration	(group	1)	
was	 compared	with	 the	 risk	 of	 CVD	after	 10	 years	 of	 disease	duration	 (group	2)	 show	 similar	
survival	distributions	that	did	not	differ	significantly	between	groups,	with	p=0.82.	The	survival	
distributions	are	presented	in	figure	2,	showing	overlapping	curves.		
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Figure	1.	Disease	duration	until	CVD	event	or	censoring	in	rheumatoid	arthritis	patients	from	the	1985	
Nijmegen	inception	cohort.	Cumulative	survival	of	cardiovascular	disease	(CVD)	or	event-free	patients	
and	the	cumulative	hazard	are	depicted	on	the	y-axis	of	panels	(A)	and	(B),	respectively.	Time	to	event	
or	censoring	(disease	duration)	 is	depicted	on	the	x-axis.	As	disease	duration	 increases,	the	relative	
increase	in	CVD	risk	remains	similar,	resulting	in	a	linear	survival	(A)	and	hazard	(B)	curve	
	
Table	2.	Effect	of	disease	duration	on	the	risk	of	cardiovascular	disease;	results	of	the	Cox	proportional	
hazards	model	with	disease	duration	until	event	or	censoring	as	the	time	variable		
	 Estimate	 SE	 Exp(B)	 p-value	 95%	CI	
	 	 	 	 	 Lower	 Upper	
Age	(years)	 0.049	 0.008	 1.051	 <.001	 1.035	 1.067	
Smoking	(Y/N)	 0.424	 0.174	 1.528	 0.015	 1.087	 2.149	
BMI	(weight[kg]/height[m]2)	 0.065	 0.018	 1.067	 <.001	 1.030	 1.105	
HDL-c	(mmol/L)	 −.664	 0.211	 0.515	 0.002	 0.340	 0.912	
Diabetes	(Y/N)	 1.050	 0.312	 2.857	 0.001	 1.549	 5.268	
Time-averaged	DAS28	 0.430	 0.081	 1.537	 <.001	 1.312	 1.802	
Bioloigical	ever	(Y/N)	 −.538	 0.227	 0.584	 0.018	 0.374	 0.912	
MTX	ever		 −.336	 0.187	 0.715	 0.072	 0.496	 1.031	
i. Cox	proportional	hazards	regression	model	with	disease	duration	until	event	or	censoring	
as	the	time	variable.	Corrected	for	confounders.	
ii. BMI;	body	mass	index,	DAS28;	28-joint	disease	activity	score,	HDL-c;	high-density	
lipoprotein	cholesterol,	MTX;	methotrexate.		
	
Disease	activity	and	the	risk	of	CVD	
The	mean±SD	 time-averaged	 DAS28	was	 3.6±1.1.	 The	 results	 of	 the	 Cox	 proportional	 hazard	
regression	with	the	time-averaged	DAS28	as	the	main	independent	variable	are	presented	in	table	
3.	After	correction	for	confounders,	the	time-averaged	DAS28	had	a	significant	effect	on	the	risk	
of	CVD	(p=0.002).	With	every	point	the	DAS28	increases,	the	hazard	for	CVD	increases	with	0.281.	
Overall	 there	 was	 a	 difference	 in	 survival	 distributions	 between	 patients	 with	 low	 (<3.2),	
the main independent variable. Age, sex, smoking (Y/N), BMI
(weight (kg)/height(m)2), systolic blood pressure (mmHg), TC
(mmol/L), HDL-c (mmol/L), DAS28 and diabetes at baseline (Y/N),
RF status (positive/negative) and initial antirheumatic treatment
(methotrexate, sulfasalazine or other), treatment with methotrexate
ever (Y/N), treatment with biological ever (Y/N) were considered as
possible confounders.
Missing values on variables were imputed using multiple
imputation analysis with ﬁve repetitions.
RESULTS
Patient characteristics and CV events
In total, 855 patients were included, comprising 9959 patient
years. Patients had me n±SD disease duration of 11.7±6.1 years.
Patient characteristics at baseline are presented in table 1 for the
whole group and separately for patients with a CVevent within the
ﬁrst 10 years following disease onset and with a CV event after
more than 10 years. In group 1, 76% of patients were treated with
MTX compared with 73% in group 2, and 30% were treated with
a biological in group 1 versus 33% in group 2. A total of 154 CV
events, of which 16 were fatal, were registered, including 64 cases
of acute coronary syndrome, 19 cases of stable angina pectoris, 30
cases of strokes, 15 cases of TIAs, 21 cases of PAD and 5
Figure 1 Diseas duration until CV event or censoring in rheumatoid arthritis patients from the 1985 Nijmegen inception cohort. Cumulative
survival of cardiovascular disease (CVD) or event-free patients and the cumulative hazard are depicted on the y-axis of panels (A) and (B),
respectively. Time to event or censoring (disease duration) is depicted on the x-axis. As disease duration increases, the relative increase in CV risk
remains similar, resulting in a linear survival (A) and hazard (B) curve.
Table 2 Effect of disease duration on the risk of cardiovascular
disease; results of the Cox proportional hazards model with disease
duration until event or censoring as the time variable
Variable Estimate SE Exp (B) p Value
95% CI
Lower Upper
Sex (male) 0.618 0.173 1.856 <0.001 1.322 2.604
Age (years) 0.049 0.008 1.051 <0.001 1.035 1.067
Smoking (Y/N) 0.424 0.174 1.528 0.015 1.087 2.149
BMI (weight (kg)/
height (m)2)
0.065 0.018 1.067 <0.001 1.030 1.105
HDL-c (mmol/L) −0.664 0.211 0.515 0.002 0.340 0.912
Diabetes (Y/N) 1.050 0.312 2.857 0.001 1.549 5.268
Time-averaged
DAS28
0.430 0.081 1.537 <0.001 1.312 1.802
Biological ever (Y/
N)
−0.538 0.227 0.584 0.018 0.374 0.912
MTX ever −0.336 0.187 0.715 0.072 0.496 1.031
Cox proportional hazards regression model with disease duration until event or
censoring as the time variable. Corrected for the confounders shown.
BMI, body mass index; DAS28, 28 joint disease activity score; HDL-c, high-density
lipoprotein cholesterol; MTX, methotrexate.
Figure 2 Survival distribution for the group of patients at risk for
cardiovascular disease (CVD) before 10 years of disease duration (group 1)
and patients still at risk for CVD after 10 years (group 2). Cumulative
survival of CVD is depicted on the y-axis, and time to a CV event or
censoring (disease duration) is depicted on the x-axis.
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moderate	(3.2–5.1)	and	high	(>5.1)	DAS28	over	time	(p=0.028).	The	survival	curve	of	patients	with	
a	consistently	high	disease	activity,	that	is,	a	time-averaged	DAS28	>5.1,	was	the	lowest	(figure	
3).	After	correction	for	confounders,	this	group	(DAS28	>5.1)	did	not	have	a	significantly	different	
effect	 on	 CVD	 risk	 compared	 with	 the	 <3.2	 group	 (p=0.074).	 Time-averaged	 ESR	 was	 not	
significantly	associated	with	CVD	(p=0.805)	(data	not	shown).	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.	Disease	Survival	distribution	for	the	group	of	patients	at	risk	for	cardiovascular	disease	(CVD)	
before	10	years	of	disease	duration	(group	1)	and	patients	still	at	risk	for	CVD	after	10	years	(group	
2).	Cumulative	survival	of	CVD	is	depicted	on	the	y-axis,	and	time	to	a	CVD	event	or	censoring	
(disease	duration)	is	depicted	on	the	x-axis.		
	
Table	3.	Effect	of	disease	activity	on	the	risk	of	cardiovascular		
	 Estimate	 SE	 Exp(B)	 p-value	 95%	CI	
	 	 	 	 	 Lower	 Upper	
Crude	model		 	 	 	 	 	 	
		Time-averaged	DAS28	 0.271	 0.073	 1.311	 <.001	 1.135	 1.514	
Adjusted	model	 	 	 	 	 	 	
		Time-averaged	DAS28	 0.281	 0.092	 1.325	 0.002	 1.106	 1.588	
		Sex	(male)	 0.675	 0.173	 1.964	 <.001	 1.399	 2.759	
		Age	(years)	 0.047	 0.008	 1.048	 <.001	 1.033	 1.065	
		BMI	(weight[kg]/height[m]2)	 0.090	 0.013	 1.094	 <.001	 1.066	 1.123	
		RF	(positive)	 0.300	 0.224	 1.349	 0.182	 0.869	 2.095	
		DAS28	at	baseline	 0.114	 0.073	 1.120	 0.118	 0.971	 1.292	
		Bioloigical	ever	(Y/N)	 −.609	 0.217	 0.544	 0.005	 0.355	 0.832	
i. Results	shown	of	the	Cox	proportional	hazards	regression	analysis	for	the	crude	model	
without	correction	for	confounders	(crude	model)	and	for	the	adjusted	model	after	
correction	for	confounders.	
ii. BMI;	body	mass	index,	DAS28;	28-joint	disease	activity	score,	RF;	rheumatoid	factor,	MTX;	
methotrexate.	
the main independent variable. Age, sex, smoking (Y/N), BMI
(weight (kg)/height(m)2), systolic blood pressure (mmHg), TC
(mmol/L), HDL-c (mmol/L), DAS28 and diabetes at baseline (Y/N),
RF status (positive/negative) and initial antirheumatic treatment
(methotrexate, sulfasalazine or other), treatment with methotrexate
ever (Y/N), treatment with biological ever (Y/N) were considered as
possible confounders.
Missing values on variables were imputed using multiple
imputation analysis with ﬁve repetitions.
RESULTS
Patient characteristics and CV events
In total, 855 patients were included, comprising 9959 patient
years. Patients had a mean±SD disease duration of 11.7±6.1 years.
Patient characteristics at baseline are presented in table 1 for the
whole group and separately for patients with a CVevent within the
ﬁrst 10 years following disease onset and with a CV event after
more than 10 years. In group 1, 76% of patients were treated with
MTX compared with 73% in group 2, and 30% were treated with
a biological in group 1 versus 33% in group 2. A total of 154 CV
events, of which 16 were fatal were regist ed, including 64 cases
of acute coronary syndrome, 19 cases of stable angina pectoris, 30
cases of strokes, 15 cases of TIAs, 21 cases of PAD and 5
Figure 1 Disease duration until CV event or censoring in rheumatoid arthritis patients from the 1985 Nijmegen inception cohort. Cumulative
survival of cardiovascular disease (CVD) or event-free patients and the cumulative hazard are depicted on the y-axis of panels (A) and (B),
respectively. Time to event or censoring (disease duration) is depicted on the x-axis. As disease duration increases, the relative increase in CV risk
remains similar, resulting in a linear survival (A) and hazard (B) curve.
Table 2 Effect of disease duration on the risk of cardiovascular
disease; results of the Cox proportional hazards model with disease
duration until event or censoring as the time variable
Variable Estimate SE Exp (B) p Value
95% CI
Lower Upper
Sex (male) 0.618 0.173 1.856 <0.001 1.322 2.604
Age (years) 0.049 0.008 1.051 <0.001 1.035 1.067
Smoking (Y/N) 0.424 0.174 1.528 0.015 1.087 2.149
BMI (weight (kg)/
height (m)2)
0.065 0.018 1.067 <0.001 1.030 1.105
HDL-c (mmol/L) −0.664 0.211 0.515 0.002 0.340 0.912
Diabetes (Y/N) 1.050 0.312 2.857 0.001 1.549 5.268
Time-averaged
DAS28
0.430 0.081 1.537 <0.001 1.312 1.802
Biological ever (Y/
N)
−0.538 0.227 0.584 0.018 0.374 0.912
MTX ever −0.336 0.187 0.715 0.072 0.496 1.031
Cox proportional hazards regression model with disease duration until event or
censoring as the time variable. Corrected for the confounders shown.
BMI, body mass index; DAS28, 28 joint disease activity score; HDL-c, high-density
lipoprotein cholesterol; MTX, methotrexate.
Figure 2 Survival distribution for the group of patients at risk for
cardiovascular disease (CVD) before 10 years of disease duration (group 1)
and patients still at risk for CVD after 10 years (group 2). Cumulative
su i al of CVD is depicted on the y-axis, nd time to a CV event or
censoring (disease duration) is depicted on the x-axis.
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Figure	3.	Survival	distributions	for	rheumatoid	arthritis	patients	divided	into	three	groups	based	on	the	
time-averaged	 DAS28	 (<3.2,	 3.2–5.1,	 >5.1).	 Cumulative	 survival	 of	 cardiovascular	 disease	 (CVD)	 is	
depicted	on	the	y-axis,	and	time	to	a	CV	event	or	censoring	is	depicted	on	the	x-axis		
	
	
DISCUSSION	
According	to	the	results	of	this	study,	disease	duration	did	not	appear	to	affect	the	risk	of	CVD	in	
patients	with	RA.	Furthermore,	our	data	showed	that	mean	RA	disease	activity	over	the	course	of	
the	disease	(time-average	DAS28)	may	contribute	to	the	risk	of	CVD.	The	survival	distribution	for	
CVD	was	 linear	as	disease	duration	 increased.	Specifically,	 the	 shape	 (linearity)	of	 the	 survival	
curves	during	the	first	10	years	of	RA	and	during	the	years	thereafter	was	very	similar,	and	the	
survival	distributions	were	not	significantly	different.	If	CVD	risk	would	increase	in	patients	with	
long-standing	disease,	the	survival	distribution	curve	would	be	expected	to	bend	upwards	as	time	
progresses.	The	EULAR	recommendations	include	disease	duration	>10	years	as	a	risk	factor	for	
CVD,	but	the	evidence	for	this	choice	is	limited.[23]	In	a	study	by	Gabriel	et	al.[1]	in	which	survival	
trends	in	the	RA	population	were	investigated,	it	was	reported	that	the	excess	mortality	did	not	
become	apparent	until	8–10	years	after	disease	onset,[1]	that	is,	after	longer	disease	duration.	
However,	this	association	was	observed	for	all-cause	mortality	and	the	effect	of	disease	duration	
on	the	risk	of	CVD	was	not	investigated	separately	in	this	study.	In	a	study	by	Naz	et	al,[28[	it	was	
reported	that	that	all-cause	and	CVD	mortality	was	increased	in	RF-positive	RA	patients	compared	
with	the	general	population.	CVD	mortality	was	increased	in	both	early	(5	years)	and	late	follow-
up	(10	years).	This	is	more	in	line	with	findings	from	several	other	studies	that	suggest	the	excess	
risk	of	CVD	is	already	present	in	the	early	stages	of	RA.[24–26]	In	our	cohort,	a	higher	prevalence	
of	CVD	was	found	in	patients	during	their	first	10	years	of	RA	compared	with	patients	still	at	risk	
for	 their	 first	CV	event	after	10	years.	 Pathophysiological	data	have	delivered	 support	 for	 the	
revascularisation procedures. Missing values ranged from 0.1% for
RF to 10.3% for smoking at baseline.
Disease duration and the risk of CVD
The linearity of both the survival and the proportional hazard
curve shows that the cumulative risk increased with a similar
rate as disease duration increased and that the risk per year
remained constant (ﬁgure 1A); also the hazard for CVD
remained similar as disease duration increased (ﬁgure 1B). If the
risk of CVD would increase as disease duration increases, the
cumulative survival and (expected) hazard lines would show a
curve upwards as time progresses. After correction for confoun-
ders (table 2), the curves did not change (not shown).
The results from the Kaplan–Meier survival analysis in which
the risk of CVD during the ﬁrst 10 years of disease duration (group
1) was compared with the risk of CVD after 10 years of disease
duration (group 2) show similar survival distributions that did not
differ signiﬁcantly between groups, with p=0.82. The survival dis-
tributions are presented in ﬁgure 2, showing overlapping curves.
Disease activity and the risk of CVD
The mean±SD time-averaged DAS28 was 3.6±1.1. The results of
the Cox proportional hazard regression with the time-averaged
DAS28 as the main independent variable are presented in table 3.
After correction for confounders, the time-averaged DAS28 had a
signiﬁcant effect on the risk of CVD (p=0.002). With every point
the DAS28 increases, the hazard for CVD increases with 0.281.
Overall there was a difference in survival distributions between
patients with low (<3.2), moderate (3.2–5.1) and high (>5.1)
DAS28 over time (p=0.028). The survival curve of patients with a
consistently high disease activity, that is, a time-averaged DAS28
>5.1, was the lowest (ﬁgure 3). After correction for confounders,
this group (DAS28 >5.1) did not have a signiﬁcantly different
effect on CV risk compared with the <3.2 group (p=0.074).
Time-averaged ESR was not signiﬁcantly associated with CVD
(p=0.805) (data not shown).
DISCUSSION
According to the results of this study, disease duration did not
appear to affect the risk of CVD in patients with RA.
Furthermore, our data showed that mean RA disease activity
over the course of the disease (time-average DAS28) may con-
tribute to the risk of CVD.
The survival distribution for CVD was linear as disease duration
increased. Speciﬁcally the shape (linearity) of the survival curves
during the ﬁrst 10 years of RA and during the years thereafter was
very similar, and the survival distributions were not signiﬁcantly
different. If CV risk would increase in patients with long-standing
disease, the survival distribution curve would be expected to bend
upwards as time progresses. The EULAR recommendations include
disease duration >10 years as a risk factor for CVD, but the evi-
dence for this choice is limited.23 In a study by Gabriel et al1 in
which survival trends in the RA population were investigated, it
Table 3 Effect of disease activity on the risk of cardiovascular
disease; results of the Cox proportional hazards model
Variable Estimate SE Exp (B) p Value
95% CI
Lower Upper
Crude model
Time-averaged DAS28 0.271 0.073 1.311 <0.001 1.135 1.514
Adjusted model
Time-averaged DAS28 0.281 0.092 1.325 0.002 1.106 1.588
Sex (male) 0.675 0.173 1.964 <0.001 1.399 2.759
Age (years) 0.047 0.008 1.048 <0.001 1.033 1.065
BMI (weight (kg)/
height (m)²)
0.090 0.013 1.094 <0.001 1.066 1.123
RF (positive) 0.300 0.224 1.349 0.182 0.869 2.095
DAS28 at baseline 0.114 0.073 1.120 0.118 0.971 1.292
Biological ever (Y/N) −0.609 0.217 0.544 0.005 0.355 0.832
Results shown of the Cox proportional hazards regression analysis for the crude
model without correction for confounders and for the adjusted model that is
corrected for the confounders shown.
BMI, body mass index; DAS28, 28 joint disease activity score; RF, rheumatoid factor;
MTX, methotrexate.
Figure 3 Survival distributions for rheumatoid arthritis patients divided into three groups based on the time-averaged 28 joint disease activity
score (<3.2, 3.2–5.1, >5.1). Cumulative survival of cardiovascular disease (CVD) is depicted on the y-axis, and time to a CV event or censoring is
depicted on the x-axis.
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notion	 of	 disease	 duration	 as	 risk	 factor	 for	 CVD,	 as	 it	 has	 been	 reported	 that	 (accelerated)	
atherosclerosis	appears	to	be	more	severe	in	RA	patients	with	established	disease.[22]	However,	
this	 cross-sectional	 association	 with	 a	 surrogate	 marker	 has	 not	 been	 shown	 to	 translate	 in	
increased	risk	for	actual	CVD.	Also,	patients	with	RA	appear	to	be	more	prone	to	plaque	instability	
and	 rupture,	 in	 addition	 to	 accelerated	 atherosclerosis.	 Inflammation	 in	 RA	 may	 therefore	
contribute	more	specifically	to	more	severe	acute	coronary	syndromes	and	strokes,[29]	which	
may	be	more	strongly	associated	with	the	presence	and	severity	of	local	or	systemic	inflammation	
than	with	disease	duration.	The	results	of	this	study	suggest	that	increased	disease	activity	over	
time	 increases	 CVD	 risk.	 Interestingly,	 ESR	 did	 not	 appear	 to	 significantly	 affect	 CVD	 risk.	
Additional	research	is	necessary	to	further	investigate	the	relationship	between	individual	DAS28	
components	and	CVD	risk.	Different	patient	groups	divided	based	on	disease	activity	(<3.2,	3.2–
5.1,	 >5.1)	 did	 not	 differ	 significantly	 from	 each	 other	 in	 terms	 of	 association	 with	 CVD	 risk.	
However,	when	looking	at	the	differences	in	the	survival	curves,	patients	with	a	consistently	high	
level	of	disease	activity	(time-averaged	DAS28>5.1)	appear	to	be	at	a	significantly	higher	risk	of	
developing	CVD	compared	with	patients	with	lower	disease	activity	levels.	In	a	previous	study,	we	
have	suggested	that	an	increased	risk	of	CVD	may	already	be	observed	in	patients	with	low	levels	
of	 disease	 activity[30]	 as	we	have	 shown	 that	 there	was	no	difference	 in	 the	 level	 of	 disease	
activity	or	 the	number	of	patients	with	 low	to	moderate	 levels	of	disease	activity	between	RA	
patients	 with	 and	 without	 MI	 (and	 similar	 disease	 duration).[30]	 This	 may	 also	 mean	 that	
complete	sustained	eradication	of	systemic	inflammation,	that	is,	sustained	clinical	remission,	is	
required	to	substantially	reduce	CVD	risk	in	RA	patients.	Indeed,	there	is	some	evidence	to	suggest	
that	remission	may	be	beneficial	in	preventing	CVD	events.[31,	32]		
There	are	some	points	that	should	be	considered	when	interpreting	the	results	of	this	study.	The	
cohort	that	was	used	in	this	study	spans	more	than	25	years	and	provides	a	relatively	large	sample	
of	RA	patients	with	 long	 follow-up	 times	and	a	considerable	number	of	 recorded	CVD	events,	
which	increases	the	reliability	of	our	findings.	However,	calendar	time	trends	in	the	prevalence	of	
CVD	may	be	a	source	of	bias.	In	the	general	population	in	both	USA	and	Western	Europe,[33–35]	
the	risk	of	CVD	has	been	reduced	in	the	past	decades,	while	in	RA	the	risk	of	CVD	does	not	appear	
to	have	changed.[1]	Therefore,	a	calendar	time	trend	on	the	prevalence	of	CVD	in	our	cohort	was	
considered	unlikely.	Also,	medication	used	to	treat	the	systemic	inflammation	in	RA,	particularly	
the	 recent	 introduction	 of	 biological	 DMARDs,	 may	 affect	 CVD	 risk.	 Initial	 anti-rheumatic	
treatment	and	treatment	with	MTX	or	a	biological	during	follow-up	were	included	in	the	analysis	
and	proved	to	be	confounders.	The	widespread	introduction	of	biologicals	may	lead	to	an	overall	
decrease	 in	 disease	 activity	 levels	 in	 the	 RA	 population	 and	 to	more	 effective	 suppression	 of	
systemic	 inflammation	 in	 individual	 RA	 patients.	We	 did	 not	 investigate	 the	 effect	 of	 specific	
dosages	 of	 anti-rheumatic	 medication	 or	 cumulative	 (biologic)	 DMARD	 use.	 The	 possible	
beneficial	effects	of	more	recently	developed	anti-rheumatic	 treatment	strategies	on	CVD	risk	
could	contribute	more	heavily	to	the	overall	CVD	risk	in	the	group	with	shorter	disease	duration	
(<10	years	disease	duration).	Subsequently,	this	skewed	distribution	could	magnify	the	possible	
effect	of	disease	duration	on	CVD	risk.	However,	this	would	only	strengthen	our	results	as	we	did	
not	find	a	significant	effect	of	disease	duration	on	CVD	risk	in	spite	of	this	potential	source	of	bias.	
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Also,	as	different	forms	of	treatment	may	be	associated	with	the	main	independent	variable,	for	
example,	disease	duration	and	DAS28,	or	act	as	a	proxy	for	determinants	of	the	DAS28	such	as	
treatment	 response	 and	 control	 of	 disease	 activity,	 this	 relationship	 is	 complex.	 The	 role	 of	
medication	on	CVD	in	RA	fell	outside	the	scope	of	this	study	and	was	not	separately	analysed.	
Investigating	the	effect	of	calendar	time	on	CVD	would	require	age-period-cohort	analysis	using	
larger	cohorts.	The	effect	of	these	recently	adapted	treatment	strategies	on	CVD	may	take	some	
time	to	become	clinically	significant.	In	addition	to	time	trends,	missed	CVD	events	due	to	random	
misclassification	 could	 lead	 to	 bias.	 However,	 patients	 enrolled	 in	 this	 cohort	 are	 seen	 and	
checked	 regularly	 (every	3–6	months).	Data,	 including	CVD	events,	 are	 gathered	during	 these	
check-ups	and	meticulously	recorded	in	our	database.	In	addition,	data	of	all	patients	that	were	
included	in	this	study	were	thoroughly	checked	and	all	events	that	were	recorded	during	follow-
up	were	double-checked	to	confirm	the	date	of	occurrence	and	type	of	the	event.	Deaths	were	
also	recorded	during	follow-up	in	the	database,	and	for	these	patients	the	cause	of	death	was	
confirmed.	 Therefore,	 missed	 events	 or	 misclassification	 of	 CVD	 events	 was	 considered	 an	
unlikely	source	of	bias	in	this	study.	
In	conclusion,	our	results	show	that	disease	duration	does	not	appear	to	independently	affect	the	
risk	 of	 CVD.	 Therefore,	 disease	 duration	 may	 not	 be	 the	 best	 choice	 for	 a	 disease-specific	
predictor	when	estimating	CVD	risk	in	individual	RA	patients,	as	recently	recommended	by	EULAR.	
Disease	activity	over	time	appears	to	contribute	to	the	risk	of	CVD	in	patients	with	RA,	particularly	
in	case	of	persistent	poorly	controlled,	high	disease	activity	over	time.	
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CHAPTER	7	
Low	disease	activity	(DAS28≤3.2)	reduces	the	risk	of	first	
cardiovascular	events	in	rheumatoid	arthritis.	A	time-dependent	
Cox	regression	analysis	in	a	large	cohort	study	
	
	
	
	
	
	
	
	
E.E.A.	Arts	
J.	Fransen	
A.A.	Den	Broeder	
P.L.C.M.	Van	Riel	
C.D.	Popa	
	
	
	
	
Submitted	
	 98	
	ABSTRACT	
Objective	
Systemic	inflammation	appears	to	contribute	to	the	excess	risk	of	cardiovascular	disease	(CVD)	in	
rheumatoid	arthritis	 (RA).	The	objective	of	 this	study	was	to	 investigate	the	effect	of	different	
levels	of	disease	activity	over	time,	particularly	low	disease	activity	and	remission,	on	CVD	risk	in	
patients	with	RA.		
Methods	
Data	from	the	Nijmegen	early	RA	inception	cohort	were	used.	The	primary	outcome	was	first	CVD	
events	within	the	first	10	years	of	follow-up.	Cut	points	of	the	DAS28	for	remission	(<2.6),	 low	
(≤3.2),	 moderate	 (3.2-5.1),	 and	 high	 (>5.1)	 disease	 activity	 were	 used.	 The	 effect	 of	 disease	
activity	on	CVD	risk	was	analyzed	using	Cox-proportional	hazards	regression	with	DAS28	as	a	time-
dependent	 covariate	 and	 also	 conventionally	 with	 time-averaged	 DAS28	 as	 the	 primary	
dependent	variable.		
Results	
Low	DAS28	(≤3.2)	was	significantly	associated	with	a	reduced	risk	of	CVD	(HR	0.65,	95%CI	0.43-
0.99)	compared	to	DAS28	>3.2,	both	when	included	as	a	time-dependent	covariate	and	as	time-
averaged	 DAS28≤3.2	 (HR	 0.52,	 95%CI	 0.33-0.81).	 Remission	 had	 a	 modest,	 non-significant	
protective	effect	against	CVD	(HR	0.67,	95%CI	0.43-1.07).		
Conclusion	
Results	of	this	study	suggest	that	low	disease	activity	is	sufficient	to	achieve	a	protective	effect	
against	CVD	in	RA.	Apparently,	remission	defined	as	DAS28<2.6	has	no	additional	protective	effect	
against	CVD	 compared	 to	 low	disease	activity.	Our	 results	 strengthen	 the	use	of	 tight-control	
strategies	in	daily	clinical	practice	to	achieve	low	stable	disease	activity	or	remission	in	RA	patients	
as	soon	as	possible.		
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INTRODUCTION	
Rheumatoid	arthritis	(RA)	is	a	chronic	inflammatory	joint	disease	that	affects	approximately	0.5-
1%	of	the	population.[1]	RA	patients	have	an	increased	risk	of	developing	cardiovascular	disease	
(CVD).[2,	3]	Evidence	suggests	the	increased	cardiovascular	risk	is	partly	–	in	addition	to	excess	of	
classical	risk	factors	-	mediated	by	systemic	inflammation,	characteristic	for	RA.	Inflammation	may	
alter	the	effect	of	existing	CVD	risk	factors	or	factors	protective	for	CVD,	leading	to	an	increased	
risk	of	CVD.[4-6]	Furthermore,	inflammation	may	accelerate	the	atherosclerotic	process	[7,	8]	and	
lead	 to	 the	 formation	 of	more	 severe	 plaques	 in	 RA	 patients.[9-12]	 In	 comparison	 to	 healthy	
controls	and	RA	patients	in	remission,	RA	patients	with	active	disease	seem	to	have	more	unstable	
plaques,	which	increases	the	probability	of	CVD.[13]	Consequently,	the	level	of	disease	activity	
has	been	 implicated	as	 a	 contributing	 factor	 to	 the	development	of	CVD,	 and	 conversely,	 the	
absence	of	inflammation	or	clinical	remission	may	be	associated	with	a	reduced	risk	of	CVD	in	RA.	
The	results	 from	a	case-control	study	showed	no	evidence	that	disease	activity	over	 time	was	
associated	with	occurrence	of	myocardial	 infarction.[14]	 In	 a	 longitudinal	 study	by	our	 group,	
results	 indicated	 that	 very	high	disease	 activity	over	 time	or	high	disease	 activity	 at	RA	onset	
significantly	contributes	to	the	risk	of	CVD	in	RA.[15]	In	a	recent	study	by	Myasoedova	et	al	it	was	
demonstrated	that	particularly	exposure	to	disease	activity	flare-ups	and	increased	cumulative	
burden	of	RA	disease	activity	 seems	 to	 contribute	 to	 this	 risk.[16]	 Furthermore,	patients	with	
active	RA	have	significantly	increased	levels	of	biomarkers	for	CVD,	whilst	RA	patients	who	were	
in	remission	did	not.[17]	Overall,	 these	findings	 led	to	the	hypothesis	that	achieving	a	state	of	
remission	may	reduce	the	risk	of	CVD	in	RA	patients.	As	a	clinical	consequence,	tight	control	of	
disease	activity	 could	 therefore	have	a	beneficial	effect	on	CVD	 risk.[18]	 It	 is	unclear	whether	
clinical	 remission	needs	 to	be	achieved	 in	order	 to	eliminate	or	diminish	 the	possible	harmful	
effects	of	systemic	inflammatory	activity	or	if	stable	low	disease	activity	over	time	is	sufficient.	
Therefore,	 the	primary	objective	of	 this	 study	 is	 to	 investigate	 the	effect	of	different	 levels	of	
disease	activity	over	time,	particularly	low	disease	activity	and	remission,	on	CVD	risk	in	patients	
with	RA.		
	
PATIENTS	AND	METHODS	
Study	design	and	patients	
This	is	a	cohort	study	using	the	prospectively	collected	data	from	the	Nijmegen	early	RA	inception	
cohort.	 Patients	 were	 included	 at	 diagnosis	 of	 RA	 (baseline)	 in	 the	 outpatient	 clinic	 of	 the	
departments	 of	 rheumatology	 of	 the	 Radboud	 University	Medical	 Centre	 (since	 1985)	 or	 the	
Maartenskliniek	 in	 Nijmegen	 (since	 1990).	 RA	 patients	 who	 fulfilled	 the	 1987	 ACR	 (inclusion	
before	2010)	or	ACR/EULAR	2010	(inclusion	after	2010)	criteria	for	the	classification	of	RA,[19]	
with	disease	duration	of	<1	year,	and	who	were	Disease	Modifying	Anti-Rheumatic	Drug	(DMARD)	
naive	were	included.	All	patients	received	written	patient	information	and	gave	written	informed	
consent.	 According	 to	 Dutch	 law	 and	 regulations,	 ethical	 review	 was	 not	 necessary	 for	 this	
observational	study.	Patients	with	confirmed	CVD	before	RA	diagnosis	and	patients	with	a	follow-
up	<12	months	or	patients	with	2	or	 less	DAS28	measurements	were	excluded	for	the	current	
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analyses.	All	disease	activity	measurements	that	were	taken	between	the	date	of	inclusion	in	the	
cohort	 and	 the	 date	 of	 a	 first	 CVD	 event	 or	 censoring	 were	 included	 in	 the	 analysis,	 with	 a	
maximum	of	10	years	of	follow-up.	
Data	collection		
The	 patients	were	 seen	 during	 scheduled	 visits	 every	 3-6	months.	 During	 these	 visits	 disease	
activity	was	measured	using	the	DAS28.[20,	21]	Baseline	variables	were	retrieved	from	the	cohort	
database	and	included;	age	(years),	gender	(male/female),	rheumatoid	factor	(RF)	positivity,	anti-
cyclic	citrullinated	peptide	(anti-CCP)	positivity,	erythrocyte	sedimentation	rate	(ESR)	(mm/hour),	
C-reactive	protein	(CRP)	(mg/L,	Swollen	Joint	Count	(SJC28),	Tender	Joint	Count	(TJC28)	and	the	
patient	Visual	Analogue	Score	 [VAS]	 for	global	disease	activity,	DAS28,	and	Health	Assessment	
Questionnaire	(HAQ)).	Data	on	traditional	CVD	risk	factors	at	baseline	were	collected	by	review	
of	 medical	 charts	 and	 electronic	 patient	 files,	 including	 current	 smoking	 status	 (Y/N),	 blood	
pressure	(mmHg),	height	(m),	weight	(kg),	diabetes	mellitus	(Y/N),	hypertension	(Y/N)	and	family	
history	of	CVD	(Y/N).	Non-fasting	total	cholesterol	(TC)	and	high-density-lipoprotein	cholesterol	
(HDL-c)	concentrations	(mmol/L)	were	measured	using	serum	from	frozen	samples	collected	at	
baseline	at	laboratory	facilities	of	Russells	Hall	Hospital,	Dudley	UK.[22]		
Primary	Outcome	
The	primary	outcome	was	occurrence	of	a	first	CVD	event	(physician	diagnosed	fatal	or	non-fatal	
cases	of	CVD),	as	retrieved	by	extensive	review	of	medical	charts	and	electronic	patient	files.	The	
following	were	classified	as	cardiovascular	events:	acute	coronary	syndrome	(ACS),	stable	angina	
pectoris	(AP),	cerebral	vascular	accident	(CVA),	transient	ischemic	attack	(TIA),	peripheral	artery	
disease	(PAD)	and	heart	 failure	(HF).	Deaths	due	to	CVD	were	verified	from	death	certificates,	
provided	 by	 Statistics	 Netherlands,[23]	 including	 deaths	 due	 to	 CVD	 and	 CVA	 but	 excluding	
cerebral	hemorrhage	and	non-coronary	cardiac	death.		
Statistical	analysis	
Baseline	variables	were	compared	between	the	CVD	event	group	and	the	non-event	group	by	
means	of	independent	samples	T-test,	Wilcoxon	or	chi-squared	statistics.	Low	disease	activity	was	
defined	 as	 DAS28	 ≤3.2	 and	 clinical	 remission	 as	 DAS28	 <2.6.[20,	 21,	 24].	 A	 Cox-proportional	
hazard	regression	model	was	chosen	as	the	primary	analysis	with	disease	activity,	 low	disease	
activity	(DAS28	<3.2)	or	clinical	remission	as	the	segmented	time-dependent	covariate	and	time	
to	first	CVD	event	as	the	primary	outcome.	This	type	of	analysis	is	suited	to	avoid	bias	introduced	
by	 analyzing	 time	 course	 (non-baseline)	 variables	 in	 combination	 with	 survival	 time.	 Disease	
activity	was	measured	regularly	in	patients	included	in	the	Nijmegen	early	RA	cohort	(every	3-6	
months).	However	as	not	all	patients	had	measures	every	3	months,	a	 six-month	 interval	was	
maintained	for	the	time-dependent	covariate	in	the	Cox-proportional	hazard	regression	analyses.	
These	time	segments	correspond	with	DAS28	measurements	at	six-month	intervals.	In	case	of	1	
isolated	 missing	 measurement,	 the	 mean	 of	 the	 measurement	 prior	 and	 the	 measurement	
following	 the	missing	 value	was	 used.	 If	more	 than	 1	 consecutive	measurement	was	missing,	
subjects	were	censored.	To	repeat	the	analysis	using	a	more	readily	interpretable	reflection	of	
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disease	 activity,	 the	 next	 step	 was	 to	 analyze	 the	 time-averaged	 DAS28	 as	 main	 dependent	
variable	 using	 conventional	 Cox-proportional	 hazard	 regression	 analysis.	 The	 time-averaged	
DAS28	was	calculated	by	taking	the	area	under	the	curve	of	the	DAS28	score	of	the	total	follow-
up	 period	 divided	 by	 the	 follow-up	 period.	 The	 analysis	 was	 performed	 again	with	 the	 time-
averaged	DAS28	as	a	binary	variable	(time-averaged	DAS28	≤3.2	or	2.6).		
In	all	analyses,	sex	and	age	were	included	in	the	model	as	confounders	by	default.	The	following	
potential	 confounders	 were	 considered;	 current	 smoking	 status,	 baseline	 measurements	 of	
systolic	 blood	pressure	 (mmHg),	 diastolic	 blood	pressure	 (mmHg)	 and	body	mass	 index	 (BMI)	
(weight	[kg]/height	[m]²),	hypertension	(physician	diagnosis),	diabetes	mellitus	(Type	I	and	II),	TC	
(mmol/L),	 HDL-c	 (mmol/L),	 family	 history	 of	 premature	 CVD,	 use	 of	 statins	 and	 use	 of	 anti-
hypertensive	 medication	 (diuretics,	 ACE/Angiotensin	 II	 inhibitors,	 beta	 blockers	 or	 calcium	
blockers)	at	baseline,	RF	status,	anti-CCP	status,	baseline	DAS28,	CRP,	and	HAQ.	Additionally,	to	
further	aid	the	understanding	of	the	relationship	between	disease	activity	and	CVD	risk	the	effect	
of	both	remission	and	of	 low	DAS28	over	time	on	survival	for	CVD	was	assessed	using	Kaplan-
Meier	 survival	 analysis.	 First,	 subgroups	 were	 made	 based	 on	 the	 time-averaged	 DAS28;	
remission	(DAS28<2.6),	low	(DAS28	2.6-3.2),	intermediate	(DAS28	3.2-5.1)	and	high	(DAS28>5.1).	
In	the	second	analysis	patients	were	divided	using	to	low	time-averaged	DAS28	(≤3.2)	as	the	cut-
off	point.	The	survival	distributions	 in	both	analyses	were	compared	using	 log-rank	testing.	All	
analyses	were	performed	using	SPSS	version	22.0	
	
RESULTS	
There	were	1157	patients	included	in	the	cohort.	After	exclusion	of	patients	with	a	prior	history	
of	 CVD,	 patients	 with	 a	 follow-up	 time	 <12months	 or	 patients	 with	 2	 or	 less	 DAS28	
measurements,	873	patients	were	included	in	the	analyses.	A	total	of	99	RA	patients	developed	
a	first	CVD	event	during	their	first	10	years	of	follow-up.	The	following	fatal	and	non-fatal	first	
CVD	 events	 occurred:	 44	 (44%)	 cases	 of	 acute	 coronary	 syndrome	 (myocardial	 infarction	 or	
unstable	angina	pectoris),	18	(18%)	cases	of	stable	angina	pectoris,	17	(17%)	cases	of	cerebral	
vascular	accident,	5	(5%)	patients	with	a	transient	ischemic	attack,	10	(10%)	cases	of	peripheral	
artery	disease	and	5	(5%)	patients	with	heart	failure.	Out	of	all	CVD	events	21%	were	fatal,	mostly	
due	 to	 acute	 coronary	 syndrome	 (43%).	 Total	 follow-up	 time	 was	 4560	 patient	 years	 with	 a	
median	 (IQR)	 follow-up	 time	 of	 5	 (3-9)	 years.	 At	 baseline,	 there	 were	 differences	 between	
patients	with	and	without	CVD	events	(table	1).	Patients	with	CVD	events	were	on	average	older,	
and	several	other	‘traditional'	risk	factors	for	CVD	were	raised	including	blood	pressure,	lipids	and	
presence	of	diabetes.	Patients	who	developed	CVD	were	more	frequently	RF	positive,	not	more	
frequently	anti-CPP	positive	and	had	higher	baseline	disease	activity	(table	1).	In	total	9151	DAS28	
measurements	were	included	during	follow-up	and	in	2738	(30%)	of	the	visits,	DAS28	was	<2.6.	
Per	patient,	the	percentage	of	their	DAS28	measurements	during	follow-up	that	were	scored	<2.6	
(time	in	remission)	was	in	median	(P25-P75)	17%	(0.0	%-50%).		
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Table	1.	Patient	characteristics	at	baseline	
	 Total	cohort	
N=873	
No	CV	event	
N=774	
CV	event	
N=99	
p-value			
(CVD	vs.	no	
CVD)	
Age	(years),	mean±SD	 54±14	 53±14	 62±9	 <.001	
Sex	(female),	n	(%)	 574(66)	 524(68)	 50(51)	 0.001	
Currently	smoking,	n	(%)	 272(31)	 235(30)	 69(40)	 0.156	
BMI	(weight[kg]/Height[m]²),	mean±SD	 26±4	 25±4	 26±4	 0.016	
Systolic	blood	pressure	(mmHg),	mean±SD	 146±24	 145±24	 153±24	 0.002	
Diastolic	blood	pressure	(mmHg),	mean±SD	 84±12	 83±12	 86±11	 0.026	
Hypertension	n	(%)	 120(14)	 94(12)	 26(26)	 <.001	
Anti-hypertensives,	n(%)	 134(15)	 110(14)	 24(24)	 0.009	
Total	Cholesterol	(mmol/L),	mean±SD	 5.2±1.2	 5.2±1.2	 5.3±1.4	 0.448	
HDL-Cholesterol,	mean±SD	 1.3±0.3	 1.3±0.3	 1.2±0.3	 0.040	
TC:HDL-c	ratio,	mean±SD	 4.1±1.0	 4.1±1.0	 4.4±1.0	 0.013	
LDL-Cholesterol,	mean±SD	 3.2±1.1	 3.1±1.0	 3.2±1.2	 0.357	
Lipid	lowering	agents,	n	(%)	 30(3.4)	 23(3)	 7(7)	 0.035	
Diabetes	mellitus	n	(%)	 37(4)	 29(4)	 8(8)	 0.044	
Family	history	of	CVD,	n	(%)	 265(30)	 232(30)	 33(33)	 0.494	
Rheumatoid	factor	(positivity),	n	(%)		 654(75)	 576(74)	 78(79)	 0.345	
Anti-CCP	(positivity),	n(%)	 554(64)	 493(64)	 61(62)	 0.686	
DAS28,	mean±SD	 5.0±1.3	 4.9±1.3	 5.4±1.3	 0.001	
CRP,	median	(IQR)	 14(2-40)	 13(2-38)	 21(3-47)	 0.083	
HAQ,	median	(IQR)	 0.6(0.3-1.1)	 0.6(0.3-1.1)	 0.7(0.3-
1.4)	
0.468	
i. Hypertension	is	defined	as	multiple	measurements	of	elevated	systolic	blood	pressure	(>140	
mmHg)	during	multiple	visits	by	a	physician.	Diabetes	mellitus	includes	both	type	I	and	type	
II.	All	variables	represent	baseline	measures,	except	when	otherwise	stated.		
ii. BMI;	body	mass	index,	HDL;	high	density	lipoprotein,	TC;	total	cholesterol,	LDL;	low	density	
lipoprotein,	CVD;	cardiovascular	disease,	anti-CCP;	anti-cyclic	citrullinated	peptide,	DAS28;	
28-joint	 disease	 activity	 score,	 CRP;	 c-reactive	 protein,	 HAQ;	 health	 assessment	
questionnaire.	
	
Cox-proportional	hazard	regression	with	a	time	dependent	covariate:	disease	activity		
When	disease	activity	was	entered	into	the	model	as	a	continuous,	segmented	time-dependent	
variable,	 the	 results	 showed	 that	 disease	 activity	 had	 a	 significant	 effect	 on	 CVD	 risk	 after	
correction	 for	 confounders	 (table	 2,	 panel	 B),	 indicating	 that	 CVD	 risk	 increases	 as	 DAS28	
increases	during	follow-up.	The	hazard	ratio	(HR),	in	table	2B	of	1.179	can	be	interpreted	as	an	
increase	in	risk	of	18%	if	the	DAS28	is	one	point	higher.	Table	2,	panel	C	shows	the	results	from	
the	analysis	with	DAS28≤3.2	 (yes/no)	as	a	 time-dependent	binary	variable	after	correction	 for	
confounders,	indicating	that	CVD	risk	is	significantly	lower	in	patients	with	DAS28≤3.2	(HR	0.65,	
95%CI	0.43-0.99)	
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Table	 2.	 Cox-proportional	 hazard	 regression	 analysis	 with	 time	 to	 first	 CVD	 event	 as	 the	 primary	
outcome	and	time-dependent	DAS28	as	the	primary	independent	variable,	before	(panel	A)	and	after	
(panel	 B)	 correction	 for	 confounders.	 Panel	 C	 shows	 results	 from	 the	 Cox-proportional	 hazards	
regression	with	DAS28	<3.2	(yes/no)	as	a	time-dependent	covariate	after	correction	for	confounders.		
i. †Antihypertensive	medication,	lipid	lowering	medication.	
ii. HDL-c;	high-density	lipoprotein	cholesterol,	LDL-c;	low-density	lipoprotein	cholesterol,	CRP;	
c-reactive	protein,	CV;	cardiovascular.	
	
Cox-proportional	hazard	regression	with	a	time	dependent	covariate:	DAS28	remission		
The	 results	 from	 the	 Cox-proportional	 hazard	 analysis	 with	 remission	 (yes/no)	 as	 a	 time-
dependent	covariate	showed	a	direction	for	a	protective	effect	of	time	in	remission	against	CVD	
(table	3,	panel	A	and	B)	with	a	HR	of	0.67.	However,	this	effect	did	not	reach	statistical	significance	
after	correction	for	confounders	(95%CI	0.43-1.07).		
Conventional	Cox-proportional	hazard	regression	analysis:	time-averaged	DAS28	
Mean±SD	time-averaged	DAS28	was	3.5±1.1	for	the	whole	group,	with	a	minimum	and	maximum	
time-averaged	 DAS28	 of	 0.7	 and	 7.3	 respectively.	 The	 mean±SD	 time-averaged	 DAS28	 was	
significantly	 lower	 in	 the	 non-event	 group	 compared	 to	 the	 event	 group	 (3.5±1.1	 vs.	 3.9±1.2	
respectively,	with	p<0.001).	Results	 from	the	conventional	Cox-proportional	hazard	 regression	
analysis	with	time-averaged	DAS28	as	the	main	independent	variable,	showed	a	significant	effect	
	 Beta	 p-value	 HR	 95%	CI	for	Exp	(B)	
Lower	 Upper	
Panel	A:	Crude	model	 	 	 	 	 	
Time	dependent	covariate	(DAS28)		 0.113	 0.119	 1.120	 0.972	 1.290	
Age		 0.064	 <.001	 2.010	 1.344	 3.005	
Gender	 0.698	 0.001	 1.066	 1.047	 1.085	
	 	 	 	 	
Panel	B:	Corrected	model	 	 	 	 	
Time	dependent	covariate	(DAS28)	 0.165	 0.032	 1.179	 1.014	 1.370	
Age	 0.062	 <.001	 1.064	 1.044	 1.084	
Gender	 0.725	 0.001	 2.065	 1.365	 3.123	
Hypertension	baseline	 1.036	 <.001	 2.818	 1.673	 4.745	
HDL-C	 -.736	 0.043	 0.466	 0.222	 0.977	
CV	medication†	 -.515	 0.026	 0.597	 0.379	 0.940	
DAS28	baseline	 0.034	 0.687	 1.035	 0.877	 1.220	
	 	 	 	 	
Panel	C:	Corrected	model	 	 	 	 	
Time	dependent	covariate	(DAS28<3.2)	 -.431	 0.044	 0.650	 0.427	 0.989	
Age	 0.064	 <.001	 1.066	 1.046	 1.087	
Gender	 0.736	 0.001	 2.088	 1.372	 3.177	
Hypertension		 0.977	 <.001	 2.656	 1.547	 4.559	
HDL-C	 -1.113	 0.009	 0.329	 0.142	 0.758	
LDL-c	 0.177	 0.097	 1.193	 0.969	 1.470	
CV	medication†	 -.541	 0.022	 0.582	 0.366	 0.925	
CRP		 -.001	 0.538	 0.999	 0.994	 1.003	
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on	CVD	risk	with	a	HR	of	1.60	(95%CI	1.28-1.99),	as	shown	in	table	4,	panel	B.	After	correction	for	
confounders,	the	hazard	for	CVD	notably	 increases	with	every	point	 increase	in	time-averaged	
DAS28.	 The	 results	 from	 the	 following	 analysis	 (table	 4,	 panel	 C)	 showed	 that	 compared	 to	
patients	with	active	disease,	low	time-averaged	DAS28	(≤3.2)	has	a	significant	protective	effect	
against	CVD	after	correction	for	confounders	(HR	0.53,	95%CI	0.34-0.84).	Again,	a	direction	for	a	
protective	effect	of	time	in	remission	against	CVD	was	observed	(not	shown)	with	a	HR	of	0.78.	
However,	this	effect	did	not	reach	statistical	significance	after	correction	for	confounders	(95%CI	
0.45-1.38).	 These	 results	 are	 in	 accordance	 with	 the	 results	 of	 the	 first	 set	 of	 analyses	 that	
included	a	time-dependent	covariate.	
Table	 3.	 Cox-proportional	 hazard	 regression	 analysis	 with	 time	 to	 first	 CVD	 event	 as	 the	 primary	
outcome	and	remission	(yes/no)	as	the	time-dependent	variable,	before	(panel	A)	and	after	(panel	B)	
correction	for	confounders.	
	 Beta	 p-value	 HR	 95%	CI	for	Exp	(B)	
Lower	 Upper	
Panel	A:	Crude	model	 	 	 	 	 	
Time	dependent	covariate	(remission)	 -.211	 0.358	 0.810	 0.516	 1.270	
Age		 0.064	 0.001	 1.066	 1.047	 1.086	
Gender	 0.665	 0.001	 1.945	 1.304	 2.901	
	 	 	 	 	 	
Panel	B:	correcte	model	 	 	 	 	
Time	dependent	covariate	(remission)	 -.395	 0.096	 0.673	 0.426	 1.066	
Age	 0.063	 <.001	 1.065	 1.045	 1.085	
Gender	 0.680	 0.001	 1.974	 1.306	 2.984	
Hypertension		 0.971	 <.001	 2.640	 1.540	 4.528	
HDL-C	 -.772	 0.039	 0.462	 0.222	 0.963	
CV	medication†	 -.526	 0.026	 0.591	 0.372	 0.938	
i. †Antihypertensive	medication,	lipid	lowering	medication.	
ii. HDL-c;	high-density	lipoprotein	cholesterol,	CV;	cardiovascular.		
	
Survival	analyses	
For	illustrative	purposes,	a	Kaplan-Meier	survival	analysis	was	performed,	investigating	the	effect	
of	 low	disease	activity	and	remission	on	time	to	first	CV	event.	Patients	were	divided	into	four	
groups;	 time-averaged	DAS28	<2.6,	 2.6-3.2,	 3.2-5.1,	 >5.1	 for	 groups	1	 through	4	 respectively.	
Event	rates	were	as	follows;	group	1	(N=189)	16	CV	events	(8.5%),	group	2	(N=163)	14	CV	events	
(8.6%),	group	3	(N=444)	55	CV	events	(12.4%)	and	group	4	(N=77)	14	CV	events	(18%).	Survival	
time	(time-to-first-CVD	event)	appears	to	decrease	as	time-averaged	DAS28	increases	(figure	1).	
Survival	distributions	differed	significantly	(p<0.027).	Patients	with	the	lowest	survival	rate	(group	
4)	had	the	highest	baseline	DAS28	at	diagnosis	(mean±SD;	6.1±1.0)	compared	to	group	1,	2	and	
3	(mean±SD;	4.1±1.3,	4.8±1.3	and	5.3±1.2	and	respectively).	Of	note,	the	survival	distributions	of	
patients	 with	 a	 time-averaged	 DAS28	 <2.6	 and	 a	 time	 averaged	 DAS28	 between	 2.6	 and	 3.2	
overlap	 indicating	 that	 these	distributions	do	not	differ	significantly	 from	each	other.	Figure	2	
shows	the	survival	distributions	of	patients	with	a	time-averaged	DAS28	≤3.2	or	very	low	disease	
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activity	over	time	and	of	patients	with	more	active	disease	(time-averaged	DAS28	>3.	2).	Survival	
distributions	(figure	2)	differed	significantly	(p=0.024).		
	
	
	
	
	
	
	
	
	
	
Figure	1.	Survival	distribution	(time	to	first	CVD	event)	for	categories	of	time-averaged	DAS28.	Survival	
distributions	differ	significantly	(p0.027).	Cumulative	survival	of	CVD	is	depicted	on	the	y-axis	and	time	
to	a	CVD	event	or	censoring	is	depicted	on	the	x-axis	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.	Survival	distribution	(time	to	first	CVD	event)	for	low	(≤3.2)	and	moderate	to	high	(>3.2)	time-
averaged	 DAS28.	 Survival	 distributions	 differ	 significantly	 (p<0.001).	 Cumulative	 survival	 of	 CVD	 is	
depicted	on	the	y-axis	and	time	to	a	CVD	event	or	censoring	is	depicted	on	the	x-axis.	
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Table	4.	Conventional	Cox-proportional	hazard	regression	analysis	with	time	to	first	CVD	event	as	the	
primary	outcome	and	time-averaged	DAS28	as	the	primary	independent	variable,	before	(panel	A)	and	
after	(panel	B)	correction	for	confounders	and	included	as	a	binary	variable	(panel	C).	
	 Beta	 p-value	 HR	 95%	CI	for	Exp	(B)	
Lower	 Upper	
Panel	A:	Crude	model	 	 	 	 	 	
Time-averaged	DAS28	 0.383	 <0.001	 1.466	 1.204	 1.786	
Age		 0.060	 <0.001	 1.062	 1.043	 1.082	
Gender	 0.848	 <0.001	 2.336	 1.549	 3.521	
	 	 	 	 	
Panel	B:	full	model	 	 	 	 	
Time-averaged	DAS28	 0.468	 <0.000	 1.597	 1.279	 1.994	
Age	 0.056	 <0.001	 1.057	 1.037	 1.077	
Gender	 0.954	 <0.001	 2.595	 1.712	 3.933	
Hypertension	baseline	 0.920	 <0.001	 2.508	 1.566	 4.018	
DAS28	baseline	 -.048	 0.587	 0.953	 0.802	 1.133	
	 	 	 	 	
Panel	D:	full	model	 	 	 	 	
Time-averaged	DAS28	binary;	(≤3.2)	 -.630	 0.007	 0.533	 0.337	 0.843	
Age	 0.058	 <0.001	 1.060	 1.040	 1.080	
Gender	 0.803	 <0.001	 2.231	 1.491	 3.339	
Hypertension	baseline	 0.882	 <0.001	 2.417	 1.506	 3.879	
DAS28	baseline	 0.042	 0.614	 1.043	 0.886	 1.228	
i. DAS28;	28-joint	disease	activity	score	
	
	
DISCUSSION	
Systemic	inflammatory	activity	in	RA	has	been	suggested	as	an	important	contributing	factor	to	
the	excess	CVD	risk	in	RA	patients.	Therefore,	it	was	hypothesized	that	achieving	a	state	in	which	
disease	activity	is	low	or	nearly	absent	could	have	a	beneficial	effect	on	CVD	risk.	In	this	study,	it	
is	shown	that	low	stable	disease	activity	over	time	has	a	significant	protective	effect	against	CVD	
in	RA.	Although	clinical	remission	(DAS28<2.6)	appears	to	have	a	modest	protective	effect	against	
developing	CVD,	it	did	not	reach	statistical	significance.		
Previous	 studies	 have	 demonstrated	 that	 inflammation	 contributes	 to	 accelerated	
atherosclerosis.[25-27]	 Atherosclerosis	 in	 turn	 is	 an	 intermediate	 in	 causing	 non-bleeding	 CV	
events.	Concordantly,	the	results	of	this	study	show	that	active	disease	in	RA	is	associated	with	
an	 increased	 risk	of	developing	CV	events.	 Furthermore,	when	 looking	at	 the	overall	 trend	of	
disease	 activity	 during	 follow-up,	 those	 patients	who	were	 able	 to	 achieve	 and	maintain	 low	
disease	activity	over	time	appear	to	have	a	significantly	lower	risk	of	CVD	than	patients	with	more	
active	disease.	 Interestingly,	 it	 appears	 that	achieving	 remission	does	not	offer	any	 significant	
added	value	over	sustained	low	disease	activity,	in	terms	of	CVD	risk	reduction.	Time	to	first	CVD	
event	was	similar	in	patients	with	low	disease	activity	and	patients	in	remission	and	these	patients	
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had	a	significantly	longer	survival	time	compared	to	patients	with	more	active	disease.	The	results	
also	showed	that	patients	with	the	lowest	survival	times	for	CVD	had	the	highest	disease	activity	
levels	at	baseline	suggesting	very	active	disease	onset	 in	 these	patients.	Several	other	 studies	
have	reported	similar	results	with	regards	to	increased	disease	activity	in	RA.[15,	16,	28]	In	a	large	
RA	cohort	study,	CRP	was	found	to	be	associated	with	the	risk	of	CVD	although	DAS28	did	not	
appear	to	be	significantly	increased	in	RA	patients	with	MI	compared	to	RA	controls.[29]	However,	
only	the	first	6	months	of	follow-up	after	inclusion	were	incorporated	for	disease	activity	in	this	
study.	By	contrast,	Myasoedova	et	al.	have	 shown	 in	a	 recent	 study	 that	particularly	bouts	of	
uncontrolled	high	disease	activity	are	associated	with	a	higher	risk	of	CVD.[16]	A	study	by	Solomon	
et	 al.	 also	 included	 longitudinal	 disease	 activity,	 demonstrating	 that	 reduced	 time-averaged	
disease	activity	in	RA	is	associated	with	fewer	CVD	events.[28]	What	our	current	study	adds	to	
that	is	notably	longer	follow-up	with	detailed	data	on	determinants	of	CVD	risk.	Also,	in	this	study	
a	Cox-proportional	hazards	regression	with	time-dependent	covariates	was	used,	as	conventional	
Cox	regression	analysis	using	DAS28	values	after	baseline	is	potentially	biased.[30]	With	regards	
to	 remission,	 another	 study	 demonstrated	 that	 RA	 patients	 in	 remission,	 defined	 as	 Clinical	
Disease	Activity	Index,	or	CDAI	≤2.8	had	significantly	lower	levels	of	CVD	risk	markers	compared	
to	 patients	with	 active	 disease,	 supporting	 remission	 as	 a	 target	 for	 CVD	 risk	management	 in	
RA.[17]	Overall,	patients	who	are	able	to	achieve	and	maintain	remission	or	low	disease	activity	
during	follow-up,	even	sporadically,	may	be	less	likely	to	develop	bouts	of	uncontrolled,	sustained	
high	systemic	inflammation,	a	contributing	factor	to	atherosclerosis	and	CVD.	RA	patients	with	
very	active	disease	at	diagnosis,	poor	treatment	response	with	more	frequent	flare-ups	as	a	result	
may	 form	a	 subgroup	within	 the	RA	population	 that	 is	particularly	at	 risk	 for	developing	CVD,	
significantly	contributing	to	the	excess	CVD	risk	in	this	population.		
In	 the	analysis	of	 the	effect	of	 low	disease	activity	or	clinical	 remission	on	CVD	risk,	 there	are	
several	 statistical	 considerations.	 Patients	 that	 were	 able	 to	 achieve	 frequent,	 longstanding	
DAS28	remission	comprised	a	relatively	small	group	in	this	study	which	could	have	contributed	to	
the	fact	that	a	protective	trend	against	CVD	was	observed	but	did	not	reach	statistical	significance.	
Disease	activity	tends	to	fluctuate	over	the	course	for	RA,	which	makes	it	difficult	to	accurately	
capture	the	level	of	exposure	of	a	patient	during	follow-up.	Also,	as	noted	above,	there	may	be	a	
risk	of	bias	as	the	patients	who	are	able	to	stay	event	free	the	longest,	also	have	inherently	more	
time	to	achieve	remission	or	low	disease	activity,	creating	a	survivor	bias	or	'immortal	time	bias'.	
Immortal	 time	 bias	 can	 be	 avoided	 by	 integrating	 the	 changes	 in	 exposure	 status	 in	 the	
analysis.[30]	 Consequently,	 for	 this	 study	 a	 Cox-proportional	 hazards	 regression	 with	 a	
segmented	 time	 dependent	 covariate	 (DAS28)	 was	 chosen.	 Furthermore,	 in	 RA,	 different	
measures	of	disease	activity	provide	various	definitions	of	remission,[20,	31-34]	which	were	not	
all	considered	in	this	study.	These	definitions	do	appear	to	strongly	correlate	with	each	other,[32,	
33]	however	including	a	different	definition	for	remission	could	have	an	effect	on	results.	DAS28	
remission	that	was	used	in	this	study	is	defined	as	disease	activity	score	<2.6	and	this	is	not	the	
same	as	the	absolute	absence	of	disease	activity.	On	the	other	hand,	remission	according	to	the	
stricter	ACR/EULAR	remission	criteria	for	RA	is	not	prevalent,	yet.	Additional	research	is	needed	
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to	determine	if	the	complete	absence	of	disease	activity	has	a	significant	added	protective	effect	
on	CVD	risk	compared	to	very	low	disease	activity.		
In	conclusion,	low	disease	activity	appears	to	have	a	significant	protective	effect	against	CVD	in	
RA.	 Achieving	 sustained	 remission,	 here	 defined	 as	 DAS28<2.6,	 is	 regarded	 as	 the	 ultimate	
treatment	target	but	does	not	seem	to	provide	a	large	advantage	over	low	disease	activity	over	
time	in	terms	further	reducing	CVD	risk.	RA	patients	with	uncontrolled	high	disease	activity	appear	
to	have	the	highest	risk	of	developing	CVD.	Our	results	strengthen	the	use	of	tight-control	(treat-
to-target)	strategies	in	daily	clinical	practice	to	achieve	low	disease	activity	or	remission	in	these	
patients,	also	with	the	aim	to	reduce	CVD	risk.		
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ABSTRACT	
Objective	
Predictive	performance	of	 cardiovascular	 disease	 (CVD)	 risk	 calculators	 appears	 suboptimal	 in	
rheumatoid	arthritis	(RA).	A	disease-specific	CVD	risk	algorithm	may	improve	CVD	risk	prediction	
in	RA.	The	objectives	of	this	study	are	to	adapt	the	Systematic	COronary	Risk	Evaluation	(SCORE)	
algorithm	with	determinants	of	CVD	risk	in	RA	and	to	assess	the	accuracy	of	CVD	risk	prediction	
calculated	with	the	adapted	SCORE	algorithm.	
Methods		
Data	from	the	Nijmegen	early	RA	inception	cohort	were	used.	The	primary	outcome	was	first	CVD	
events.	The	SCORE	algorithm	was	recalibrated	by	re-weighing	included	traditional	CVD	risk	factors	
and	 adapted	 by	 adding	 other	 potential	 predictors	 of	 CVD.	 Predictive	 performance	 of	 the	
recalibrated	and	adapted	SCORE	algorithms	was	assessed	and	the	adapted	SCORE	was	externally	
validated.	
Results		
Of	 the	1016	 included	patients	with	RA,	103	patients	experienced	a	CVD	event.	Discriminatory	
ability	 was	 comparable	 across	 the	 original,	 recalibrated	 and	 adapted	 SCORE	 algorithms.	 The	
Hosmer–Lemeshow	 test	 results	 indicated	 that	 all	 three	 algorithms	 provided	 poor	 model	 fit	
(p<0.05)	for	the	Nijmegen	and	external	validation	cohort.	The	adapted	SCORE	algorithm	mainly	
improves	 CVD	 risk	 estimation	 in	 non-event	 cases	 and	 does	 not	 show	 a	 clear	 advantage	 in	
reclassifying	patients	with	RA	who	develop	CVD	(event	cases)	into	more	appropriate	risk	groups.	
Conclusions		
This	study	demonstrates	for	the	first	time	that	adaptations	of	the	SCORE	algorithm	do	not	provide	
sufficient	 improvement	 in	 risk	 prediction	 of	 future	 CVD	 in	 RA	 to	 serve	 as	 an	 appropriate	
alternative	 to	 the	 original	 SCORE.	 Risk	 assessment	 using	 the	 original	 SCORE	 algorithm	 may	
underestimate	CVD	risk	in	patients	with	RA.	 	
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INTRODUCTION	
In	 rheumatoid	 arthritis	 (RA),	 cardiovascular	 disease	 (CVD)	 morbidity	 and	 mortality	 are	
increased.[1,	2]	Inflammation	may	contribute	to	the	increased	risk	of	CVD,[3–10]	suggesting	that	
inflammatory	markers	should	be	incorporated	in	CVD	risk	prediction	models	for	RA.	For	example,	
high-sensitivity	C	 reactive	protein	 (CRP)	was	 included	 in	 the	 recently	developed	Reynolds	Risk	
Score	(RRS),	which	is	therefore	better	able	to	classify	premenopausal	women	into	different	risk	
groups.[11,	12]	Similarly,	disease	activity	measures,	such	as	the	28-joints	Disease	Activity	Score	
(DAS28),	may	be	useful	 in	CVD	risk	algorithms	for	patients	with	RA.	Additionally,	 inflammation	
may	add	and	modulate	traditional	CVD	risk	factors.[13,	14]	Existing	weights	attributed	to	each	
individual	 risk	 factor	 included	 in	currently	available	CVD	risk	algorithms	may	therefore	require	
adjustment.	The	use	of	other	CVD-related	parameters	not	incorporated	in	the	present	CVD	risk	
algorithms,	such	as	carotid	artery	intima-media	thickness	and/or	the	presence	of	atherosclerotic	
carotid	plaques	 in	 these	patients,	may	also	be	considered.[15–17]	Current	CVD	risk	prediction	
models,	for	example,	Framingham	Risk	Score	(FRS)	or	the	Systematic	COronary	Risk	Evaluation	
(SCORE)	 algorithm,	 have	 been	 developed	 for	 use	 in	 the	 general	 population.[18–20]	 Their	
performance	 in	 patients	 with	 RA	 appears	 to	 be	 suboptimal.[21–23]	 Therefore,	 it	 has	 been	
suggested	that	CVD	risk	algorithms	based	solely	on	traditional	risk	factors	may	not	be	suited	for	
use	 in	 the	 RA	 population.	 As	 a	 first	 step	 towards	 more	 accurate	 CVD	 risk	 prediction,	 it	 was	
proposed	in	the	European	League	Against	Rheumatism	(EULAR)	recommendations	for	CVD	risk	
management	in	RA	to	apply	a	multi-	plication	factor	of	1.5	to	the	calculated	CVD	risk	by	SCORE	in	
selected	patients	to	enhance	the	risk	estimates.[24]	However,	recent	studies	have	shown	that	
this	 multiplication	 factor	 does	 not	 significantly	 improve	 CVD	 risk	 prediction	 in	 patients	 with	
RA.[25–27]	A	disease-specific	CVD	risk	algorithm	could	perhaps	improve	prediction	of	CVD	risk	in	
patients	with	RA.	In	Europe,	the	SCORE	algorithm	is	widely	used.	A	logical	next	step	would	be	to	
evaluate	whether	the	SCORE	algorithm	can	be	adapted	to	more	accurately	estimate	the	risk	of	
CVD	 in	patients	with	RA.	 Therefore,	 the	objectives	of	 this	 study	were	 (1)	 to	 adapt	 the	 SCORE	
algorithm	with	determinants	of	CVD	risk	in	patients	with	RA	and	(2)	to	compare	the	performance	
of	the	modified	SCORE	calculator	to	the	original	SCORE	risk	algorithm	with	regards	to	CVD	risk	
prediction	in	patients	with	RA.	
	
PATIENTS	AND	METHODS	
Study	design	and	patients	
Data	 from	 the	 Nijmegen	 early	 RA	 inception	 cohort	 were	 used	 for	 this	 study.	 Patients	 were	
included	at	diagnosis	of	RA	(baseline)	in	the	outpatient	clinic	of	the	Departments	of	Rheumatology	
of	 the	Radboud	University	Medical	Centre	 (since	1985)	or	 the	Maartenskliniek	 (since	1990)	 in	
Nijmegen,	 The	 Netherlands.	 Patients	 with	 RA	 who	 fulfilled	 the	 1987	 American	 College	 of	
Rheumatology	(ACR;	inclusion	before	2010)	or	ACR/EULAR	2010	criteria	(inclusion	after	2010)	for	
the	classification	of	RA,[28]	with	disease	duration	of	<1	year,	and	who	were	disease-modifying	
antirheumatic	drug	naive	were	included.	All	patients	gave	written	informed	consent.	Patients	with	
a	history	of	confirmed	CVD	before	RA	diagnosis	and	patients	with	a	follow-up	<18	months	were	
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excluded.	Patients	were	censored	after	10	years	of	follow-up	or	at	the	time	of	the	first	CVD	event.	
The	10-year	risk	estimates	for	patients	with	a	follow-up	<10	years	at	the	time	of	censoring	(30	
September	 2011)	 were	 adjusted	 proportionally	 according	 to	 the	 actual	 follow-up	 time	 and	
calculated	as	a	proportion	of	10	years.[22]	The	SCORE	algorithm	for	the	prediction	of	both	fatal	
and	non-fatal	disease	in	the	Dutch	population	was	used.[20]	
Baseline	predictors	of	cardiovascular	disease		
In	 addition	 to	 the	 traditional	 risk	 factors	 used	 in	 the	 SCORE	 algorithm,	 potential	 RA-specific	
predictors	 for	 CVD	 were	 collected.	 Baseline	 characteristics	 were	 retrieved	 from	 the	 cohort	
database	including;	age	(years),	gender	(male/female),	rheumatoid	factor	(RF)	status,	anti-cyclic	
citrullinated	peptide	(anti-CCP)	status,	DAS28,	erythrocyte	sedimentation	rate	(ESR;	mm/hour),	
swollen	joint	count	(SJC),	tender	joint	count	(TJC)	and	the	patient	Visual	Analogue	Score	(VAS)	for	
global	 disease	 activity,	 Health	 Assessment	 Questionnaire	 (HAQ)	 and	 CRP	 (mg/L).	 Data	 on	
traditional	CVD	risk	factors	at	baseline	were	collected	by	medical	chart	and	electronic	patient	file	
review,	including	current	smoking	status	(Y/N),	blood	pressure	(mm	Hg),	height	(m),	weight	(kg),	
diabetes	mellitus	(Y/N),	hypertension	(Y/N)	and	family	history	of	premature	CVD	(Y/N).	Lipid	levels	
were	 measured	 using	 serum	 from	 frozen	 samples	 collected	 at	 baseline.	 Non-fasting	 total	
cholesterol	(TC)	and	high-density-lipoprotein	cholesterol	(HDL-c)	concentrations	(mmol/L)	were	
measured	using	laboratory	facilities	of	Russells	Hall	Hospital,	Dudley,	UK.	
Primary	outcome	
The	primary	outcome	was	first	CVD	events	(physician	diagnosed	fatal	or	non-fatal	CVD	events),	
which	 were	 retrieved	 by	 extensive	 review	 of	 medical	 charts	 and	 electronic	 patient	 files.	We	
included	the	following	CVD	events:	acute	coronary	syndrome	(myocardial	infarction	and	unstable	
angina	pectoris),	cerebral	vascular	accident	(CVA)	and	heart	failure	(HF).	Deaths	due	to	CVD	were	
verified	from	death	certificates,	provided	by	Statistics	Netherlands,[29]	including	deaths	due	to	
CVD	and	CVA	but	excluding	cerebral	hemorrhage	and	non-coronary	cardiac	death.	
Statistical	analysis	
The	analysis	consisted	of	two	phases:	(1)	the	recalibration	and	adaptation	of	the	SCORE	algorithm	
in	our	cohort	and	(2)	evaluation	of	the	predictive	performance	of	the	recalibrated	and	adapted	
SCORE	algorithms.	For	the	recalibration	of	the	SCORE	algorithm,	the	regression	coefficients	(the	
weights)	of	 the	predictors	originally	 included	 in	SCORE	 (current	 smoking	 status,	 systolic	blood	
pressure	 and	 TC:HDL-c	 ratio)	 were	 newly	 estimated	 by	 means	 of	 Cox-proportional	 hazards	
regression	analysis.	The	SCORE	algorithm	as	developed	by	Conroy	et	al.[18]	is	fit	for	use	in	patients	
aged	≤65	years	for	the	prediction	of	fatal	CVD.	Van	Dis	et	al.[20]	recalibrated	the	SCORE	for	the	
prediction	of	fatal	and	non-fatal	CVD	in	the	Dutch	population	and	for	individuals	both	aged	≤65	
and	>65	years.	The	SCORE	algorithm	was	incorporated	in	the	most	recent	version	of	the	Dutch	
national	 guideline	 for	 cardiovascular	 risk	management	 and	we	 used	 this	 version.[30]	 For	 the	
adaptation	of	the	SCORE	algorithm,	other	potential	predictors	were	added	to	the	existing	SCORE	
variables.	 Variables	 with	 a	 significance	 level	 p<0.1	 in	 univariate	 Cox	 proportional	 hazards	
regression	analysis	were	evaluated	in	a	multivariate	Cox	proportional	hazard	regression	analysis.	
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In	 the	multivariate	analysis,	 traditional	CVD	risk	 factors	 included	 in	 the	SCORE	algorithm	were	
predetermined	to	stay	 in	 the	model	and	other	new	predictors	were	 included	at	a	deliberately	
more	liberal	p	value	of	<0.2.	The	following	potential	risk	factors	were	considered:	body	mass	index	
(BMI;	weight	(kg)/	height	(m)2),	hypertension	(physician	diagnosis),	diabetes	mellitus	(type	I	and	
II),	 diastolic	 blood	 pressure	 (mmHg),	 TC	 (mmol/L),	 HDL-c	 (mmol/L),	 low-density	 lipoprotein	
cholesterol	(mmol/L),	triglycerides	(mmol/L),	family	history	of	premature	CVD,	RF	status,	anti-CCP	
status,	DAS28,	CRP,	ESR	(mm/hour),	SJC,	TJC,	VAS	and	HAQ.	All	analyses	were	performed	with	
CVD	events	as	the	dependent	variable	and	follow-up	time	(time	since	RA	diagnosis)	as	the	time	
variable.	Discrimination,	that	is,	the	number	of	patients	who	are	correctly	grouped	into	the	event	
and	the	non-event	group,	was	 tested	using	 the	concordance	statistic	 (c-statistic)	and	the	area	
under	 the	 receiver	 operating	 characteristic	 (ROC)	 curve.[31]	 Calibration	 was	 assessed	 by	
comparing	the	agreement	between	the	observed	number	of	CVD	events	and	the	number	of	CVD	
events	predicted	by	the	SCORE	algorithms,	in	deciles	of	predicted	CVD	risk.	Hosmer–Lemeshow	
(H–L)	tests	and	calibration	plots	were	used	to	assess	model	fit.	Clinical	relevance	of	the	models	
was	assessed	based	on	the	number	of	patients	reclassified	 into	another	CVD	risk	group:	<10%	
(low	 risk),	 10%–20%	 (intermediate	 risk)	 and	 >20%	 (high	 risk).[20,	 30]	 The	 analyses	 were	
performed	using	SPSS	V.21.0.	Missing	values	on	individual	variables	were	imputed	using	multiple	
imputations	with	five	repetitions.	
External	validation	
The	 performance	 of	 the	 original,	 recalibrated	 and	 adapted	 SCORE	 algorithms	 concerning	 the	
prediction	of	 fatal	 and	non-fatal	CVD	was	also	analyzed	 in	external	 cohorts,	 consisting	of	400	
patients	 with	 RA	 from	 the	 UK	 (DRACCO	 cohort)	 and	 204	 patients	 from	 a	 Norwegian	 cohort	
(EURIDISS/ORAreg).[32,	33]	
	
RESULTS	
A	 total	of	141	patients	with	a	 follow-up	 time	of	<18	months	or	documented	CVD	prior	 to	RA	
diagnosis	were	excluded,	leaving	1016	patients	for	analysis	(table	1).	During	follow-up,	103	first	
CVD	 events	 occurred,	 including	 cases	 of	 acute	 coronary	 syndrome	 (n=66),	 ischaemic	 stroke	
(n=26),	HF	(n=4)	and	CVD	deaths	(n=7).	At	the	time	of	event	or	censoring,	patients	had	a	mean±SD	
disease	duration	of	7.8±3.5	years.	
Model	development	
When	recalibrating	the	SCORE	algorithm	only	the	traditional	CVD	risk	factors	were	included	in	the	
Cox-proportional	hazard	regression,	changing	the	regression	coefficients	(weights)	as	a	result.	For	
the	adaptation	of	 the	SCORE	model	new	variables	were	added	(please	see	the	supplementary	
tables	 S1	 and	 S2	 for	 further	 information).	 The	 following	 CVD	 risk	 factors	 were	 significant	
predictors:	current	smoking	status,	systolic	blood	pressure,	TC:HDL	ratio,	BMI,	diabetes	mellitus	
at	baseline,	hypertension	at	baseline,	high	baseline	DAS28	(cut-off	point	>5.1).	The	median	(IQR)	
10-year	CVD	risk	scores	calculated	by	the	original	and	the	adapted	SCORE	algorithm	were	9.1%	
(2.7%–26.6%)	and	6.7%	(1.6%–18.4%)	respectively.		
8		
Predictive	performance	of	the	original	and	adapted	SCORE	algorithm	
	 118	
Table	1.	Patients	characteristics	
	 Total	cohort		
(n	=	1016)	
No	CVD		
(n=	913)	
CVD		
(n	=	103)	
p-value	
Age	(years),	mean±SD	 54±13	 53±14	 62±10	 <.001	
Sex	 (	female),	n(%)	 674	(66.3)	 620	(67.9)	 54	(52.4)	 0.002	
Currently	smoking,	 n(%)	 313	(30.8)	 280	(30.7)	 40	(38.8)	 0.133	
BMI	 (weight(kg)/height(m)
2
),	mean±SD	 25.5±4.3	 25.5±4.3	 26.9±4.1	 0.004	
Systolic	blood	 pressure	(mm	Hg),	mean±SD	 146±24	 145±24	 156±25	 <.001	
Diastolic	blood	pressure	(mm	Hg),	mean±SD	 84±11	 84±12	 87±9	 0.004	
Hypertension	(	physician	diagnosis)	 	 	 	 	
			At	baseline,	n(%)	 144	(14.2)	 117	(12.8)	 27	(26.2)	 <.001	
			During	follow-up,	 n(%)	 260	(25.6)	 220	(24.1)	 40	(38.8)	 0.002	
Antihypertensives,	 n(%)	 159	(15.6)	 130	(14.2)	 29	(28.2)	 <.001	
Total	cholesterol	 (mmol/L),	mean±SD	 5.2±1.3	 5.2±1.3	 5.2±1.3	 0.743	
HDL-cholesterol,	mean±SD	 1.3±0.3	 1.3±0.3	 1.2±0.3	 0.018	
TC:HDL-c	 ratio,	mean±SD	 4.2±1.0	 4.1±1.1	 4.5±1.2	 0.037	
LDL-cholesterol,	mean±SD	 3.2±1.1	 3.2±1.0	 3.2±1.1	 0.526	
Non-HDL	 cholesterol,	mean±SD	 3.9±1.1	 3.9±1.1	 4.0±1.2	 0.296	
Lipid-lowering	agents,	n(%)	 40	(3.9)	 33	(3.6)	 7	(6.8)	 0.191	
Diabetes	mellitus	 	 	 	 	
			At	baseline,	n(%)	 44	(4.3)	 36	(3.9)	 8	(7.8)	 0.121	
			During	follow-up,	 n(%)	 84	(8.3)	 69	(7.6)	 15	(14.6)	 0.024	
Family	history	 of	CVD,	n(%)	 312	(30.7)	 274	(30.0)	 38	(36.9)	 0.180	
Rheumatoid	 factor	 (	positivity),	 n(%)	 761	(74.9)	 680	(74.5)	 81	(78.6)	 0.427	
Anti-CCP	 (	positivity),	n(%)	 643	(63.3)	 592	(64.8)	 68	(66)	 0.803	
DAS28,	mean±SD	 4.9±1.3	 4.9±1.3	 5.3±1.3	 0.002	
Swollen	joint	count,	median		 (IQR)	 8	(5–12)	 8	(5–12)	 9	(5–13)	 0.104	
Tender	joint	count,	median		 (IQR)	 5	(3–10)	 5	(3–10)	 7	(2–12)	 0.057	
ESR,	median	(IQR)	 25	(16–45)	 24	(16–45)	 35	(21–50)	 0.002	
VAS,	median	(IQR)	 41	(30–57)	 40	(29–56)	 48	(32–65)	 0.008	
CRP,	median	(IQR)	 16	(3–42)	 15	(3–41)	 26	(6–48)	 0.023	
HAQ,	median	(IQR)	 0.6	(0.3–1.1)	 0.6	(0.3–1.1)	 0.8	(0.3–1.1)	 0.054	
MTX	 treatment	ever,	n(%)	 555	(54.6)	 506	(55.4)	 49	(47.6)	 0.158	
Biological		DMARDs	ever,	n(%)	 221	(21.8)	 213	(23.3)	 8	(7.8)	 <.001	
i. Hypertension	is	defined	as	multiple	measurements	of	elevated	systolic	blood	pressure	(>140	
mm	Hg)	during	multiple	visits	by	a	physician.	Diabetes	mellitus	includes	both	type	I	and	type	
II.		
ii. All	variables	represent	baseline	measures,	except	when	otherwise	stated.	
iii. Anti-CCP,	anti-cyclic	citrullinated	peptide;	BMI,	body	mass	 index;	CRP,	C	 reactive	protein;	
CVD,	 cardiovascular	 disease;	 DAS28,	 28-joint	 disease	 activity	 score;	 DMARDs,	 disease-
modifying	 antirheumatic	 drugs;	 ESR,	 erythrocyte	 sedimentation	 rate;	 HAQ,	 Health	
Assessment	 Questionnaire;	 HDL,	 high-density	 lipoprotein;	 LDL,	 low-density	 lipoprotein;	
MTX,	methotrexate;	TC,	total	cholesterol;	VAS,	Visual	Analogue	Scale	(patient	global	VAS).		
	
Discrimination	
Discriminatory	performance	was	comparable	across	the	original,	recalibrated	and	adapted	SCORE	
algorithms,	with	an	area	under	the	curve	of	0.78	(95%	CI	0.74	to	0.82),	0.78	(0.74	to	0.83)	and	
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0.80	 (0.75	 to	 0.84),	 respectively.	 The	 corresponding	 ROC	 curves	 for	 the	 original	 and	 adapted	
SCORE	are	presented	in	figure	1.	The	c-statistic	values	were	similar	between	0.75	and	0.76	for	all	
three	algorithms.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	Receiver	operating	 	 characteristic	 (ROC)	curves	 	 for	the	original	 Systematic	 COronary	 Risk	Evaluation	
(SCORE)	 and	the	adapted	SCORE	 algorithms.	 Area	under	the	curve	 values	 were	(95%	CI)	 0.78	(0.74	 to	0.82)	
and	0.80	(0.76	to	0.84)	for	the	original	and	adapted	SCORE	 algorithm,	respectively.	
Calibration	
Patients	 were	 grouped	 into	 deciles	 based	 on	 ascending	 predicted	 CVD	 risk.	 In	 each	 of	 these	
groups	the	observed	number	of	CVD	events	was	compared	with	the	calculated	(expected)	risk	for	
CVD	 events.	 It	 appeared	 that	 when	 using	 the	 original	 SCORE	 algorithm,	 the	 CVD	 risk	 was	
underestimated	in	the	lower	and	middle	deciles	and	was	greatly	overestimated	in	the	top	decile	
(figures	2A	and	3A).	The	H–L	test	indicated	a	poor	model	fit	with	a	p	value	of	<0.001.	Next,	the	
recalibrated	 algorithm	 that	 included	 only	 the	 ‘re-weighted’	 traditional	 risk	 factors	
underestimated	CVD	risk	across	all	deciles	with	a	p	value	of	<0.001	for	the	H–L	test,	also	indicating	
poor	model	fit	(not	shown).	Then,	the	adapted	SCORE	algorithm	underestimated	CVD	risk	in	the	
lower	and	middle	deciles	and	overestimated	CVD	risk	in	the	highest	decile,	with	a	p	value	for	the	
H–L	test	of	0.04	(figures	2B	and	3B).	
Reclassification	of	CVD	risk	
For	clinical	care,	patients	usually	are	classified	into	risk	groups.	The	number	of	patients	classified	
by	the	original	SCORE	and	the	adapted	SCORE	in	each	of	the	three	risk	groups	(>10%,	10%–20%	
and	>20%	CV	risk)	is	presented	in	tables	2	and	3.	Although	the	clinically	important	10%–20%	risk		
were registered including 17 acute coronary events, ﬁve cases of
stroke, two c ses of HF a d wo cases of other CV death. Due
to missing values on non-traditional CVD risk factors, 24 events
were available for analysis related to the validation the adapted
SCORE algorithm. Missing values ranged from 0% to 5%
(DAS28). Discriminatory ability of the adapted SCORE algo-
rithm was inferior to the original SCORE algorithm with an
area under the curve of 0.76 (95% CI 0.68 o 0.84), 0.74 (0.66
to 0.83) for the original and adapted SCORE algorithm,
respectively. The H–L test indicated a poor model ﬁt for both
models with a p value of <0.001.
DISCUSSION
In RA, risk assessment by traditional CVD risk models such as
SCORE appears to be suboptimal.21 22 27 Therefore, the aim of
this study was to adapt the SCORE algorithm to improve the
accuracy of CVD risk estimates in patients with RA, by changing
the weights (recalibration) and by adding new variables (adapta-
tion). Unfortunately, recalibration and adaptation of the SCORE
algorithm with additional RA-speciﬁc CVD risk factors did not
lead to major improvements in the accuracy of CVD risk predic-
tion in patients with RA.
Several RA-speciﬁc predictors were considered and some of
them, such as high DAS28 at baseline, showed signiﬁcant pre-
dictive power. However, in the end the SCORE algorithm
adapted with RA-speciﬁc predictors showed a rather modest
improvement in discriminatory ability in comparison with the
original SCORE. Furthermore, the adapted SCORE algorithm
mainly improved overestimation of CVD risk in patients not
getting CVD and in the highest risk groups. Overestimation of
CVD risk may be harmful as patients receive unnecessary treat-
ment. However, overestimation of CVD risk mostly affected
intermediate-risk to high-risk patients, in which case overesti-
mation would only reafﬁrm treatment indication and would not
change the indication for treatment. Improvement of CVD risk
estimates in these patients therefore is less important for clinical
purposes. Much could be gained from improving the classiﬁca-
tion of patients with RA who later develop CVD (event cases)
into higher risk groups so these patients become eligible for pre-
ventive treatment. The adapted SCORE does not show a signiﬁ-
cant improvement in this area, leaving undetected high-risk
patients with RA at risk of being under treated. In general,
underestimation of CVD risk in RA appears to be the main
problem with the original SCORE as shown by us as well as by
others.21 27 Similar results have been reported for other CVD
risk calculators such as FRS.22 The FRS signiﬁcantly underesti-
mated CVD risk, especially in older patients and in patients
with positive RF and persistently elevated ESR. This indicates
that i RA disease severity and inﬂammation that are not
accounted for in current CVD risk algorithms may play a role.
However, our adaptation of the SCORE algorithm including
these variables did not solve the issue.
Figu e 1 Receiver operating characteristic (ROC) curves for the
original Systematic COronary Risk Evaluation (SCORE) and the adapted
SCORE algorithms. Area under the curve values were (95% CI) 0.78
(0.74 to 0.82) and 0.80 (0.76 to 0.84) for the original and adapted
SCORE algorithm, respectively.
Figure 2 Calibration plots. Probabilities depicted at the y axis, and the predicted probabilities depicted at the x axis as calculated by the original
Systematic COronary Risk Evaluation (SCORE) algorithm (A) and the adapted SCORE algorithm (B). A line was ﬁtted between the observed and
predicted probabilities of cardiovascular disease events using cubic spline.
Arts EEA, et al. Ann Rheum Dis 2016;75:674–680. doi:10.1136/annrheumdis-2014-206879 677
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Figure	2.	Calibration	plots.	Observed	probabilities	depicted	at	the	y	axis,	and	the	predicted	probabilities	
depicted	 at	 the	 x	 axis	 as	 calculated	 by	 the	 original	 Systematic	 COronary	 Risk	 Evaluation	 (SCORE)	
algorithm	 (A)	 and	 the	 adapted	 SCORE	 algorithm	 (B).	 A	 line	 was	 fitted	 between	 the	 observed	 and	
predicted	probabilities	of	cardiovascular	disease	events	using	cubic	spline.		
Figure	3.	Bar	chart	with	the	observed	number	of	events	(%)	depicted	at	the	y	axis,	and	the	deciles	of	
predicted	risk	depicted	at	the	x	axis	as	calculated	by	the	original	Systematic	COronary	Risk	Evaluation	
(SCORE)	algorithm	(A)	and	the	adapted	SCORE	algorithm	(B).	CV,	cardiovascular.		
	
group	did	 increase	in	numbers	for	the	adapted	SCORE,	not	all	patients	with	a	CVD	event	were	
reclassified	appropriately	because	their	predicted	risk	remained	too	low.	In	total,	six	patients	with	
an	event	were	 reclassified	 to	 the	 low-risk	 group	by	 the	adapted	SCORE	compared	with	 seven	
patients	who	were	correctly	reclassified	to	a	higher	risk	group.	The	adapted	SCORE	model	did	
perform	noticeably	better	reclassifying	the	non-event	patients	(i.e.,	their	predicted	risk	became	
appropriately	lower).	Overall,	estimates	of	CVD	risk	by	the	original	SCORE	and	the	adapted	SCORE	
algorithms	were	 similar	 for	 the	majority	of	patients	 and	did	not	 lead	 to	a	 reclassification	 into	
another	risk	group	for	most	patients	(68%).	
were registered including 17 acute coronary events, ﬁve cases of
stroke, two cases of HF and two cases of other CV death. Due
to missing values on non-traditional CVD risk factors, 24 events
were available for analysis related to the validation the adapted
SCORE algorithm. Missing values ranged from 0% to 5%
(DAS28). Discriminatory ability of the adapted SCORE algo-
rithm was inferior to the original SCORE algorithm with an
area under the curve of 0.76 (95% CI 0.68 to 0.84), 0.74 (0.66
to 0.83) for the original and adapted SCORE algorithm,
respectively. The H–L test indicated a poor model ﬁt for both
models with a p value of <0.001.
DISCUSSION
In RA, risk assessment by traditional CVD risk models such as
SCORE appears to be suboptimal.21 22 27 Therefore, the aim of
this study was to adapt the SCORE algorithm to improve the
accuracy of CVD risk estimates in patients with RA, by changing
the weights (recalibration) and by adding new variables (adapta-
tion). Unfortunately, recalibration and adaptation of the SCORE
algorithm with additional RA-speciﬁc CVD risk factors did not
lead to major improvements in the accuracy of CVD risk predic-
tion in patients with RA.
Several RA-speciﬁc predictors were considered and some of
them, such as high DAS28 at baseline, showed signiﬁcant pre-
dictive power. However, in the end the SCORE algorithm
adapted with RA-speciﬁc predictors showed a rather modest
improvement in discriminatory ability in comparison with the
original SCORE. Furthermore, the adapted SCORE algorithm
mainly improved overestimation of CVD risk in patients not
getting CVD and in the highest risk groups. Overestimation of
CVD risk may be harmful as patients receive unnecessary treat-
ment. However, overestimation of CVD risk mostly affected
intermediate-risk to high-risk patients, in which case overesti-
mation would only reafﬁrm treatment indication and would not
change the indication for treatment. Improvement of CVD risk
estimates in these patients therefore is less important for clinical
purposes. Much could be gained from improving the classiﬁca-
tion of patients with RA who later develop CVD (event cases)
into higher risk groups so these patients become eligible for pre-
ventive treatment. The adapted SCORE does not show a signiﬁ-
cant improvement in this area, leaving undetected high-risk
patients with RA at risk of being under treated. In general,
underestimation of CVD risk in RA appears to be the main
problem with the original SCORE as shown by us as well as by
others.21 27 Similar results have been reported for other CVD
risk calculators such as FRS.22 The FRS signiﬁcantly underesti-
mated CVD risk, especially in older patients and in patients
with positive RF and persistently elevated ESR. This indicates
that in RA disease severity and inﬂammation that are not
accounted for in current CVD risk algorithms may play a role.
However, our adaptation of the SCORE algorithm including
these variables did not solve the issue.
Figure 1 Receiver operating characteristic (ROC) curves for the
original Systematic COronary Risk Evaluation (SCORE) and the adapted
SCORE algorithms. Area under the curve values were (95% CI) 0.78
(0.74 to 0.82) and 0.80 (0.76 to 0.84) for the original and adapted
SCORE algorithm, respectively.
Figure 2 Calibration plots. Probabilities depicted at the y axis, and the predicted probabilities depicted at the x axis as calculated by the original
Systematic COronary Risk Evaluation (SCORE) algorithm (A) and the adapted SCORE algorithm (B). A line was ﬁtted between the observed and
predicted probabilities of cardiovascular disease events using cubic spline.
Arts EEA, et al. Ann Rheum Dis 2016;75:674–680. doi:10.1136/annrheumdis-2014-206879 677
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Table	2.	Patients	grouped	per	CVD	risk	category	for	the	original	SCORE	and	the	adapted	SCORE	
	 Original	SCORE	 Adapted	SCORE	
n(%)	 <10%	 10-20%	 >20%	 <10%	 10-20%	 >20%	
CVD		
(n	=	103)	
	
24	(23.3)	
	
17	(16.5)	
	
62	(60.2)	
	
27	(26.2)	
	
24	(23.3)	
	
52	(50.5)	
No	CVD		
(n	=	913	
	
586	(64.2)	
	
137	(15.0)	
	
190	(20.8)	
	
658	(72.1)	
	
130	(14.2)	
	
125 (13.7)	
i. CVD,	cardiovascular	disease;	SCORE,	Systematic	COronary	Risk	Evaluation.		
	
	
Table	3.	CVD	risk	group	reclassification	of	RA	patients	when	using	the	original	SCORE	and	the	adapted	
SCORE	algorithms		
CVD	 (n	=	103)								 Adapted	 SCORE	 	 	 	
Original	SCORE																																						 	 <10%	 10-20%	 >20%	
	 <10%	 21	(20.4)	 2	(1.9)	 1	(1.0)	
	 10%–20%	 4	(3.9)	 9	(8.7)	 4	(3.9)	
	 >20%	 2	(1.9)	 13	(12.6)	 47	(45.6)	
No	CVD	(n	=	913)	 Adapted	SCORE	 	 	 	
Original	SCORE	 	 <10%	 10-20%	 >20%	
	 <10%	 570	(62.4)	 14	(1.5)	 2	(0.2)	
	 10%–20%	 66	(7.2)	 57	(6.2)	 14	(1.5)	
	 >20%	 22	(2.4)	 59	(6.5)	 109 1.9)	
i. CVD,	cardiovascular	disease;	SCORE,	Systematic	COronary	Risk	Evaluation.		
	
External	validation	
After	exclusion	of	93	patients	with	a	history	of	CVD	at	baseline,	511	patients	were	included	for	
external	 validation	 (please	 see	 supplementary	 table	 S3	 for	 further	 details).	 Patients	 had	 a	
mean±SD	 follow-up	 of	 7.5±2.2	 years.	 A	 total	 of	 26	 first	 fatal	 or	 non-fatal	 CVD	 events	 were	
registered	including	17	acute	coronary	events,	ﬁve	cases	of	stroke,	two	cases	of		HF	and	two	cases	
of	other	CV	death.	Due	 to	missing	 values	on	non-traditional	CVD	 risk	 factors,	 24	events	were	
available	for	analysis.	Missing	values	ranged	from	0%	to	5%	(DAS28).	Discriminatory	ability	of	the	
adapted	SCORE	algorithm	was	 inferior	to	the	original	SCORE	algorithm	with	an	area	under	the	
curve	 of	 0.76	 (95%	 CI	 0.68	 to	 0.84),	 0.74	 (0.66	 to	 0.83)	 for	 the	 original	 and	 adapted	 SCORE	
algorithm,	respectively.	The	H–L	test	indicated	a	poor	model	ﬁt	for	both	models	with	a	p	value	of	
<0.001.	
	DISCUSSION	
In	RA,	risk	assessment	by	traditional	CVD	risk	models	such	as	SCORE	appears	to	be	suboptimal.[21	
22	27]	Therefore,	the	aim	of	this	study	was	to	adapt	the	SCORE	algorithm	to	improve	the	accuracy	
of	CVD	risk	estimates	in	patients	with	RA,	by	changing	the	weights	(recalibration)	and	by	adding	
new	variables	(adaptation).	Unfortunately,	recalibration	and	adaptation	of	the	SCORE	algorithm	
with	additional	RA-speciﬁc	CVD	risk	factors	did	not	lead	to	major	improvements	in	the	accuracy	
of	CVD	risk	prediction	in	patients	with	RA.	
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Several	RA-speciﬁc	predictors	were	considered	and	some	of	them,	such	as	high	DAS28	at	baseline,	
showed	signiﬁcant	predictive	power.	However,	in	the	end	the	SCORE	algorithm	adapted	with	RA-
speciﬁc	predictors	showed	a	rather	modest	improvement	in	discriminatory	ability	in	comparison	
to	 the	 original	 SCORE.	 Furthermore,	 the	 adapted	 SCORE	 algorithm	 mainly	 improved		
overestimation	 of	 CVD	 risk	 in	 patients	 without	 CVD	 and	 in	 the	 highest	 CVD	 risk	 groups.	
Overestimation	of	CVD	risk	may	be	harmful	as	patients	receive	unnecessary	treatment.	However,	
mostly	intermediate-risk	to	high-risk	patients	were	affected	by	CVD	risk	overestimation,	in	which	
case	this	would	only	reafﬁrm	treatment	indication	and	would	not	change	the	indication	overall.	
Improvement	 of	 CVD	 risk	 estimates	 in	 these	 patients	 is	 therefore	 less	 important	 for	 clinical	
purposes.	Much	could	be	gained	from	improving	the	classiﬁcation	of	patients	with	RA	who	later	
develop	CVD	(event	cases)	into	higher	risk	groups	so	these	patients	become	eligible	for	preventive	
treatment.	 The	adapted	SCORE	does	not	 show	a	 signiﬁcant	 improvement	 in	 this	 area,	 leaving	
undetected	high-risk	patients	with	RA	at	risk	for	being	under	treated.	In	general,	underestimation	
of	CVD	risk	in	RA	appears	to	be	the	main	problem	with	the	original	SCORE	as	shown	by	us	as	well	
as	by	others.[21	27]	Similar	 results	have	been	 reported	 for	other	CVD	 risk	 calculators	 such	as	
FRS.[22]	The	FRS	signiﬁcantly	underestimated	CVD	risk,	especially	in	older	patients	and	in	patients	
with	 positive	 RF	 and	 persistently	 elevated	 ESR.	 This	 indicates	 that	 disease	 severity	 and	
inﬂammation,	which	are	not	accounted	for	in	current	CVD	risk	algorithms,	may	play	a	role	in	CVD	
risk	prediction	in	patients	with	RA.	However,		our	adaptation	of	the	SCORE	algorithm		including	
these	variables	did	not	solve	the	issue.	It	is	not	clear	why	CVD	risk	generally	is	underestimated	in	
RA.	One	explanation	may	be	that	 the	atherosclerotic	burden	 in	patients	with	RA	 is	not	always	
mirrored	by	the	SCORE	or	other	risk	calculators.[23,	25,		34]		In	patients	with	RA,	the	SCORE	risk	
estimates	did	not	associate	well	with	subclinical	carotid	atherosclerosis[25]	and	patients	with	RA	
with	high	coronary	artery	calciﬁcation	were	infrequently	assigned	to	be	at	elevated	risk	by	the	
FRS	or	the	RRS.[23]	Calciﬁcations	and	plaques	of	coronary	arteries	also	occurred	in	patients	with	
RA	classiﬁed	as	having	low	CV	risk	(<1%)	according	to	the	SCORE.[34]	Therefore,	in	RA,	important	
subclinical	atherosclerosis	is	not	reﬂected	in	CVD	risk	when	applying	these	risk	calculators.	
This	study	has	several	limitations.	For	one,	the	external	validation	cohort	consists	of	patients	with	
both	 early	 and	 established	 RA	 from	 varying	 geographical	 areas.	 Conﬂicting	 results	 have	 been	
reported	with	regards	to	the	onset	of	the	increased	risk	of	CVD	in	patients	with	RA.[24,		35–38]	It	
may	prove	to	be	difﬁcult	to	develop	a	singular	CVD	risk	algorithm	that	can	be	applied	successfully	
in	 all	 RA	 populations	 across	 different	 countries.	 Furthermore,	 the	 	 baseline	 risk	 that	 	 was	
determined	 in	the	general	population	for	the	original	SCORE	was	also	 included	 in	the	adapted	
algorithm	and	this	may	contribute	to	systematic	underestimation	of	CVD	risk	by	this	algorithm.	
As	 the	 baseline	 risk	 for	 CVD	 is	 increased	 in	 an	 individual	 with	 RA	 compared	 to	 a	 healthy	
counterpart	of	similar	age	and	sex,[1,	2]	it	may	be	necessary	to	adapt	this	baseline	risk.	However,		
although		our	cohorts		are		among		the		largest		RA	cohorts		available		with	sufﬁcient	data	on	CVD	
risk	 factors	 and	 follow-up,	 the	 number	 of	 available	 patients	 with	 RA	 and	 CVD	 events	 in	 this	
individual	cohort	was	still	deemed	insufﬁcient	to	determine	a	reliable,	robust	baseline	risk	that	
could	 be	 extrapolated	 	 to	 other	 	 RA	 populations.	 Furthermore,	 the	 adapted	 SCORE	 algorithm	
developed	in	this	study	is	a	basic	revision	of	the	original	SCORE	including	all	traditional	CVD	risk	
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factors	 already	 included	 in	 the	 original	 SCORE.	 Although	 this	 approach	 is	 suitable	 for	 smaller	
cohorts	it	also	comes	with	restrictions	in	terms	of	predictor	selection.	The	structure	and	format	
of	the	SCORE	are		largely	maintained,	regardless	of	whether	this	would	provide	the	best	ﬁt	for	the	
RA	population.	Hypothetically,	some	of	the	well-established	traditional	risk	factors	that	form	the	
base	 of	 the	 CVD	 risk	 algorithms	 that	 are	 currently	 used,	 may	 require	 replacement	 by	 other,		
stronger,	RA-speciﬁc	predictors		of	CVD	risk.	These	predictors		may	be	more	sensitive	to	the	subtle	
differences	between	low-risk	and	high-risk	patients	in	the	RA	population.	The	results	of	this	study	
showed	a	signiﬁcant	relationship	between	high	baseline	disease	activity	and		CVD		risk.	This	is	in	
concurrence	with	other	research.[17,	38]	
In	conclusion,	this	study	demonstrates	that	adaptations	of	the	SCORE	algorithm	did	not	provide	
sufﬁcient	improvement	in	the	predictive	performance	to	serve	as	an	appropriate	alternative	to	
the	original	SCORE	for	the	prediction	of	the	10-year	risk	of	CVD	in	RA.	A	larger	cohort	with	a	higher	
number	of	CVD	events	might	be	used	 to	develop	a	RA-speciﬁc	CVD	 risk	 algorithm	 taking	 into	
consideration	 other	 factors,	 most	 intuitively	 related	 to	 the	 disease	 pathogenesis	 and	
inﬂammation.	Alternatively,	additional	 investigations	such	as	carotid	ultrasound	may	provide	a	
substantial	 	 improvement	 	 of	 	 correct	 	 classiﬁcation	 	 of	 	 these	patients,	 even	when	using	 the	
original	 SCORE.	 Future	 studies	 should	 address	 these	 hypotheses	 to	 shed	more	 light	 onto	 this	
matter	and	contribute	to	more	efﬁcient	CVD	risk	management	in	RA,	eventually	decreasing	CVD		
morbidity	and	mortality	in	this	population.	
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Supplementary	tables		
Table	S1.	Results	from	the	multivariate	Cox-proportional	hazard	regression	analysis.		
	 B	 P-value	 OR	 95%	CI	for	OR	
	 	 		 	 Lower		 Upper	
SCORE	Recalibrated	<65	years	 	 	 	 	 	
Smoking	 0.341	 0.165	 1.406	 0.865	 2.285	
Systolic	blood	pressure	*	 0.019	 <0.001	 1.019	 1.011	 1.027	
TC:HDL-c	ratio*	 1.407	 0.004	 4.085	 1.574	 10.60	
	 	 	 	 	 	
SCORE	Recalibrated	>65	years		 	 	 	 	 	
Age*	 0.061	 <0.001	 1.063	 1.044	 1.082	
Sex	 0.570	 0.005	 1.769	 1.188	 2.634	
Smoking	 0.382	 0.148	 1.465	 0.867	 2.473	
Systolic	blood	pressure*	 0.008	 0.061	 1.008	 1.000	 1.017	
TC:HDL-ratio	 1.228	 0.011	 3.414	 1.324	 8.806	
	 	 	 	 	 	
SCORE	Adapted	 	 	 	 	 	
Smoking	 0.380	 0.115	 1.462	 0.909	 2.350	
Systolic	blood	pressure*	 0.012	 0.009	 1012	 1.003	 1.021	
TC:HDL-c	ratio*	 1.387	 0.006	 4.005	 1.488	 10.78	
BMI	 0.038	 0.068	 1.039	 0.997	 1.082	
Diabetes	at	baseline	 0.695	 0.068	 2.004	 0.949	 4.233	
Hypertension	at	baseline	 0.725	 0.003	 2.065	 1.273	 3.348	
DAS28	>5.1		 0.557	 0.006	 1.745	 1.170	 2.601	
i. TC;	 total	 cholesterol,	 HDL-c;	 high-density	 lipoprotein	 cholesterol,	 BMI;	 body	mass	 index,	
DAS28;	28-joint	disease	activity	score,	OR;	odds	ratio,	CI;	confidence	interval		
	
Table	S2.	SCORE	recalibrated	and	adapted	SCORE	algorithms	
Recalibrated	SCORE:	
*≤65	years	old:	
SCORE	recalibrated	=	1-Baseline	Risk	**	EXP[0.019	x	 (systolic	blood	pressure	 -	140	mmHg)	+	1.407	x	
natural	logarithm	(TC:HDL-c	-	1.061)+0.340824	(if	currently	smoking)]	x	100%	
*>65	years	old:	 	
SCORE	recalibrated	=	1	-	0.93884	**	EXP[0.570	(if	male)	+	0.061	*	(age	-	55)	+	0.382	(if	currently	smoking)	
+	0.008	x	(systolic	blood	pressure	-	137	mmHg)	+	1.228	x	natural	logarithm	(TC:HDL-	1.608)]	x	100%.	
Adapted	SCORE:	
SCORE	updated	=	1-Baseline	Risk	**	EXP(0.012	x	(systolic	blood	pressure	-140	mmHg)	+	1.387	x	natural	
logarithm	(TC:HDL-c	-	1.061)	+	0.379527	(if	currently	smoking)	+	0.038	x	BMI	+	0.695	(in	case	of	diabetes	
mellitus)	+	0.725	x	(in	case	of	hypertension)	+	0.557	(if	DAS28	>	5.1))*100.	
i. SCORE;	 Systemic	 COronary	 Risk	 Evaluation,	 TC;	 total	 cholesterol,	 HDL-c;	 high-density	
lipoprotein	cholesterol,	BMI;	body	mass	 index,	DAS28;	28-joint	disease	activity	score,	OR;	
odds	ratio,	CI;	confidence	interval		
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Table	S3.	Patient	characteristics	of	the	external	validation	cohort.		
		 	 Whole	group	
(n=511)	
CV	event	
(n=26)	
No	CV	event	
(N=485)	
Age	(years),	mean±SD	 60±12.3	 69±9	 60±12	
Sex	(female),	n(%)	 393	(77)	 16	(62)	 377	(78)	
Smoking,	n(%)	 111	(22)	 4	(15)	 107	(22)	
BMI	(weight[kg]/Height[m]²),	mean±SD	 26.9±5.1	 26±3.5	 26.9±5.1	
Systolic	blood	pressure	(mmHg),	mean±SD	 144±23	 155±24	 143±22	
Diastolic	blood	pressure	(mmHg),	mean	±SD	 81±12	 81±12	 81±12	
Hypertension,	n(%)	 340	(66.5)	 23	(89)	 317	(65)	
Treated	with	anti-hypertensives,	n(%)	 162	(32)	 13	(50)	 149	(31)	
Total	Cholesterol	(mmol/L),	mean±SD	 5.5±1.2	 6.1±1.2	 5.4±1.2	
HDL-Cholesterol,	mean±SD	 1.7±0.5	 1.7±0.5	 1.7±0.5	
TC:HDL-c	ratio,	mean±SD	 3.6±1.1	 3.8±1.1	 3.5±1.1	
LDL-Cholesterol,	mean±SD	 3.2±1.2	 3.8±1.2	 3.2±1.1	
Treatment	with	statins/fibrates,	n(%)	 60	(12)	 3	(12)	 57	(12)	
Diabetes,	n(%)	 36	(7)	 1	(4)	 35	(7)	
Rheumatoid	factor	(positivity),	n(%)		 349	(68)	 18	(69)	 331	(68)	
Anti-CCP	(positivity),	n(%)	 319	(62)	 20	(77)	 299	(62)	
Disease	duration	at	baseline	(years),	mean±SD	 12.6±8.8	 18.2±11.5	 12.3±8.6	
DAS28,	mean±SD	 4.1±1.4	 3.9±1.4	 4.1±1.4	
				Swollen	joint	count,	median	(IQR)	 4	(1-7)	 2	(0-7)	 4	(1-7)	
				Tender	joint	count,	median	(IQR)		 3	(1-8)	 2	(1-6)	 3	(1-8)	
				ESR,	(IQR)	 17	(9-32)	 18	(10-36)	 17	(9-31)	
				VAS,	(IQR)	 40	(20-60)	 38	(20-60)	 40	(20-60)	
DAS28	>5.1,	n(%)	 113	(22)	 4	(15)	 109	(23)	
CRP,	median	(IQR)	 7	(3-16)	 8	(3-18)	 7	(3-16)	
HAQ,	median,	mean±SD	 1.3	(0.4-1.9)	 1.2	(0.3-2.1)	 1.3	(0.4-1.9)	
SCORE	original	(%),	median	(P25-P75)	 8.3	(2.7-25.6)	 32	(14-64)	 8	(3-24)	
SCORE	updated	(%),	median	(P25-P75)	 8.2	(2.7-19.9)	 23	(12-43)	 7	(2-19)	
i. BMI;	body	mass	index,	TC;	total	cholesterol,	HDL;	high	density	lipoprotein,	LDL;	low	density	
lipoprotein,	CVD;	cardiovascular	disease,	anti-CCP;	anti-cyclic	citrullinated	peptide,	DAS28;	
28-joint	disease	activity	 score,	 ESR;	erythrocyte	 sedimentation	 rate,	VAS;	 visual	 analogue	
scale	(patient	global	VAS),	CRP;	c-reactive	protein,	HAQ;	health	assessment	questionnaire.	
Hypertension	is	defined	as	multiple	measurements	of	elevated	systolic	blood	pressure	(>140	
mmHg)	during	multiple	visits	by	a	physician.	Diabetes	mellitus	includes	both	type	I	and	type	
II.	All	variables	represent	baseline	measures,	except	when	otherwise	stated.		
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The	risk	of	developing	CVD	is	notably	higher	in	RA	patients	compared	to	the	general	population.	
Although	a	decrease	has	been	reported	 in	recent	years,	CVD	mortality	remains	elevated	 in	RA	
patients.[1]	In	order	to	reduce	this	risk,	CVD	risk	management	should	be	an	integral	part	of	clinical	
care	for	patients	with	RA.	This	would	entail	screening	for	CVD	risk	factors	and	identifying	patients	
with	a	high	risk	of	CVD.	It	was	hypothesized	that	risk	algorithms	used	in	the	general	population	
may	be	less	suitable	to	use	for	CVD	risk	assessment	in	RA	as	traditional	risk	factors	do	not	fully	
account	for	the	excess	CVD	risk	in	RA	patients.[2,	3,	4,	5]	In	addition,	certain	RA	specific	factors	
may	serve	as	a	predictor,	particularly	chronic	systemic	inflammation.[6,	7]	Systemic	inflammation	
is	 a	 hallmark	 of	 RA,	 which	 has	 been	 a	 focal	 point	 of	 research	 investigating	 CVD	 risk	 in	 this	
population.	Whilst	 there	 are	 various	ways	 in	which	 systemic	 inflammation	 is	 hypothesized	 to	
increase	CVD	risk,	the	exact	mechanism	underlying	the	association	between	inflammation	and	
CVD	in	RA	remains	largely	unknown.	Evidence	supporting	the	application	of	(disease	specific)	CVD	
risk	management	 guidelines	 in	 RA	 is	 limited.	 It	 is	 unclear	 what	 strategy	 is	most	 effective	 for	
accurate	detection	of	RA	patients	at	risk	for	developing	CVD,	and	what	predictors	would	be	best	
suited	for	CVD	risk	estimation	in	RA.	This	information	is	of	importance	for	appropriate	allocation	
of	 preventative	 treatment,	 thus	 for	 the	 reduction	 of	 CVD	 morbidity	 and	 mortality	 in	 this	
population.	Therefore,	the	main	focus	of	this	thesis	was	on	CVD	risk	prediction	and	on	the	CVD	
risk	 profile	 in	 RA	 patients.	 The	 first	 objective	 was	 to	 evaluate	 the	 predictive	 performance	 of	
various	CVD	risk	algorithms	used	 in	the	general	population	and	to	develop	and	evaluate	a	risk	
algorithm	that	includes	disease	specific	risk	factors	in	RA	patients.	The	second	objective	was	to	
shed	more	light	on	the	relationship	between	disease	activity	and	the	risk	of	developing	CVD	in	
these	patients.	In	summary,	the	main	conclusions	of	this	thesis	are	as	follows.	
	 Chapter	2:	A	modest	storage	decay	effect	on	lipoproteins	determined	in	frozen	serum	
samples	was	found	that	 is	unlikely	to	significantly	affect	CVD	risk	stratification.	Serum	samples	
that	have	been	stored	long-term	(>10	years)	can	be	used	to	obtain	valid	lipid	measurements	for	
developing	CVD	risk	prediction	models	in	RA	cohorts,	even	without	applying	a	decay	correction	
factor.	
Chapter	 3:	 Risk	 estimates	 by	 traditional	 CVD	 risk	 algorithms,	 when	 applied	 in	 RA	
population,	were	found	to	be	 less	accurate	compared	to	reports	 from	the	general	population.	
Overall,	 they	 largely	 underestimated	 CVD	 risk	 in	 RA	 patients,	 which	 may	 lead	 to	 insufficient	
application	of	preventive	measures	and	therapies.	
	 Chapter	4	&	5:	The	TC:HDL-c	ratio,	or	atherogenic	index	(AI)	and	HDL-function	may	be	
more	suitable	parameters	of	the	lipid	profile	to	serve	as	CVD	risk	predictors	in	patients	with	RA	
than	individual	measurements	of	lipids.	Based	on	the	available	literature,	it	appears	that	biological	
DMARDs	are	able	to	modulate	the	 lipid	profile	 in	RA.	 Interestingly,	these	changes	 in	 individual	
lipid	 levels	do	not	always	translate	 into	changes	 in	the	AI	or	are	not	sustained	 long	enough	to	
significantly	affect	 this	 ratio.	 Inflammation	may	also	diminish	 the	beneficial	effect	of	HDL-c	by	
affecting	 its	 composition.	 This	may	 additionally	 reduce	 the	predictive	 value	of	 the	 lipoprotein	
concentrations	used	in	CVD	risk	assessment	in	RA.	Perhaps	these	effects	differ	between	men	and	
women.	To	counteract	these	harmful	effects	of	inflammation	on	the	lipid	profile,	striving	for	tight	
control	of	disease	activity	may	be	of	importance.	
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	 Chapter	6	&	7:	Disease	duration	alone	does	not	 independently	affect	the	risk	of	CVD	
and	may	therefore	not	be	suitable	as	a	disease-specific	predictor	when	estimating	CVD	risk	 in	
individual	 RA	 patients.	 Disease	 activity	 on	 the	 other	 hand	 appears	 to	 augment	 CVD	 risk,	
particularly	 high	uncontrolled	disease	 activity	 over	 time.	 Conversely,	 low	disease	 activity	 over	
time	was	found	to	be	protective	against	CVD	in	this	population.	RA	patients	with	a	DAS28	over	
time	≤3.2	have	a	significantly	lower	risk	of	CVD	than	patients	with	active	disease.	DAS28-remission	
does	not	appear	to	significantly	add	to	this	beneficial	effect.	These	findings	further	support	the	
rationale	of	using	tight	control	as	a	preventive	strategy	in	CVD	risk	management	in	RA	patients.	
	 Chapter	8:	Adaptations	of	the	SCORE	algorithm	that	include	disease	specific	risk	factors	
do	not	provide	sufficient	improvement	in	the	predictive	performance	of	this	model	and	therefore	
it	 is	 not	 an	 appropriate	 alternative	 to	 the	 original	 SCORE.	However,	 risk	 estimation	 using	 the	
original	SCORE	algorithm	may	underestimate	CVD	risk	in	RA	patients.		
Cardiovascular	disease	risk	prediction	in	RA		
A	 risk	 prediction	 algorithm	 is	 a	 useful	 tool	 for	 identifying	 individuals	 at	 significant	 risk	 for	
developing	CVD	and	subsequently	for	allocating	preventive	treatment	to	those	patients.	Effective	
CVD	risk	management	requires	assessment	of	(modifiable)	risk	factors,	and	includes	treatment	
and	lifestyle	changes	that	will	significantly	reduce	CVD	risk	in	individuals.[8]	As	alluded	before,	the	
traditional	risk	factors	that	are	used	for	this	purpose	in	the	general	population	do	not	fully	account	
for	the	excess	risk	that	is	reported	in	the	RA	population,	even	though	some	of	the	traditional	risk	
factors	appear	to	be	more	prevalent	in	RA	patients.[2-5,	9-12,	13]	We	have	demonstrated	that	
the	 predictive	 performance	 of	 four	 currently	 available	 CVD	 risk	 models,	 which	 are	 based	 on	
traditional	 risk	 factors,	 is	 not	 satisfactory.[Chapter	 3]	 Accordingly,	 the	 risk	 of	 future	 CVD	 is	
underestimated	 in	 a	 large	 group	 of	 RA	 patients,	 which	 may	 hamper	 adequate	 and	 timely	
preventive	action	in	patients	with	intermediate	and	high	risk	of	CVD.	This	finding	is	supported	by	
the	results	of	other	studies	in	which	the	predictive	performance	of	traditional	CVD	risk	models	in	
RA	patients	were	evaluated	in	US	and	Southern	European	populations.[14-16]	These	findings	raise	
questions	concerning	the	role	of	currently	available	CVD	risk	algorithms	in	clinical	decision	making	
and	allocation	of	preventive	care	in	RA	patients.	In	the	2011	EULAR	recommendations	for	CVD	
risk	management	in	RA	it	was	suggested	that	in	the	presence	of	certain	disease	specific	risk	factors	
(disease	duration	>10	years,	rheumatoid	factor	or	anti-CCP	positivity,	presence	of	extra-	articular	
manifestations)	a	1.5	multiplication	factor	should	be	applied	to	the	risk	estimate	calculated	with	
a	risk	algorithm	such	as	SCORE.	Although	these	recommendations	generated	attention	for	CVD	
risk	 management	 in	 RA,	 the	 multiplication	 factor	 appears	 to	 be	 too	 crude	 a	 measure	 to	
significantly	 improve	CVD	 risk	predictions,	as	was	demonstrated	by	us	and	others.[15,	17,	18]	
Also,	disease	duration,	rheumatoid	factor	and	anti-CCP	positivity	were	found	not	to	be	significant	
predictors	of	CVD	in	our	cohort.	However,	there	is	no	suitable	alternative	at	the	moment	that	is	
proven	to	be	more	accurate	or	superior	as	a	CVD	risk	prediction	tool	in	RA.	Therefore	a	recent	
update	 of	 the	 EULAR	 recommendations	 for	 CVD	 risk	 management	 in	 the	 RA	 population	 still	
advocates	the	use	of	this	multiplication	factor	as	the	most	evidence	based	CVD	risk	algorithm	in	
RA	patients,	 in	 addition	 to	9	other	 recommendations.[19]	As	 existing	prediction	 rules	 tend	 to	
underestimate	CVD	risk	in	a	large	portion	of	RA	patients	and	the	suggested	multiplication	factor	
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does	not	appear	to	reclassify	sufficient	RA	patients	to	a	more	fitting	risk	category,	there	is	a	risk	
of	 under-treating	 modifiable	 traditional	 risk	 factors	 in	 RA	 patients	 when	 following	 these	
guidelines.	Further	insight	into	the	relationship	between	disease	specific	risk	factors	and	CVD	may	
facilitate	development	of	a	more	accurate	risk	prediction	algorithm.		
The	role	of	systemic	inflammation	in	the	cardiovascular	disease	risk	profile	in	RA	
When	it	comes	to	the	excess	risk	of	CVD	in	RA	and	the	search	for	potential	RA	specific	CVD	risk	
factors,	there	has	been	a	particular	interest	in	systemic	inflammatory	activity,	which	seems	to	be	
associated	with	 the	 development	 of	 CVD.[2,	 6,	 7,	 20,	 21]	 The	 complexity	 of	 the	mechanisms	
underlying	 the	 effect	 of	 systemic	 inflammation	 on	 CVD	 risk	 are	 still	 is	 not	 fully	 understood.	
Atherosclerosis	has	been	described	as	an	inflammatory	disease,[7]	which	led	to	the	hypothesis	
that	chronic	systemic	inflammation	may	augment	this	process.	Furthermore,	inflammation	may	
work	synergistically	with	traditional	risk	factors	to	further	augment	CVD	risk.	Increased	cytokine	
levels	 in	 RA	 have	 been	 associated	 with	 insulin	 resistance.[22]	 In	 combination	 with	 reduced	
physical	activity	levels	this	may	lead	to	the	development	of	metabolic	syndrome;	a	collection	of	
risk	 factors	 for	 the	 development	 of	 CVD.[23,	 24]	 Furthermore,	 fluctuations	 in	 inflammatory	
activity	or	disease	activity	in	RA	patients	appear	to	affect	lipoproteins	levels.	The	AI	seems	to	be	
less	affected	and	more	stable,	rendering	it	a	more	suitable	determinant	for	CVD	risk.[Chapter	5]	
Use	 of	 this	 ratio	 is	 therefore	 also	 advised	 in	 the	 EULAR	 recommendations	 for	 CVD	 risk	
management	in	RA.[19]	Overall,	lipoproteins	appear	to	decrease	under	the	influence	of	systemic	
inflammation.	The	traditional	interpretation	of	decreased	cholesterol	levels	would	be	that	this	is	
effect	is	therefore	beneficial	as	it	would	reduce	CVD	risk.	However,	inflammation	appears	to	have	
another	effect	on	lipoproteins.	 In	RA	patients,	the	composition	of	HDL-c	 is	altered	[Chapter	4]	
and	the	anti-	atherogenic	function	of	HDL-c	may	be	diminished,	even	become	pro-atherogenic	as	
a	 result	 of	 the	 effects	 of	 systemic	 inflammation.[25-28]	Of	 note,	 these	 changes	 appear	 to	 be	
associated	with	an	increased	CVD	event	rate.	A	high	apolipoprotein	(apo)B/apoA1	ratio	was	found	
to	 be	 predictive	 of	 CVD	 events	 during	 18	 years	 of	 follow-up	 in	 74	 RA	 patients	 with	 active	
disease.[29]	ApoA1	is	an	important	protein	constituent	of	HDL-c,	involved	in	reversed	cholesterol	
transport,	contributing	heavily	to	the	anti-atherogenic	properties	of	HDL-c.	These	findings	could	
also	have	consequences	for	the	predictive	power	of	the	AI,	that	includes	HDL-c,	when	assessing	
CVD	risk	 in	patients	with	active	disease	 [Chapter	4,	5]	Conversely,	anti-rheumatic	 therapies	 in	
responding	 RA	 patients	 can	 increase	 lipid	 levels,	 reflecting	 the	 suppression	 of	 inflammatory	
activity.[Chapter	5]	In	addition	to	an	increase	of	HDL-c,	the	anti-atherogenic	properties	of	HDL-c	
were	found	to	be	improved.[25,27,	30]	The	long-term	effects	of	these	changes	on	CVD	morbidity	
and	mortality	have	yet	to	be	determined.	Other	traditional	risk	factors	have	been	investigated	in	
RA	as	well.	Hypertension	appears	to	be	more	prevalent	in	RA	[31]	and	was	a	significant	predictor	
for	CVD	in	our	cohort.	Male	gender	and	age	are	non-modifiable	CVD	risk	factors	in	the	general	
population.	However,	 in	a	 study	by	Fransen	et	al.[32]	male	and	 female	patients	with	RA	were	
shown	to	have	similarly	increased	relative	risks	of	CVD,	which	is	interesting	considering	that	male	
gender	alone	is	regarded	as	an	 important	risk	factor	for	CVD	in	the	general	population.	 In	this	
study,	the	youngest	patients	were	also	found	to	have	the	highest	relative	risk	of	developing	CVD	
when	compared	to	the	oldest	patients.[32]	Another	study	demonstrated	that	male	gender,	as	
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well	as	 smoking	and	cardiac	history	had	weaker	associations	with	CVD	compared	 to	a	non-RA	
population.[4]	These	findings	could	indicate	that	in	RA,	the	predictive	power	of	certain	traditional	
risk	factors	such	as	gender	and	age	is	different	from	the	general	population.	Overall,	inflammation	
appears	 to	modify	 the	effect	of	 traditional	CVD	 risk	 factors,	 effectively	 changing	 their	 relative	
contributions	to	CVD	risk	in	RA.	Therefore,	the	performance	of	CVD	risk	algorithms	could	benefit	
from	recalibration	of	the	respective	weights	of	individual	risk	factors	in	these	models.	
In	addition	to	interacting	with	traditional	risk	factors,	inflammation	may	also	be	an	independent	
risk	 factor	 for	developing	CVD.	Overall,	 determining	 in	precise	 terms	 the	association	between	
systemic	inflammation	and	the	development	of	actual	CVD	events	has	proven	to	be	challenging.	
In	part,	this	may	be	due	to	the	fact	that	disease	activity	tends	to	fluctuate	over	time	in	most	RA	
patients	and	the	measurements	reflect	just	moments	of	disease	activity	during	follow-up.	There	
are	many	other	factors	that	may	affect	either	disease	activity	and/or	the	risk	of	CVD,	and	could	
potentially	act	as	confounders	for	this	relationship.	These	methodological	aspects	are	not	always	
properly	accounted	for	in	the	available	literature	on	this	topic.	In	the	studies	discussed	in	Chapter	
6	and	7	 these	 factors	were	 taken	 into	account.	Based	on	our	 research	 it	appears	 that	disease	
duration,	 or	 the	 time	 that	 disease	 activity	 exerts	 its	 influence,	 is	 not	 a	 strong	 independent	
predictor	 for	 future	 CVD	 in	 RA.[Chapter	 6]	 Disease	 activity	 however	 does	 appear	 to	 have	 a	
significant	effect	on	the	risk	of	CVD	which	seems	to	be	most	apparent	in	patients	who	are	more	
consistently	 on	 the	higher	 or	 lower	 end	of	 the	disease	 activity	 spectrum.	 Illustratively,	 a	 high	
DAS28	at	baseline	and	moderate	to	high,	uncontrolled	disease	activity	over	time	were	found	to	
significantly	augment	CVD	risk.[Chapter	6,	7]	We	were	able	to	demonstrate	this	effect	in	a	large	
cohort	of	RA	patients	with	prolonged	 follow-up.	Recently,	others	have	also	demonstrated	 the	
unfavorable	effect	of	a	high	cumulative	burden	of	severe	RA	disease,	and	frequent	flare-ups	on	
CVD	risk.[33,	34]	Conversely,	patients	who	are	able	to	achieve	very	low	disease	activity	over	time	
have	a	significantly	lower	risk	of	CVD	compared	to	patients	with	more	active	disease.[Chapter	7]	
Of	note,	remission	does	not	appear	to	significantly	add	to	this	beneficial	effect.	Achieving	low,	
stable	disease	activity	(DAS28≤3.2)	may	be	a	significant	step	towards	substantially	reducing	CVD	
risk	in	RA.		
Overall,	a	considerable	body	of	evidence	supports	the	notion	that	systemic	inflammation	has	an	
important	role	in	the	development	of	CVD	in	RA.	In	concurrence	with	these	findings,	the	results	
discussed	in	this	thesis	indicate	a	significant	association	of	disease	activity	with	occurrence	of	CVD	
in	RA	although	this	is	most	apparent	in	patients	with	sustained	high	or	very	low	disease	activity	
over	 time.	 Our	 findings	 underline	 the	 importance	 of	 tight	 control	 as	 a	 strategy	 in	 CVD	 risk	
management	in	the	RA	population,	now	also	propagated	by	several	other	research	groups.[1,	19,	
35]	A	subgroup	of	RA	patients	with	severe,	poorly	controlled	disease	may	have	the	most	to	gain	
from	adequate	CVD	risk	management.	
Cardiovascular	disease	risk	management	in	RA	
The	 evidence	 supporting	 the	 role	 of	 systemic	 inflammation	 as	 both	 an	 independent	 CVD	 risk	
factor	and	a	modulator	of	traditional	risk	factors	has	led	to	the	‘smaller	slice	of	a	large	pie’-concept	
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(see	figure	1.1,	in	the	introduction).[36]	This	hypothesis	states	that	the	overall	risk	of	CVD	is	higher	
in	RA	and	although	traditional	risk	factors	do	contribute	to	the	CVD	risk	profile	of	RA	patients,	
their	relative	contribution	to	CVD	risk	is	smaller	compared	to	the	general	population.	As	discussed	
before,	the	CVD	risk	profile	of	those	RA	patients	who	have	a	high	risk	of	developing	CVD	may	be	
significantly	 different	 from	 the	 risk	 profile	 in	 the	 general	 population.	 Simply	 adjusting	 or	
recalibrating	an	existing	CVD	risk	algorithm	does	not	seem	to	be	sufficient	as	it	does	not	result	in	
a	 significant	 improvement	 in	 the	accuracy	of	10-year	CVD	 risk	estimates	 [Chapter	8].	 The	 risk	
estimates	calculated	with	the	adjusted	SCORE	algorithm	did	correct	some	of	the	underestimation	
of	CVD	risk,	also	including	a	portion	of	RA	patients	who	would	otherwise	be	categorized	as	low	or	
intermediate	 CVD	 risk	 and	 who	 would	 therefore	 be	 unlikely	 to	 receive	 adequate	 preventive	
therapy.	 Unfortunately,	 the	 predictive	 performance	 of	 the	 adjusted	 SCORE	 algorithm	 did	 not	
significantly	improve	compared	to	the	original	SCORE.[Chapter	8]	A	more	radical	approach	would	
be	to	build	a	prediction	model	from	scratch	without	including	traditional	risk	factors	‘by	default’.	
This	could	perhaps	generate	a	more	powerful	and	accurate	CVD	prediction	algorithm.	Several	
other	CVD-related	parameters	that	have	been	discussed	elsewhere,	such	as	carotid	artery	intima-
media	 thickness	 and	 presence	 and	 composition	 of	 atherosclerotic	 carotid	 plaques	 could	
contribute	 to	more	 accurate	 CVD	 risk	 prediction.	 Screening	 for	 asymptomatic	 atherosclerotic	
plaques	by	means	of	carotid	ultrasound	has	been	recommended	as	part	of	CVD	risk	assessment	
in	 RA	 patients.[19]	 Although	 these	 measurements	 may	 have	 potential	 as	 predictors	 used	 to	
identify	RA	patients	who	are	most	at	risk	for	developing	CVD,	several	other	aspects	play	a	role	
when	determining	what	CVD	risk	factors	are	suitable	for	use	in	clinical	practice.[37,	38,	39,	40]	
The	practicality	and	cost-benefit	ratio	of	measuring	and	monitoring	certain	disease	specific	risk	
factors	in	clinical	practice	should	also	be	considered.	On	a	different	note,	there	is	no	evidence	to	
suggest	that	treatment	strategies	or	lifestyle	changes	aimed	at	reducing	traditional	risk	factors	
would	 be	 ineffective.	 In	 the	 2015/2016	 update	 of	 the	 EULAR	 recommendations	 for	 CVD	 risk	
management	the	authors	point	out	that	statins	appear	to	be	equally	effective	in	RA	patients.[19]	
Results	 from	 the	 Trial	 of	 Atorvastatin	 for	 the	 primary	 prevention	 of	 Cardiovascular	 Events	 in	
patients	with	Rheumatoid	Arthritis	(TRACE-	RA)	that	included	2986	RA	patients	with	7908	patient	
years	of	 follow-up	show	that	statins	are	safe	and	effective	for	use	 in	RA	patients.	A	significant	
reduction	 in	 LDL-c	 levels	was	 achieved	 in	 patients	 randomized	 to	 40mg	 of	 atorvastatin	 daily,	
compared	 to	 placebo.	 Also,	 a	 34%	 reduction	 in	 CVD	 events	was	 reported	 in	 the	 intervention	
group,	 although	 this	 difference	 did	 not	 reach	 statistical	 significance.[41]	 Smoking	 cessation,	 a	
healthy	diet	and	exercise	is	recommended	as	a	part	of	RA	management	for	beneficial	effects	on	
both	CVD	risk	and	disease	outcomes.[19]	Even	though	traditional	risk	factors	do	not	fully	explain	
the	excess	CVD	risk,	they	should	not	be	considered	irrelevant.	At	this	point,	there	is	no	reason	to	
withhold	appropriate	preventive	measures	targeting	traditional	CVD	risk	factors	in	patients	with	
RA.	
Conclusion	and	future	recommendations	
RA	patients	have	an	 increased	 risk	of	CVD,	 and	 systemic	 inflammation	 is	 likely	 to	be	a	 crucial	
contributor	herein,	both	as	an	independent	risk	factor	and	by	modulating	other	traditional	CVD	
risk	 factors.	Currently	available	CVD	risk	algorithms	provide	suboptimal	 risk	estimates	 in	 these	
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patients,	which	may	lead	to	ineffective	allocation	of	preventive	measures.	A	disease	specific	CVD	
risk	 algorithm,	 tailored	 to	 the	 CVD	 risk	 profile	 of	 RA	 patients,	may	 provide	 a	 solution	 to	 this	
problem	although	a	 simple	adjustment	of	existing	 risk	algorithms	does	not	 seem	sufficient.	 In	
addition	 to	 the	 individual	 predictive	 ability	 of	 traditional	 risk	 factors	 and	 disease	 activity,	 the	
relative	contribution	of	each	risk	factor	should	be	carefully	evaluated	when	developing	a	disease	
specific	CVD	risk	algorithm.	Until	an	 improved	alternative	 is	available,	using	existing	guidelines	
and	recommendations	may	be	the	best	option	for	CVD	risk	assessment	and	management	in	RA	
patients.	Creating	awareness	of	the	increased	CVD	risk	and	of	the	drawbacks	of	using	existing	risk	
algorithms	and	guidelines	in	the	RA	population	among	healthcare	providers	may	contribute	to	
improved	 allocation	 of	 preventive	 care.	 Additionally,	 as	 disease	 activity	 appears	 to	 be	 an	
important	 addition	 to	 the	 CVD	 risk	 profile	 of	 RA	 patients,	 striving	 for	 tight	 control	 of	 disease	
activity	during	the	course	of	RA	is	of	 importance,	not	only	to	prevent	joint	damage	but	also	to	
reduce	the	risk	of	CVD.	Particularly	patients	with	severe	disease	activity	at	diagnosis	and/or	those	
who	 are	 inadequately	 responding	 to	 anti-rheumatic	 therapy	 over	 time	may	 require	 stringent	
monitoring	of	disease	activity	and	traditional	risk	 factors	whilst	maintaining	 low	thresholds	for	
initiating	preventive	care	to	effectively	prevent	future	CVD.	Additional	research	is	necessary	to	
investigate	the	added	value	of	more	tailored,	disease	specific	strategies	to	assess	and	reduce	CVD	
risk	in	patients	with	RA.	This	means	further	elucidating	the	mechanisms	underlying	the	effect	of	
systemic	 inflammation	on	CVD	risk,	 investigating	the	 long-term	effects	of	tight-control	on	CVD	
risk	and	to	continue	to	explore	the	potential	of	disease	specific	CVD	risk	factors	that	may	facilitate	
the	identification	of	high	risk	patients.	
Lastly,	 this	 thesis	 hopefully	 encourages	 rheumatologists	 individually	 to	 take	 steps	 to	 embed	
cardiovascular	risk	management	in	the	routine	care	of	their	RA	patients.	
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Patients	with	 rheumatoid	arthritis	 (RA)	have	an	 increased	 risk	of	 cardiovascular	disease	 (CVD)	
compared	 to	 the	 general	 population.	 In	 order	 to	 reduce	 the	 risk	 of	 CVD,	 cardiovascular	 risk	
management	should	be	an	integral	part	of	(clinical)	care	for	patients	with	RA.	The	main	focus	of	
this	thesis	was	on	CVD	risk	prediction	in	RA	and	on	the	CVD	risk	profile	in	RA	patients.	The	first	
objective	was	to	evaluate	in	RA	patients	the	predictive	performance	of	various	CVD	risk	algorithms	
that	are	used	in	the	general	population	to	predict	the	10-year	risk	of	CVD.	Additionally,	a	CVD	risk	
algorithm	that	 includes	disease	specific	 risk	 factors	was	developed	and	evaluated.	The	second	
objective	was	to	investigate	the	role	of	inflammation	in	the	CVD	risk	profile	of	RA	patients	and	to	
particularly	 shed	 more	 light	 on	 the	 relationship	 between	 disease	 activity	 and	 the	 risk	 of	
developing	CVD.	For	the	research	discussed	in	this	thesis,	the	1985	early	RA	inception	cohort	was	
used	as	the	main	source	of	data.	Cholesterol	levels	were	not	measured	systematically,	as	is	the	
case	in	many	large	RA	cohorts.	Therefore,	the	first	step	was	to	validate	the	use	of	frozen	serum	
samples.	As	described	in	Chapter	2,	only	a	modest	storage	decay	effect	on	lipoproteins	was	found	
that	was	unlikely	to	significantly	affect	CVD	risk	stratification.	It	was	demonstrated	that	even	after	
long	time	storage	frozen	serum	samples	are	a	valid	source	to	obtain	lipid	measurements	for	CVD	
oriented	 research	 in	 RA.	 Next	 the	 performance	 of	 four	 traditional	 CVD	 risk	 algorithms	 was	
evaluated	in	the	RA	cohort	in	Chapter	3.	These	four	algorithms	proved	to	be	less	accurate	in	RA	
patients	compared	to	results	from	the	general	population.	Further	insight	into	the	relationship	
between	disease	specific	risk	factors	and	CVD	may	facilitate	development	of	a	more	accurate	risk	
prediction	algorithm.	There	has	been	a	particular	interest	in	systemic	inflammatory	activity,	as	it	
seems	to	be	associated	with	the	development	of	CVD.	In	Chapter	4	the	effect	of	inflammation	on	
lipids	was	investigated	by	comparing	the	composition	of	HDL-c	in	RA	patients	to	healthy	controls.	
Inflammation	appears	to	change	the	composition	of	HDL-c,	which	may	contribute	to	diminished	
anti-atherogenic	 properties	 of	 HDL-c	 in	 RA	 patients.	 Altered	 function	 of	 HDL-c	 as	 a	 result	 of	
inflammatory	 activity	 was	 also	 found	 when	 reviewing	 the	 literature	 on	 the	 effect	 of	 anti-
inflammatory	therapy	on	lipoproteins	in	Chapter	5.	Furthermore,	results	showed	that	biological	
DMARDs	appear	to	be	able	to	modulate	the	lipid	profile	in	RA	whilst	these	changes	often	do	not	
translate	into	changes	in	the	relative	TC:HDL-c	ratio	or	atherogenic	index	(AI).	Therefore,	AI	and	
HDL-function	may	be	more	suitable	parameters	of	the	lipid	profile	as	determinants	of	CV	risk	in	
patients	with	RA.	In	addition	to	an	interaction	with	traditional	risk	factors,	systemic	inflammation	
may	also	be	an	 independent	 risk	 factor	 for	developing	CVD.	 In	Chapter	6	 this	hypothesis	was	
explored	by	investigating	the	effect	of	both	disease	duration	and	disease	activity	on	the	risk	of	
CVD	in	RA.	Disease	duration	alone	does	not	significantly	affect	the	risk	of	CVD.	Disease	activity	
over	time	on	the	other	hand	appears	to	augment	CVD	risk,	particularly	high	uncontrolled	disease	
activity	over	 time.	 Furthermore,	 as	demonstrated	 in	Chapter	7,	 it	was	 found	 that	 low	disease	
activity	over	time	(DAS28≤3.2)	is	protective	against	the	development	of	CVD.	Of	note,	remission	
does	not	appear	to	significantly	add	to	this	beneficial	effect.	These	results	further	support	the	
rationale	of	using	tight	control	as	a	preventive	strategy	in	CVD	risk	management	in	RA	patients.	
Furthermore,	 it	appears	that	the	risk	profile	of	RA	patients	who	are	at	high	risk	for	developing	
CVD	 is	 significantly	 different	 from	 that	 of	 the	 general	 population.	 This	 also	 affects	 CVD	 risk	
prediction.	Unfortunately,	as	was	shown	in	Chapter	8,	simply	adjusting	or	recalibrating	an	existing	
CVD	risk	algorithm	does	not	seem	to	be	sufficient	as	it	does	not	result	in	a	significant	improvement	
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in	 the	 accuracy	 of	 CVD	 risk	 estimates.	 A	 more	 rigorous	 approach	 for	 developing	 a	 CVD	 risk	
algorithm,	 that	also	 incorporates	 re-evaluation	of	 the	 individual	contributions	of	all	 traditional	
CVD	risk	factors	to	the	RA	specific	CVD	risk	profile,	may	yield	more	promising	results.		
	
In	conclusion,	RA	patients	have	an	increased	risk	of	CVD	and	systemic	inflammation	is	likely	to	be	
a	crucial	contributor	herein.	Inflammation	appears	to	act	as	an	independent	risk	factor	and	also	
by	modulating	other	traditional	CVD	risk	factors.	Currently	available	CVD	risk	algorithms	provide	
suboptimal	risk	estimates	in	RA	patients.	However,	as	there	is	no	suitable	alternative	available	at	
this	 time,	using	existing	guidelines	and	recommendations	may	be	the	best	option	for	CVD	risk	
assessment	and	management	whilst	keeping	in	mind	the	drawbacks	of	using	these	tools	in	the	RA	
population.	In	addition	to	monitoring	and	treatment	of	traditional	CVD	risk	factors,	striving	for	
tight	control	of	disease	activity	during	the	course	of	RA	is	of	importance	in	this	regard.		
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Patiënten	met	reumatoïde	artritis	(RA)	hebben	een	verhoogd	risico	op	cardiovasculaire	ziekten	
ofwel	 hart-	 en	 vaatziekten	 (HVZ)	 in	 vergelijking	met	 de	 algemene	 populatie.	 Om	 dit	 risico	 te	
verminderen	zou	cardiovasculair	risicomanagement	een	integraal	onderdeel	moeten	vormen	van	
de	zorg	voor	patiënten	met	RA.	In	dit	proefschrift	is	gefocust	op	de	predictie	van	het	individuele	
risico	op	hart-	en	vaatziekten	bij	RA	patiënten	en	op	het	verder	definiëren	van	het	cardiovasculair	
risicoprofiel	van	patiënten	met	RA.	Eerst	 is	daarom	de	toepassing	van	verschillende	bestaande	
cardiovasculaire	risicomodellen	in	de	RA-populatie	geëvalueerd	en	is	er	een	bestaand	risicomodel	
aangepast	door	RA-specifieke	risicofactoren	voor	het	ontwikkelen	van	HVZ	te	includeren	in	het	
model.	Daarnaast	is	de	rol	van	ontstekingsactiviteit	in	het	cardiovasculaire	risicoprofiel	van	RA-
patiënten	onderzocht	waarbij	specifiek	is	gekeken	naar	de	relatie	tussen	gemeten	ziekteactiviteit	
en	 het	 risico	 op	 hart-	 en	 vaatziekten	 bij	 patiënten	met	 RA.	 Voor	 het	 verrichte	 onderzoek	 dat	
besproken	wordt	 in	dit	proefschrift	 is	het	Nijmeegse	vroege	RA	 inceptiecohort	gebruikt	als	de	
belangrijkste	bron	van	data.	In	dit	cohort	werden	cholesterolmetingen	niet	routinematig	verricht,	
wat	het	geval	is	in	veel	grote	RA-cohorten.	Daarom	bestond	de	allereerste	stap	uit	het	valideren	
van	het	gebruik	van	bevroren	serummonsters,	die	wel	voorhanden	waren	voor	deze	patiënten,	
voor	de	cholesterolmetingen.	Zoals	beschreven	in	Hoofdstuk	2,	werd	er	als	gevolg	van	het	verval	
van	 lipoproteïnepartikels	 in	 het	 serum	 tijdens	 langdurige	 opslag	 een	 bescheiden	 effect	
geobserveerd	op	de	hoogte	van	de	gemeten	lipoproteïne	waardes.	Het	is	onwaarschijnlijk	dat	dit	
een	 significant	 effect	 heeft	 op	 schattingen	 van	 het	 cardiovasculair	 risico.	 Als	 volgende	 stap	
werden	vier	bestaande	cardiovasculaire	risicomodellen,	veel	gebruikt	in	de	algemene	populatie,	
in	 een	 RA-cohort	 geëvalueerd.	 Dit	 is	 besproken	 in	 Hoofdstuk	 3.	 Deze	 vier	 modellen	 bleken	
duidelijk	minder	 accurate	 schattingen	 van	 het	 cardiovasculair	 risico	 te	 geven	 in	 de	 groep	 RA-
patiënten	in	vergelijking	met	behaalde	resultaten	in	de	algemene	populatie.	Resultaten	lieten	zien	
dat	het	cardiovasculair	risico	in	een	grote	groep	RA-patiënten	werd	onderschat.	Dieper	inzicht	in	
de	relatie	tussen	ziekte	specifieke	risicofactoren	en	HVZ	kan	het	ontwikkelen	van	een	accurater	
predictiemodel	 gericht	 op	 de	 RA-patiënt	 verder	 faciliteren.	 In	 dat	 opzicht	 is	 het	 met	 name	
interessant	 te	 kijken	 naar	 systemische	 ontstekingsactiviteit,	 wat	 geassocieerd	 wordt	 met	 de	
ontwikkeling	van	HVZ	bij	patiënten	met	RA.	In	Hoofdstuk	4	wordt	de	studie	besproken	waarin	het	
effect	van	inflammatie	op	lipiden	is	onderzocht	door	de	samenstelling	van	het	als	gunstig	bekend	
staande	high-density	lipoprotein	cholesterol	(HDL-c)	bij	RA-patiënten	te	vergelijken	met	gezonde	
controles.	 De	 compositie	 van	 HDL-c	 partikels	 lijkt	 onder	 invloed	 van	 ontstekingsactiviteit	 te	
veranderen,	wat	kan	bijdragen	aan	de	verminderde	anti-atherogene,	gunstige,	functie	van	HDL-
c.	 Een	 veranderde	 functie	 van	 HDL-c	 werd	 ook	 gerapporteerd	 door	 andere	 studies	 die	 zijn	
besproken	 in	 de	 systematische	 literatuur	 review	 in	 Hoofdstuk	 5.	 Daarnaast	 lieten	 resultaten	
gepresenteerd	in	dit	hoofdstuk	ook	zien	dat	disease	modifying	anti-rheumatic	drugs	(DMARDs)	
die	 ontstekingsactiviteit	 onderdrukken	 invloed	 lijken	 te	 hebben	 op	 het	 lipidenprofiel	 bij	 RA-
patiënten.	Deze	veranderingen	 leiden	echter	meestal	niet	 tot	significante	veranderingen	 in	de	
relatieve	 TC:HDL-c	 ratio,	 ofwel	 atherogenic	 index	 (AI).	 Gezien	 deze	 bevindingen	 lijken	 deze	
TC:HDL-c	 ratio	 en	 HDL-c	 functie	 meer	 geschikte	 parameters	 van	 het	 lipidenprofiel	 om	 te	
includeren	 in	 het	 cardiovasculair	 risicoprofiel	 van	 RA-patiënten.	 Naast	 een	 interactie	 tussen	
ontstekingsactiviteit	 en	 traditionele	 risicofactoren	 lijkt	 ontsteking	 ook	 als	 een	 onafhankelijke	
risicofactor	 te	werken.	 In	Hoofdstuk	 6	werd	 dit	 verder	 onderzocht	 door	 het	 effect	 van	 zowel	
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ziekteactiviteit	 als	 ziekteduur	 op	 het	 risico	 op	HVZ	 bij	 RA-patiënten	 te	 analyseren.	 Ziekteduur	
alleen	 lijkt	 geen	 significante	 onafhankelijke	 risicofactor	 te	 zijn	 in	 dat	 opzicht.	 Hoge	
ongecontroleerde	ziekteactiviteit	daarentegen	lijkt	onafhankelijk	het	risico	op	HVZ	significant	te	
verhogen.	 Verder	 werd	 gevonden	 dat	 lage	 ziekteactiviteit	 beschermend	 werkt	 tegen	 de	
ontwikkeling	van	HVZ,	zoals	behandeld	in	Hoofdstuk	7.	Opvallend	genoeg	bleek	uit	de	besproken	
resultaten	 dat	 remissie	 gemeten	met	 de	 DAS28	 (score	 voor	 ziekteactiviteit)	 geen	 significante	
toevoeging	lijkt	te	leveren	aan	dit	gunstige	effect.	Deze	bevindingen	ondersteunen	de	motivering	
voor	 direct	 strakke	 regulering	 of	 ‘tight	 control’	 van	 ziekteactiviteit	 bij	 patiënten	 met	 RA	 als	
preventieve	 strategie	 voor	 het	 voorkomen	 van	 HVZ	 in	 deze	 populatie.	 Daarnaast	 lijkt	 het	
cardiovasculair	risicoprofiel	van	patiënten	met	RA	aanzienlijk	te	verschillen	van	het	risicoprofiel	
in	 de	 algemene	 populatie.	 Dit	 beïnvloed	 daarmee	 ook	 de	 risicoschatting	 met	 behulp	 van	
risicomodellen	die	gebaseerd	zijn	op	enkel	traditionele	risicofactoren	uit	de	algemene	populatie.	
Helaas	lijkt	een	eenvoudige	aanpassing	van	een	bestaand	risicomodel	niet	voldoende	voor	een	
significante	verbetering	van	 individuele	schattingen	van	het	cardiovasculair	 risico	bij	patiënten	
met	RA.[Hoofstuk	8]	
Concluderend	 hebben	 patiënten	 met	 RA	 een	 verhoogd	 risico	 op	 HVZ	 waarbij	 systemische	
ontstekingsactiviteit	een	centrale	rol	lijkt	te	spelen;	zowel	als	een	onafhankelijke	risicofactor,	als	
door	effectmodulatie	van	andere	traditionele	risicofactoren.	Het	risicoprofiel	van	RA-patiënten	
lijkt	 daarmee	 te	 opvallend	 te	 verschillen	 van	 de	 algemene	 populatie.	 De	 beschikbare	
cardiovasculaire	 risicomodellen	 leveren	 suboptimale	 risicoschattingen	 bij	 RA-patiënten.	 Er	 is	
echter	geen	geschikt	alternatief	beschikbaar	op	dit	moment.	Daarom	is	het	gebruik	van	bestaande	
richtlijnen	en	aanbevelingen	op	het	gebied	van	cardiovasculair	risicomanagement	mogelijk	voor	
nu	 de	 beste	 oplossing,	 waarbij	 men	 bovengenoemde	 resultaten	 in	 het	 achterhoofd	 houdt	
wanneer	 deze	 toegepast	 worden	 op	 patiënten	 met	 RA.	 Naast	 aandacht	 voor	 traditionele	
risicofactoren	 is	 het	 nastreven	 van	 een	 strakke	 regulatie	 van	 ziekteactiviteit	 gedurende	 het	
beloop	van	RA	daarbij	belangrijk.		
	
	
	
		
	
	
		
11		
Samenvatting	
	 150	
	
	
	 	
		
	
	
DANKWOORD	
	 	
	 152	
Dit	hoofdstuk	zal	voor	de	meeste	lezers	het	eerste	(en	soms	het	enige)	hoofdstuk	zijn	dat	goed	
bekeken	wordt.	Het	is	in	mijn	beleving	dan	ook	een	erg	belangrijk	hoofdstuk.	Dit	proefschrift	dient	
als	een	proeve	van	bekwaamheid	tot	het	zelfstandig	beoefenen	van	de	wetenschap.	In	mijn	geval	
levert	het	ook	het	bewijs	voor	de	inzet,	steun	en	hulp	van	een	heel	fijne	groep	mensen	waarvan	
ik	mezelf	gelukkig	een	deelgenoot	mag	noemen.	Graag	wil	ik	jullie	hiervoor	bedanken.	 
Als	eerste	Prof.	van	Riel,	Piet,	mijn	promotor.	Je	hebt	me	aangenomen	vers	uit	de	schoolbanken	
en	me	de	kans	gegeven	om	mijn	project	mede	vorm	te	geven,	vertrouwen	te	krijgen	en	mezelf	te	
ontwikkelen.	Toen	er	zich	de	mogelijkheid	voordeed	om	met	mijn	onderzoek	onderdeel	te	gaan	
uitmaken	van	een	internationaal	samenwerkingsverband	heb	jij	 je	daar	enorm	voor	ingezet	en	
gezorgd	dat	er	voor	mij	een	rol	was	weggelegd.	Toen	ik	met	je	besprak	dat	ik	weer	wilde	gaan	
studeren	heb	je	me	hierin	gesteund	en	geholpen	dit	mogelijk	te	maken	voor	mij.	Ik	heb	zelfs	nog	
een	tijdje	bij	 je	in	dienst	mogen	werken	als	onderzoeker	toen	er	elders	een	leuk	project	lag.	Ik	
kwam	graag	bij	je	langs	voor	advies	of	om	even	bij	te	praten.	Bedankt!	
Jaap,	als	copromotor	heb	je	mij	al	die	jaren	bijgestaan	met	gedegen	advies,	hulp	en	een	luisterend	
oor.	Je	was	zelf	vaak	een	man	van	weinig	woorden,	en	de	woorden	die	gesproken	werden	volgden	
elkaar	in	bijna	onnavolgbare	snelheid	op.	Ik	vind	het	hier	op	papier	nu	wel	veilig	om	toe	te	geven	
dat	de	eerste	maand	van	mijn	aanstelling	ik	vaak	op	goed	geluk	interpreteerde	wat	je	tegen	me	
zei.	Altijd	kon	 ik	bij	 je	terecht	met	zorgen	over	het	onderzoek.	 Jouw	rust	en	bedachtzaamheid	
gaven	mij	het	vertrouwen	dat	geen	enkele	crisis	onoverkoombaar	was.	Ik	dumpte	mijn	stress	als	
het	ware	op	jouw	bureau	en	kon	dan	weer	met	een	helder	hoofd	jouw	werkkamer	verlaten.	Zelfs	
mijn	vaardigheden	op	het	gebied	van	methodologie	en	statistiek	heb	ik	dankzij	jouw	begeleiding	
uit	het	slop	weten	te	trekken.	Het	stelt	me	nu	in	staat	mijn	eigen	werk,	maar	ook	dat	van	anderen	
kritisch	te	beoordelen	en	op	waarde	te	schatten.	Dit	maakt	me	een	beter	onderzoeker	en	een	
betere	dokter.	Bedankt	dat	je	altijd	kritische	vragen	stelde,	dat	je	eindeloos	geduld	met	me	had	
als	ik	zelf	met	duizend	vragen	kwam	of	het	niet	direct	begreep.	En	bedankt	voor	de	vreugde	die	
ik	 bij	 je	 bespeurde	 als	 ik	 zelf	 een	 probleem	 had	 geconstateerd	 en	 opgelost,	 dat	 was	 een	
belangrijke	motivator.	
Calin,	nadat	ik	jouw	proefschrift	aan	het	begin	van	mijn	promotietraject	onder	ogen	kreeg	was	ik	
hiervan	behoorlijk	onder	de	indruk	en	werd	de	lat	meteen	een	paar	verdiepingen	hoger	gelegd.	
Jouw	inbreng	en	feedback	op	mijn	stukken	was	altijd	scherp	en	zorgde	ervoor	dat	ik	een	beter	
schrijver	werd.	Bedankt	voor	je	fijne	begeleiding	als	copromotor.	Je	hebt	bij	mij	het	enthousiasme	
voor	het	onderwerp	van	mijn	thesis	verder	aangewakkerd	en	ervoor	gezorgd	dat	er	een	duidelijke	
lijn	kwam	in	mijn	ideeën.	Samen	hebben	we	ook	gewerkt	aan	een	cardiovasculaire	screening	op	
de	poli	reumatische	ziekten.	Hoewel	ik	soms	het	idee	had	dat	je	mijn	felheid	of	mijn	manier	van	
doen	wel	vermakelijk	vond	voelde	ik	me	altijd	serieus	genomen	en	op	waarde	geschat.	Bedankt.		
Rogier,	menig	ingewikkeld	statistisch	vraagstuk	heb	ik	bij	jou	neergelegd	en	hoe	druk	je	ook	was,	
altijd	kwam	er	een	oplossing.	Bedankt	daarvoor.	
En	dan	mijn	Reuma-collega’s.	Bea,	met	 jou	deelde	 ik	als	eerste	een	kamer	en	mijn	onderzoek	
borduurde	deels	voort	op	het	werk	dat	jij	al	had	verricht.	Bedankt	dat	je	me	op	sleeptouw	nam.	
Franka	en	Sjoukje,	bedankt	voor	jullie	gezelligheid	en	de	interesse	die	jullie	altijd	hebben	getoond	
in	de	(idiote)	dingen	die	ik	allemaal	bedenk.	Han,	bedankt	voor	de	fijne	samenwerking.	Je	bood	
me	een	fris	perspectief	en	jouw	rust	en	genuanceerde	kijk	op	de	zaken	heb	ik	altijd	erg	kunnen	
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waarderen.	Wietske,	 jij	was	niet	officieel	mijn	begeleider	maar	zo	heb	ik	dat	stiekem	wel	altijd	
een	beetje	ervaren.	Een	sterke	ambitieuze	vrouw	ontbrak	namelijk	nog	aan	dat	rijtje.	Ik	kon	het	
altijd	goed	met	 je	vinden	en	soms	enorm	met	 je	 lachen.	Zo	denk	 ik	nog	weleens	terug	aan	de	
avond	dat	we	aan	een	krakkemikkig	tafeltje	op	het	terras	van	een	piepklein	restaurantje	ergens	
verscholen	in	Rome	zo’n	anderhalf	uur	de	slappe	lach	hebben	gehad.	Geen	idee	meer	waar	het	
over	ging	maar	wel	een	heel	fijne	herinnering	aan	mijn	eerste	congres.	Bedankt!			
Jos,	Kavish,	Sanne,	Sofie,	Yvonne,	Marieke	en	Wieneke.	Met	jullie	heb	ik	deels	in	de	barakken	en	
deels	op	‘de	-2’	mogen	bivakkeren,	beide	onvergetelijke	werkplekken.	Naast	dat	ik	aan	jullie	fijne	
sparringpartners	heb	gehad	om	te	praten	over	het	onderzoek	en	alles	wat	daarbij	komt	kijken,	
kon	ik	ook	bij	jullie	terecht	als	de	frustraties	hoog	opliepen	en	heb	ik	aan	jullie	allemaal	heel	fijne,	
gezellige	collega’s	gehad.	Bedankt!	En	wat	een	hoop	onzin	is	er	uitgekraamd	en	uitgespookt,	met	
name	 door	 het	 illustere	 duo	 Hendrikx	 en	 Bhansing,	 tot	 veel	 vermaak	 van	 mij	 en	 jullie	
kamergenoten.	Woorden	die	omhoog	borrelen	zijn,	rotjes,	slingers	en	feestmutsen,	mandarijnen	
en	‘practical	jokes’.	Dankzij	jullie	heb	ik	bij	‘wie	is	de	mol’	nu	naast	het	voelen	van	intense	afkeer	
ook	een	aantal	positieve	associaties.	Wat	erg	fijn	is	omdat	dit	programma	waarschijnlijk	nog	25	
seizoenen	lang	uitgezonden	gaat	worden.	Wieneke	en	Kavish,	bij	jullie	kon	ik	altijd	terecht	met	
vragen	over	de	opleiding	geneeskunde	en	alle	keuzes	en	overwegingen	over	het	traject	daarna,	
wat	mijn	episodische	opvlammingen	van	toekomststress	absoluut	ten	goede	is	gekomen.	Jos,	je	
bent	er	als	enige	verantwoordelijk	voor	dat	ik	ooit	begonnen	ben	aan	het	zelf	schrijven	van	SPSS-
syntax.	Dat	gebruik	 ik	nu	nog	om	indruk	te	maken	op	feestjes.	Ook	voor	vragen	over	de	beste	
breedhoeklens,	 filters,	computerprogramma’s,	 tips	voor	het	zelf	 regelen	van	reizen	naar	verre	
bestemmingen	 of	 wanneer	 ik	 enthousiastelingen	 nodig	 had	 voor	 een	 roadtrip	 kon	 ik	 bij	 jou	
terecht.	Dankjewel!	Sofie,	jouw	gevoel	voor	humor,	no-nonsense	houding	en	gematigde	blijheid	
op	de	maandagochtend	heb	ik	altijd	erg	gewaardeerd	en	ik	kon	met	jou	ook	heerlijk	over	andere	
bezigheden	dan	onderzoek	ouwehoeren.	Bedankt!	Yvonne,	het	feit	dat	je	in	mijn	ogen	altijd	je	
eigen	plan	hebt	getrokken	bewonder	ik	aan	jou.	Bedankt	voor	de	vele	fijne	gesprekken	die	ik	met	
jou	 heb	 gehad,	 ik	 voelde	 me	 altijd	 erg	 gehoord.	 Marieke	 en	 Sanne,	 bedankt	 voor	 jullie	
collegialiteit,	gezelligheid	en	nuchtere	kijk	op	de	wereld.	Graag	wil	ik	ook	nog	iedereen	van	het	
datacentrum,	het	 secretariaat	 en	alle	 andere	 voormalig	 collega’s	 van	de	afdeling	 reumatische	
ziekten	bedanken	voor	de	fijne	samenwerking	en	hulp	die	ik	heb	mogen	ontvangen!	
Eugene,	ik	kwam	nogal	last-minute	bij	je	met	het	verzoek	een	ontwerp	voor	mijn	kaft	te	maken.	
Ik	stak	hierbij	een	warrig	verhaal	af	over	mijn	sterke	gevoelens	jegens	primaire	kleurcombinaties,	
cliché	symbolen	en	stock-foto’s,	eigenlijk	alles	wat	ik	níét	wilde.	Op	de	een	of	andere	manier	heb	
je	daar	precies	uit	opgemaakt	wat	ik	mooi	vind	en	wat	bij	mij	past.	Enorm	bedankt	hiervoor.		
Cogroep	178;	Anissa,	Dominique,	Claudia,	Eva,	 Jiska,	Karlijn,	Kelly,	Koen,	Lars,	Laura,	Leontien,	
Liset,	Marc,	Melanie,	Milad,	Mirthe,	Moniek,	Nadine,	Roel,	Stefanie,	Vivianne,	Wout,	Mehmed,	
Rowie,	 Ngoc	 Lan,	 Daan	 en	 Bart	 (ik	 hoop	 dat	 ik	 niemand	 vergeet!).	 Halverwege	 mijn	
promotietraject	kwamen	jullie	op	mijn	pad.	Wat	een	mooie,	gekke	ervaring	hebben	we	met	elkaar	
gedeeld	en	wat	fijn	dat	jullie	deze	oude	bok	gewoon	opnamen	in	de	groep.	Dankzij	jullie	is	mijn	
geestelijke	veroudering	wat	afgeremd	en	heb	ik	mijn	studententijd	nog	ongegeneerd	een	aantal	
jaar	mogen	rekken.	Moniek,	over	een	paar	jaar	kan	ik	het	dankwoord	in	jouw	boekje	te	lezen!		
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Laura,	bedankt	voor	je	enthousiasme	en	levenslust,	dat	werkt	aanstekelijk.	Stefanie	bedankt	voor	
al	die	keren	dat	je	met	een	blik	al	aan	het	lachen	kon	maken,	voor	je	gezelligheid	en	je	eigenheid.	
Marc,	bedankt	voor	je	scherpe	en	geraffineerde	gevoel	voor	humor,	voor	al	die	keren	dat	je	me	
uitdaagt,	bedankt	dat	ik	zo	lekker	met	je	kan	discussiëren	en	dat	je	mijn	dokters-zielenmattie	bent.		
Aan	iedereen	thuis,	bedankt	voor	alle	keren	dat	we	elkaar	troffen	in	de	kroeg/aan	tafel/langs	de	
lijn/tijdens	het	aflopen	van	de	drukke	sociale	dorpskalender,	en	jullie	interesse	toonden	of	juist	
afleiding	boden.	
Mijn	paranimfen,	Miranda	en	Carli,	bedankt	dat	jullie	‘ja’	hebben	gezegd!	Miranda,	we	kennen	
elkaar	al	vanaf	de	puberjaren	en	met	jou	heb	ik	een	aantal	van	de	mooiste	ervaringen	van	mijn	
leven	tot	nu	toe	mogen	beleven.	Ook	al	zien	we	elkaar	niet	meer	zoveel	als	vroeger,	ik	hoop	je	
nog	tot	we	oud	en	grijs	zijn	in	mijn	vizier	te	houden.	Carli,	ook	van	jou	kan	ik	me	niet	eens	meer	
goed	herinneren	dat	 je	er	niet	was	en	in	al	die	tijd	 is	er	denk	ik	geen	onderwerp	onbesproken	
gebleven.	 Je	 geeft	 me	 het	 gevoel	 dat	 ik	 altijd	 bij	 je	 kan	 aankloppen,	 en	 je	 humor,	 steun	 en		
weloverwogen	advies	waardeer	ik	enorm.	Bedankt	voor	al	onze	gesprekken,	voor	je	gezelligheid	
en	alle	dagjes	weg	de	afgelopen	jaren!	
Cheryl,	Vera	en	Daphne;	ooit	 vriendinnen	van	 langs	de	 lijn	en	 inmiddels	vriendinnen	voor	het	
leven	wat	mij	betreft.	Jullie	zijn	een	inspiratiebron	voor	mij	op	alle	fronten.	Bedankt	voor	jullie	
niet	aflatende	enthousiasme,	 inspiratie,	 interesse,	attentie	en	niet	 te	vergeten	alle	dansjes	en	
wijntjes	 die	 we	 inmiddels	 gedeeld	 hebben.	 Ik	 voel	 me	 rijk	 in	 jullie	 midden.	 Wat	 zijn	 jullie	
prachtmensen!	
Wiep,	bij	zo	ongeveer	elke	mijlpaal	in	mijn	leven	(groot	en	klein)	was	je	daar,	camera	in	de	aanslag	
om	 het	 allemaal	 vast	 te	 leggen.	 Bedankt	 dat	 je	 er	 bent,	 voor	 je	 belangstelling	 en	 voor	 het	
verzamelen	van	genoeg	beeldmateriaal	om	bij	mijn	eerstvolgende	verjaardag	iedereen	te	kunnen	
trakteren	op	een	avondvullende	PowerPointpresentatie	van	mijn	prestaties.	
Ria,	mijn	surrogaat	oma	en	eerste	brenger	van	girlpower	in	mijn	leven,	bedankt.	
Hetty,	Geurt,	Jozef,	Guus,	Janneke	en	Saskia,	bedankt	voor	jullie	steun,	gezelligheid	en	interesse	
in	mijn	bezigheden.	Mirthe	en	Sven,	heerlijke	moppies,	iedere	zaterdag	is	het	voor	mij	weer	een	
feest	overladen	te	worden	met	zoveel	liefde.		
Kleine	broertjes	die	inmiddels	geen	kleine	broertjes	meer	zijn.	Stef,	relaxt	met	een	hoofdletter	R,	
niet	drukker	maken	dan	nodig	is,	en	stoïcijns	vertrouwen	hebben	in	die	levensvisie,	daarin	ben	jij	
mijn	 voorbeeld.	 Derk,	 wellicht	 de	 intelligentste	 van	 ons	 drie	 en	 in	 ieder	 geval	 de	 denker,	 de	
filosoof	en	zeker	de	grootste	en	de	luidste.	Je	houdt	me	scherp	en	zorgt	tijdens	familieactiviteiten	
altijd	voor	kwaliteitsentertainment.	Bedankt	bruurkes.		
Lieve	pap	en	mam,	het	feit	dat	dit	boekje	er	ligt	heb	ik	in	de	eerste	plaats	aan	jullie	te	danken.	De	
basis	 is	door	 jullie	 gelegd.	Pap,	 ik	herken	veel	 van	de	 trekjes	en	karaktereigenschappen	die	 ik	
waardeer	aan	mezelf	in	jou.	Jij	hebt	me	meer	dan	wie	ook	laten	zien	wat	het	waard	is	om	iets	te	
mogen	 doen	 waar	 je	 plezier	 in	 hebt	 en	 waar	 je	 voldoening	 uit	 haalt.	 Mam,	 mijn	 ambitie,	
doorzettingsvermogen,	zelfvertrouwen	en	liefde	voor	de	zorg	heb	ik	vooral	aan	jou	te	danken.	
Bedankt	voor	jullie	onvoorwaardelijke	steun	en	voor	het	vertrouwen	in	dat	jullie	in	mij	hebben.	
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Lieve	Daan,	inmiddels	al	langer	met	jou	dan	zonder	jou.	Ik	wil	me	mijn	leven	niet	meer	voorstellen	
zonder.	Bedankt	dat	ik	altijd	op	je	kan	terugvallen,	dat	je	zoveel	geduld	met	me	hebt	gehad	de	
afgelopen	jaren,	dat	je	me	zoveel	liefde	geeft	en	hier	nooit	aan	lijkt	te	twijfelen,	dat	je	altijd	zonder	
blikken	of	blozen	een	stap	terug	doet	om	mij	en	mijn	wilde	plannen	voor	te	laten	gaan.	We	zijn	
zo	ongeveer	elkaars	tegenpolen	en	dat	maakt	dat	het	nooit	saai	is	met	jou.	Zonder	jou	was	ik	niet	
zover	gekomen.	Mijn	dank	is	het	grootst.	
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Elke	Arts,	auteur	van	dit	proefschrift,	werd	geboren	op	26	juni	1986	
in	het	Radboud	UMC	te	Nijmegen.	Zij	behaalde	in	2004	haar	vwo-
diploma,	met	het	profiel	 ‘economie	en	maatschappij’	en	biologie	
en	Frans	in	het	vrije	deel,	aan	het	Merlet	College	in	Cuijk.	Hierna	
startte	 zij	 met	 de	 opleiding	 Gezondheidswetenschappen	 aan	 de	
Universiteit	 van	 Maastricht	 waar	 zij	 zich	 specialiseerde	 in	
zorgwetenschappen	 en	 bewegingswetenschappen.	 Tijdens	 deze	
periode	 studeerde	 ze	 drie	 maanden	 in	 Zweden	 aan	 Mälardalen	
University	in	Våsteras.	In	2008	behaalde	ze	haar	diploma	voor	de	
master	 Health	 Services	 Innovation	 waarvan	 de	 afstudeerscriptie	
getiteld	 “Transferring	 diabetes	 care	 from	 the	 physician	 tot	 he	 diabetes	 nurse	 by	 means	 of	
substitution”	tot	een	publicatie	geleid	heeft,	onder	begeleiding	van	Prof.	B.	Vrijhoef	en	Prof.	N.	
Schaper.	Na	een	aantal	maanden	gereisd	te	hebben	in	Australië	en	Zuidoost-Azië	vervolgde	ze	
in	2009	haar	wetenschappelijke	carrière	met	een	promotietraject	op	de	afdeling	Reumatische	
ziekten	van	het	Radboud	UMC	te	Nijmegen	onder	leiding	van	Prof.	P.	Van	Riel,	Dr.	J.	Fransen	en	
Dr.	C.	Popa.	Ze	heeft	hier	onderzoek	verricht	naar	het	risico	op	hart-	en	vaatziekten	bij	patiënten	
met	 reumatoïde	 artritis,	 in	 het	 bijzonder	 naar	 risicomodellen	 en	 de	 rol	 van	 systemische	
ontstekingsactiviteit.	 Op	 verschillende	 nationale	 en	 internationale	 congressen	 heeft	 ze	 de	
resultaten	van	dit	onderzoek	mogen	presenteren.	Dit	werk	heeft	 in	2016	geresulteerd	 in	het	
proefschrift	dat	voor	u	ligt.	Tijdens	haar	promotietraject	is	ze	in	2011	begonnen	met	de	studie	
geneeskunde	 aan	 de	 Radboud	Universiteit	 te	Nijmegen.	Haar	masterdiploma	 behaalde	 ze	 in	
2016.	Momenteel	 is	 ze	 werkzaam	 als	 art-assistent	 op	 de	 spoedeisende	 hulp	 in	 het	 Canisius	
Wilhelmina	 Ziekenhuis	 te	 Nijmegen	 en	 verricht	 ze	 onderzoekstaken	 voor	 de	 afdeling	
kinderchirurgie	van	het	RadboudUMC	te	Nijmegen.		
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